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PREFACE
This dissertation was a sequence of six investigations conducted in two phases, as
a collaboration between the Department of Kinesiology at Louisiana State University,
Baton Rouge, Louisiana, and the Department(s) of Biology and Exercise and Sports
Science, Brigham Young University – Hawaii, Laie, Hawaii. The first phase was a series
of three pilot studies, while the second phase was three experiments. The presentation
style is based on that adopted by Acta Physiologica Scandinavica for publication of
medical dissertations (New Series No. 641 ISSN 0346-6612 ISBN 91-7191-748-9, Acta
Physiologica Scandinavica Volume 168 Supplementum 646, January 2000). Chapter 1
provides a critical review of the literature, presentation of the problem, and discussion of
the rationale for experimentation. Chapter(s) 2, 3, and 4, present each experiment,
respectively. Chapter 5 presents overall discussion and conclusions, and suggestions for
future work.
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ABSTRACT
PURPOSE: To examine the effect of L-Aspartic Acid (L-Asp) supplementation
on short-term arm-crank power (i.e. W·min-1) and exercise-induced hyperammonemia in
two gender-specific investigations. METHODS: The male investigation (MALE) used
nine highly-trained intercollegiate water polo players (WP) and nine moderately-trained
college students (MOD); the female investigation (FEM) used 18 recreationally-trained
college students. All exercised to exhaustion on two occasions following
counterbalanced double-blind ingestion of 12.5g x 2 of L-Asp or placebo (P). The warmup phase began at 25 W·min-1 and increased in 25 W·min-1 stages every 30 seconds
(constant 100 rpm). Performance began (i.e. the subjects turned the crank ‘as fast as
possible for as long as possible’) with stage completion of rating of perceived exertion of
17 (6-20 scale) in MOD and FEM and at the 4-minute mark (200 W·min-1) for WP.
Individual warm-up time in session 1 for MOD and FEM was used as warm-up time for
session 2, respectively. Venous blood samples were drawn at 3 minutes post-exercise
and assayed for blood NH3 [µM/L]. A 2 x 2 ANOVA with repeated measures was used
for MALE, and a one-way ANOVA with repeated measures for FEM, with Tukey’s t-test
for post hoc differences. RESULTS: Blood NH3 [µM/L] decreased with L-Asp (vs. P) in
WP (241.0 ± 18.4 vs. 200.6 ± 20.5, p < 0.01) and MOD (219.7 ± 20.8 vs. 185.6 ± 27.5, p
< 0.05). Performance power (W·min-1) with L-Asp improved (p < 0.01) in WP (270.2 ±
19.7 vs. 227.6 ± 14.3) but not (p > 0.05) in MOD (220.1 ± 9.1 vs. 204.4 ± 8.3). There
was no treatment effect in FEM. CONCLUSION: These results suggest that 12.5 g x 2
QD of L-Asp reduces hyperammonemia and enhances short-term power in intercollegiate
water polo players. Conversely, in MOD and FEM, 12.5 g x 2 QD of L-Asp does not
attenuate exercise-induced hyperammonemia sufficiently to improve power.

x

CHAPTER 1. REVIEW OF LITERATURE
1.1 Introduction
Ammonia (NH3) is a normal metabolic product. At high physiological levels,
however, NH3 is adverse to clinical status, metabolic function, and exercise performance.
Blood ammonia concentrations are normally < 50 µM/L at rest (Fischbach, 1988).
However, as reviewed by Batshaw (1984), prolonged symptomatic blood concentrations
exceeding 100 µM/L comprise the medical condition known as clinical hyperammonemia
(CH). The symptomatic etiology of CH is encephalopathy preceded by hepatic dysfunction
(Allen and Conn, 1960; Bessman and Bradley, 1955). Strenuous physical activity elevates
blood ammonia concentrations to the criteria for mild to moderate CH (100 µM/L – 500
µM/L). Interestingly, the symptoms and blood ammonia values of mild to moderate CH
are similar to those observed during physical exhaustion with ‘exercise-induced
hyperammonemia’ (EIH). These include confusion, hyperventilation, and muscular
dysfunction. If prolonged, CH symptoms may exacerbate to convulsions, coma, and death.
With EIH, maintenance of high power is difficult, and exhaustion is imminent (Allen and
Conn, 1960; Banister et al., 1983; Hermansen and Stensvold, 1972; Wilkerson et al., 1977).
Treatments for lowering CH and EIH are similar, and include: 1) restriction of dietary
protein, 2) increasing carbohydrate (%) intake, 3) administration of amino acids (AA’s)
that enhance ammonia clearance into (the less toxic) urea, and 4) correction of the
underlying metabolic etiology. A major focus of sports nutrition physiology is
performance improvement by enhancing ATP production, glycogen storage, and sportsspecific training. As reviewed by Graham et al. (1997), Yuan and Chan (2000), and noted
by Brooks et al. (1996), "amino acids and proteins are, in fact, integrally involved in the
metabolic adjustment to exercise". Although understood that lower blood ammonia levels
are desirable for optimal performance, few report the impact of acutely reducing EIH by
1

supplementation with ammonia-reducing amino acids (e.g. L-arginine, L-ornithine, Laspartate). Further, the impact of lowering blood ammonia in this manner to improve
short-term high-intensity performance is unknown. Therefore, the primary focus of this
dissertation is to critically address the importance of metabolic ammonia and the impact of
reducing ammonia on exercise performance.
As reviewed by Graham et al. (1997), there is an apparent beneficial association
between exercise performance, reduced blood ammonia concentration, and improved
training status. For instance, Lo and Dudley (1987) reported that endurance trained
subjects had lower plasma ammonia levels than untrained subjects at the same absolute
power output during a short-term incremental protocol. Data from Snow et al. (1992)
demonstrated the benefits of seven weeks of sprint training include absolute increases in
power and reduced blood ammonia at a given relative exercise intensity. As suggested by
Holloszy and Coyle (1984) and demonstrated by Denis et al. (1989) and Green et al.
(1991), short-term endurance training lowers blood ammonia at a submaximal intensity.
However, as cited by Graham et al. (1997), it is doubtful that two weeks of endurance
training (Denis et al., 1989) is sufficient to increase mitochondrial density, plus, sprint
training should not tax the mitochondria. Therefore, there must be some other
mechanism(s) (in an overall or combined fashion) for the reduction of blood ammonia with
training. To date, it is unclear whether the blood ammonia response to training reflects
reduced muscular production, greater removal from the blood, enhanced buffering in either
muscle or blood, or increased conversion into amino acid(s) (i.e. branched chain amino
acids).
As described by Mutch and Banister (1983), fatigue is the decreased ability of an
organism or one of its parts to respond or function because of prolonged exertion or
repeated stimulation. Although muscular fatigue is a well-known phenomenon and
2

"exercised until exhaustion" is understood, a myriad of factors contribute to fatigue. These
include:
1)
2)
3)
4)

Substrate depletion of adenosine triphosphate (ATP), phosphocreatine (PC),
and carbohydrate (CHO),
+
Accumulation of waste products (e.g. CO2, H , NH3, hypoxia),
Inhibition of metabolic function, and/or
Central factors (e.g. tryptophan uptake by the brain, leading to seratonin
accumulation).

For example, Frumerie (1913) pointed out that the onset of physical fatigue is experienced
initially at the joints and tendons, while Mosso (1915) suggested that fatigue was a
consequence of "a kind of poisoning resulting from products derived from chemical
changes in cells". The hydrogen ion hypothesis (i.e. muscular fatigue as a result of tissue
acidosis) was first proposed by Hill et al. (1924), who noticed a consistent relationship
between the rate of recovery from a tetanic contraction and the rate of disappearance of
lactic acid from muscle.
At rest, circulating ammonia exists in minute quantities [10 - 40 µM/L] and is
tolerated without symptoms. However, prolonged clinical hyperammonemia ([100 - 2000
µM/L]) interferes with respiration, cell and mitochondrial permeability, and central nervous
system (CNS) function (Batshaw, 1984). Deterioration of brain function in response to
hyperammonemia is progressive, and if exacerbated, is often fatal. As reviewed by Mutch
and Banister (1983), ammonia is produced both centrally and peripherally, and depletes
reserves of glutamate, aspartate, and GABA, essential neurotransmitters. Further, Mutch
and Banister (1983), and Banister et al. (1985) have suggested that the accumulation of
ammonia is a contributing factor to muscular exhaustion. It is well known that strenuous
muscular activity elevates blood ammonia to the symptomatic levels observed in clinical
hyperammonemia (> [100 µM/L]) (Allen and Conn, 1960; Banister et al., 1983; Hermansen
and Stensvold, 1972; Wilkerson et al., 1977). Data from Eriksson et al. (1985) and Graham
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et al. (1990) suggest that the blood ammonia rise with exercise reflects production rate
exceeding removal. Further, Washio and Mahima (1963) and Heald et al. (1975)
demonstrated progressively inhibited in situ contractile responses of skeletal muscle in
concentrated extracellular ammonium ion solutions. Washio and Mashima (1963)
demonstrated that the majority of muscle fibers (e.g., 22 of 25) become electrically
inexcitable following progressive exposure to ammonium ions. These observations suggest
that 1) muscular performance and ammonia levels are inversely related, and 2) excessive
ammonia accumulation is a regulator of performance.
Fortunately, acute and chronic reductions of hyperammonemia generally improve
clinical prognosis and muscular performance (Batshaw, 1984). In apparently healthy
populations, the magnitude of EIH reduction to improve performance is not established,
nor are target population(s) and methods (e.g. exercise modalities, intensities, and
duration). In the clinical setting, the amino acids L-Aspartate, L-Ornithine, L-Arginine,
and/or L-Glutamate reduce CH and increase desirable prognosis (Balesteiri et al., 1967;
DuRuisseau et al., 1956; Najarian et al., 1958; Winitz et al., 1956). However, exercise
studies using similar supplementation (Denis et al., 1991; Edwards and Day, 2000; and Eto
et al., 1994) indicate that L-Ornithine, L-Arginine, and/or L-Glutamate are ineffective as an
ergogenic aid for the acute reduction of EIH and/or improvement in exercise performance.
Alternatively, data from animal and human studies suggests that in certain
situations administration of L-Aspartic Acid, (or one of the magnesium-potassium salts of
L-Aspartate) lowers blood ammonia concentration (Kendrick, 1976; Keul, 1971; Laborit et
al., 1958; Wesson et al., 1988) and enhances performance (Ahlborg et al., 1968; Franz and
Chintanaseri, 1977; Gupta and Srivastava, 1973). Application of the results is
controversial, possibly due to the variability in training status of testing populations, dosage
regimes, and modalities. Although data from Derave et al. (1997) demonstrate gender
4

differences in ammonia response, the effect of aspartate supplementation on exercise
performance in women is unknown. The impact of aspartate ingestion to reduce transient
EIH and enhance short-term high-intensity (> 90% VO2max) power when blood ammonia
levels peak, has not been reported. Therefore, this critical review and dissertation will
focus on the bioenergetics and impact of L-Aspartic Acid supplementation to reduce EIH
and improve high-intensity exercise performance in men and women.
1.2 Bioenergetics: ATP Production, NH3 Production, NH3 Removal
1.2.1 Introduction
The high-energy compound ATP (Adenosine Triphosphate), derived from
foodstuffs, provides essentially all of the energy required for physiological functions.
However, due to a low amount of ATP readily available in cells, specific metabolic
pathways for digested components (ATP-PC, carbohydrate, amino acids, triacylglycerol
derivatives) produce ATP for energy. As discussed by Astrand and Rodahl (1986),
recruitment of substrate for ATP production is mediated by:
1)
2)
3)
4)
5)

Exercise intensity, duration, modality, type (continuous or intermittent)
State of training
Diet
State of health
Availability and source of substrate.

Table 1.1 lists the various biochemical pathways, energy sources, production
characteristics, and waste products of ATP metabolism, assuming 10 kcal/mole ATP
(Brooks et al., 1996). Muscular activity increases ATP utilization rate, demand for
replenishment, and waste product formation (e.g. NH3, H+, CO2). The waste products
generated depend on the source, speed, and amount of substrate consumed. Ammonia, for
instance, accumulates rapidly with 1) accelerated ATP hydrolysis (i.e. during short bursts
of high-intensity activity) and/or 2) inhibited removal (e.g., limitation(s) in urea cycle
enzyme efficiency, urea cycle substrate availability, and hepatic blood flow). As
5

Table 1.1. ATP sources, production characteristics, and waste products.

Estimated
Capacity
(moles)
Very Low (0.5
ATP)

Metabolic
Pathway(s)
ATP-PC

Energy
Source
Intramuscular
ATP
Phosphocreatine

Estimated Rate
(moles/min)
Very Fast
(> 3.6 ATP/min)

Waste
Products
Pi
NH3

Glycolysis
(exclusively)

Glucose
Glycogen

Fast
(1.5 ATP/min)

Low
(500g CHO –
9 ATP)

H

Glycolysis + TCA
+ ETC

Glucose
Glycogen

Somewhat
Fast
(1 ATP/min)

Med
(500g CHO 114 ATP)

CO2

Gluconeogenesis;
Transamination/
Oxidation –
TCA Cycle, ETC
β-Oxidation -TCA
Cycle, ETC

BCAA’s
Glycerol
Lactate
Alanine
Fatty acids
Glycerol
Ketones

Variable

High (2500g
PRO-175
ATP)

NH3
CO2

Very Slow

Very High
(>15,000g Fat
– 8,000 ATP)

CO2

+

depicted in Table 1.1, maximal ammonia production occurs in short term high-intensity
athletic events (e.g. 400 – 800 meter run, water polo sprints), which accelerate ATPase,
adenylate kinase, and adenosine monophosphate (AMP) deaminase activity (Astrand and
Rodahl, 1986). During intense exercise, a 50% reduction in muscular [ATP] yields up to a
20-fold change in adenosine diphosphate [ADP], and 700-fold increase in [AMP] (Astrand
and Rodahl, 1986). Elevated blood NH3 occurs also with long duration exercise, but to a
smaller degree, from the metabolism of branched chain amino acids (BCAA’s) used for
gluconeogenesis. The amount of ammonia produced with endurance exercise is far greater
6

(and more tolerable) versus short-term high-intensity exercise, due to a lower rate of
production (Graham et al., 1995a; Wagenmakers et al., 1990). The demand for ATP,
availability of substrate, and status of training are principal factors in ammonia metabolism.
The bioenergetic sources, fates, and impact of ATP, ammonia, and aspartate are discussed
in the following sections of this chapter.
1.2.2 ATP - PC System
ATP is a readily available energy source in active muscle, consisting of a base
(adenine), a sugar (ribose), and a chain of three phosphates. During short-term intense
exercise, ATP depletion (i.e. demand exceeding supply) occurs rapidly (i.e. < 1 minute). In
response, additional pathways are activated to 1) reproduce ATP quickly (i.e. glycolysis,
gluconeogenesis), and 2) transport and remove waste products (i.e. NH3) efficiently (e.g.
transamination, Cori Cycle activity, urea cycle activity,). Ammonia is a deamination byproduct of the very fast phosphagen (ATP-PC) pathway for ATP production, utilization,
and regeneration (Sabina et al., 1984). ATP hydrolysis elevates ADP, AMP, inosine
monophosphate (IMP), and ammonia via coupling of ATPase, AMP deaminase, and the
purine nucleotide cycle (PNC) (Hellsten et al., 1999). The impact of ATP hydrolysis, the
PNC, and ammonia production on bioenergetics are presented and discussed in this
chapter.
Schmidt (1928) first reported that AMP deamination, in response to accelerated
ATP hydrolysis, is a major source of ammonia production in active muscle. As presented
below in reactions (1) and (2), the ATP-PC pathway is a 2-reaction cycle. Accelerated in
response to high-intensity exercise, the products of the ATPase (1) (ADP, Pi) become
reactants for ATP regeneration either by either a reversal of reaction (1) (utilizing energy
released); or by myokinase in reaction (2) (ADP + ADP <=> ATP + AMP). The
production of NH3 by AMP deaminase (AMP + H2O => IMP + NH3), is the primary source
7

of the NH3 (reaction (3)) rise with short-term intense activity (Sabina et al., 1984; Schmidt,
1928; Wajzer et al., 1956). Studies by Meyer and Terjung (1979; 1980) have shown a 50%
conversion rate of ATP into IMP and ammonia during short-term intermittent stimulation
(5 min) of rat gastrocnemius muscle.
ATP + H2O <=> ADP + Pi
ADP + ADP <=> AMP + ATP
AMP + H2O => IMP + NH3

(ATPase)
(myokinase)
(AMP deaminase)

(1)
(2)
(3)

1.2.3 Purine Nucleotide Cycle
Ammonia production via AMP deaminase is proportional to the rate of ATP
hydrolysis. Although AMP deaminase (AMP + H2O => IMP + NH3) is irreversible, AMP
may be regenerated (reactions 4,5) by a process termed the purine nucleotide cycle (PNC)
(Goodman and Lowenstein, 1977; Lowenstein, 1972; Wheeler and Lowenstein, 1979).
According to Banister et al. (1983), maintenance of the total amount (TAN) of adenine
nucleotides (ATP + ADP + AMP) during exercise is desirable. Further, the PNC requires
aspartate as a substrate (reaction 4). Thus, aspartate administration stimulates the
regeneration of AMP assisting the maintenance of TAN’s. In addition, the TCA cycle
intermediate fumarate (reaction 5) is a product of the PNC. The PNC steps are:
AMP + H2O => IMP + NH3
(AMP deaminase)
(3)
IMP + Aspartate + GTP => Adenylosuccinate + GDP + Pi (adenylosuccinate
synthetase)
(4)
Adenylosuccinate <= > AMP + Fumarate (adenylosuccinase)
(5)
The overall summary is:
Aspartate + GTP + H2O => Fumarate + NH3 + GDP + Pi

(6)

The bioenergetic results of the PNC are:
1)
Regeneration of AMP
2)
Deamination of aspartate to fumarate, and
3)
Liberation of ammonia.
Data from several studies (Gerez and Kirsten, 1965, Meyer and Terjung, 1979;
Raggi et al., 1969; Winder et al. 1974) indicates that recruitment of fast-twitch muscle
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fibers (vs. slow twitch) increases AMP deaminase activity and ammonia production. AMP
deaminase is activated also by high intramuscular [ADP], [AMP], and a fall in pH -- and
inhibited by high [ATP], [GTP], and [Pi] (Wheeler and Lowenstein, 1979). On the other
hand, slow-twitch muscle fibers contain low amounts of AMP deaminase (Gerez and
Kirsten, 1965; Meyer and Terjung, 1979; Raggi et al., 1969; Winder et al. 1974), and
therefore produce less ammonia. Thus, mitochondria-rich muscle (slow oxidative)
produces less ammonia with high-intensity exercise than mitochondria-poor (fast
glycolytic) muscle. Washio and Mashima (1963), and Heald (1975) demonstrated inhibited
in situ skeletal muscle contractile responses in a concentrated extracellular ammonium ion
solution. Therefore, recruitment of fast-twitch muscle fibers accelerates ATP hydrolysis,
AMP deamination, PNC activity, and intramuscular [NH3].
Summarizing, the resynthesis of AMP by the PNC requires aspartate for the
maintenance of total adenine nucleotides. Secondly, the PNC and aspartate provide
carbons for fumarate for TCA cycle bioenergetics (Lowenstein, 1972). The impact of
removing (or buffering) the toxic ammonia product is a priority, and will be discussed in
detail in the section on ammonia removal.
1.2.4 Glycolysis and Pyruvate Oxidation
Second in speed to the ATP-PC system for ATP production is glycolysis. As
discussed by Miller (1992), glycolysis is the 10-reaction catabolism of the 6-C glucose in
the cytosol into two 3-C molecules of pyruvate. Glycolysis generates a net of two ATP
(i.e. 4 ATP created, minus 2 ATP utilized). Glycolysis is a process of energy transfers
where the phosphate is carried from substrate to ADP to ATP via the phosphate ion itself,
and thus, is termed ‘substrate-level phosphorylation’. Glycolysis does not require oxygen.
Two NADH molecules are produced, which result in six additional ATP produced by the
electron transport chain (ETC). Intense muscular activity (e.g. where exhaustion occurs in
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less than 2 minutes) accelerates glycolytic rate and produces (and utilizes) a relatively large
amount of ATP in a short period. As a potent activator of the glycolytic rate-limiting
enzyme phosphofructokinase (PFK), elevated [NH3] concentrations accelerate glycogen
depletion, ATP production, and ATP hydrolysis (Felig and Wahren, 1971; Lowenstein,
1972; Sugden and Newsholme, 1975).
Pyruvate metabolism is dependent upon ATP supply and demand. When conditions
favor pyruvate oxidation (e.g. during moderate continuous physical activity), pyruvate is
converted into acetyl-CoA by the pyruvate dehydrogenase complex (PDH) within the
mitochondria. The PDH complex is a series of the three enzymes E1 (pyruvate
dehydrogenase), E2 (lipoate acyltransferase), and E3 (dihydrolipoyl dehydrogenase). Also
termed ‘oxidative decarboxylation’, the PDH sequence is important in highly oxidative
tissue such as muscle and heart, by promoting pyruvate conversion into acetyl-CoA for
entry into the TCA cycle. The PDH complex converts the 3-C pyruvate molecule to 2-C
acetyl-CoA, NADH, releasing CO2, as summarized as follows:
PDH complex
+
Pyruvate + NAD + CoASH <==========> Acetyl-CoA + NADH + H + CO2
+

Advantages of pyruvate decarboxylation include 1) more ATP produced per unit glucose
and 2) reduced lactate, H+, and ammonia accumulation. However, a noteworthy
disadvantage is the slower rate of ATP production with pyruvate oxidation.
On the other hand, when ATP needs are accelerated during short bursts of intense
activity, hydrogens accumulate and combine with pyruvate. In this case, lactate and NAD+
form rapidly, due to the near equilibrium of lactate dehydrogenase (LDH) reaction. Lactate
may be converted back (i.e. gluconeogenesis) into 1) glucose in the liver, or 2) pyruvate by
the heart or oxidative fibers (Broberg and Sahlin, 1988). Advantages of lactate production
include 1) faster rate of ATP production and 2) the recycling of NAD+ into NADH for
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anaerobic production of ATP to continue, and 3) providing NAD+ to accept additional
hydrogens generated in glycolysis. However, the disadvantages of accelerated lactate
formation include: 1) very fast depletion of a very limited supply (~ 500g) of carbohydrate,
and 2) rapid accumulation of lactic acid, H+ and subsequent ammonia from ATP hydrolysis
– each inhibiting muscular contraction and promoting fatigue. Therefore, the responses to
accelerated glycolytic fiber activity include 1) faster production and utilization of ATP and
NADH, 2) elevated lactate and H+ production, 3) elevated ammonia (from ATP
hydrolysis), and 4) excitatory feedback activation of PFK by ammonia (Felig and Wahren,
1971; Lowenstein, 1972; Sugden and Newsholme, 1975).
1.2.5 Tricarboxylic Acid (TCA) Cycle
The primary purpose of the TCA cycle is to provide high energy reducing
equivalents (NADH, FADH2) for the electron transport chain for ATP production within
the mitochondria. Acetyl-CoA is the common entry point into the TCA cycle for
carbohydrate, fat, and protein catabolism. In this process, the 4-C TCA intermediate
oxaloacetate (OAA) condenses with the 2-C acetyl-CoA to yield the 6-C TCA intermediate
citrate. Summarizing, the TCA cycle strips the hydrogens and carbons from the acetyl CoA shell, producing:
1)
2)
3)

2 molecules of CO2
1 ATP equivalent
Eight hydrogen atoms in the form(s) of NADH and FADH2, carrying high
energy transfer potential to the electron transport chain for NAD+ and ATP
production.

1.2.6 Electron Transport Chain
In 1961, a paper by Peter Mitchell introduced the chemiosmotic hypothesis (i.e. ‘the
electron transport chain’) for the production of ATP within the mitochondria (Mitchell,
1961). The electron transport chain (ETC) is the process of ATP production within the
mitochondria utilizing the high-energy potential of the electrons of the hydrogen atoms in
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the transfer to molecular oxygen. The reducing equivalents NADH and FADH2 (produced
in various metabolic pathways) transfer this high-energy potential (Miller, 1992) across the
inner mitochondrial membrane. As described below, the energy transfers promote ATP
production at three ‘sites’, utilizing specific electron carriers, respectively. Each site
phosphorylates ADP into ATP (i.e. 'oxidative phosphorylation'), liberating a large amount
of energy.
The passage of electrons to the final carrier of oxygen occurs at three sites with
ATP produced at each. ADP is phosphorylated into ATP by electrical gradients created by
the pumping of H+ across the inner mitochondrial wall and cristae through the ATPases.
NADH electrons enter the ETC at site #1, while that of FADH2 enter at site #2. At site #3,
the electrons of NADH and FADH2 both combine with oxygen to produce ATP and H2O.
The remaining energy is released as heat. Three ATP are produced for each NADH, while
two ATP are produced with each FADH2. The electron source(s) and transfer
characteristics for each site are:
Site #1 Site #2 Site #3 -

NADH electrons are transferred to coenzyme Q by NADH
dehydrogenase (producing 1 ATP)
NADH and FADH2 electrons are transferred from coenzyme Q, to
cytochrome b, to cytochrome c1 (producing a second ATP)
NADH and FADH2 electrons are transferred from cytochrome c1, to
cytochromes c, a, a3, to oxygen (producing a third ATP, and water)

The energy released during the transfers promotes the phosphorylation of ADP into ATP,
producing H2O, and releasing heat. Oxygen is the final electron acceptor. The effects of
NH3 on the coupling of electron transport, proton gradients, and ATP production are
unknown. However, as discussed in the following paragraph, ammonia and aspartate
fluctuations may affect the malate-aspartate shuttle for reducing equivalent transport in the
ETC.
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The inner mitochondrial membrane is impermeable to NADH. To participate in the
ETC, NADH is shuttled across the membrane to site #1 or site #2 by one of two
mechanisms: 1) the malate aspartate shuttle and/or 2) the glycerol phosphate shuttle
(Miller, 1992). Site #1 of the ETC utilizes the malate aspartate shuttle to transfer electrons
from NADH to NAD+ resulting in 38 ATP from one glucose molecule. Site #2 utilizes the
glycerol phosphate shuttle to transfer electrons from NADH to NAD+, resulting in 36 ATP
from one glucose molecule. Since the site using the aspartate shuttle produces more ATP
per glucose molecule, it appears advantageous for bioenergetics to have more aspartate
available for the ETC.
Therefore, as discussed by Miller (1992) aspartate availability may enhance ETC
productivity by:
1)
2)
3)

Promoting the shuttling of reducing equivalents across the inner
mitochondrial membrane,
Producing 2 additional ATP via ETC site #1 versus site #2, and
Providing substrate for the PNC for the maintenance of total adenine
nucleotides.

1.2.7 β-Oxidation
The conversion of fat (triacylglycerol) for ATP integrates several metabolic
pathways, and culminates in the splitting of the fatty acid molecule into 2-C acetyl
fragments, NADH and FADH2 for utilization by the TCA cycle and the ETC (McArdle et
al., 1996). Although fatty acid oxidation is slower than glycolysis, the relative (and
absolute) amount of ATP produced from it is much higher (~130 ATP per 16-C palmitate)
than glycolysis. Ammonia is not a product of β-oxidation, nor are fatty acids a substrate
for glucose synthesis. However, glucose and fatty acid oxidation link ATP production. For
example, a prolonged shortage of the 4-C TCA intermediate OAA results in 1) undesirable
ketone (acetone, acetoacetate, β-hydroxybutyrate) formation from excess acetyl-CoA
buildup, and 2) decreased OAA for gluconeogenesis TCA continuity. As described by
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Brooks et al. (1996), the sequence for lipid catabolism for ATP production (beginning with
triacylglycerol cleavage) is as follows:
1)

2)
3)
4)
5)
6)

7)

Mobilization - initiation of exercise triggers a release of epinephrine,
promotes triacylglycerol breakdown (by hormone sensitive lipases, HSL)
into three fatty acids and a glycerol backbone, per triacylglycerol. Glycerol
may contribute carbons for glucose synthesis, or enter glycolysis as 3phosphoglyceraldehyde. The complete breakdown of glycerol yields 19
ATP, synthesized from substrate level phosphorylation and release of
hydrogen atoms to NAD+ with subsequent pyruvate oxidation
Circulation - free fatty acid (FFA) transport via the blood to muscle (usually
with albumin as the carrier)
Uptake - the entry of free fatty acids (FFA) into muscle
Activation - resembling the first step in glycolysis, ATP and coenzyme A
activate the fatty acid in the cytoplasm, forming fatty acyl-CoA for transport
into the mitochondria
Translocation - carnitine shuttles the fatty acyl-CoA into the inner
mitochondria
β-oxidation - a cycle where the carbons of the activated fatty acid chain (e.g,
palmitate, 16-C) are stripped away two at a time (between the first carbon
from the carboxyl end - the α; and the second carbon - the β) producing a 2C acetyl-CoA, NADH, and FADH2 per turn of the cycle. This process is
repeated until the entire carbon chain of the fatty acyl-CoA is utilized. The
final spin of the cycle (when only 2 C are left) produces acetyl-CoA only.
Combining subsequent mitochondrial oxidation (TCA cycle and ETC), each
acetyl-CoA yields 12 ATP (TCA and ETC); each NADH yields 3 ATP
(ETC); and each FADH2 yields 2 ATP (ETC). The total amount of ATP
produced, depends on the number of carbons in the fatty acid.
Mitochondrial Oxidation - the TCA cycle and ETC produce ATP from
acetyl-CoA, NADH, and FADH2. For example, the complete oxidation of a
16-C palmitate FA yields a net total of 130 ATP [(12 x 8 = 96 ATP from
acetyl-CoA) + (7 x 3 = 21 ATP from NADH) + (7 x 2 = 14 ATP from
FADH2) - 1 ATP invested for activation], or approximately 390 ATP per
palmitic triglyceride (exclusive of glycerol).

Thus, for a 16 carbon FA, the first seven cycles of β-oxidation yield:
1)
2)
3)

7 Acetyl-CoA (= 84 ATP),
7 NADH (= 21 ATP), and
7 FADH2 (= 14 ATP).

The last revolution of β-oxidation yields one acetyl Co-A (= 12 ATP), producing a total of
131 ATP, (minus 1 ATP invested for FA activation), for a net of 130 ATP per molecule of
palmitate.
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1.2.8 Amino Acids: Digestion, Bioenergetics, Ammonia, and Aspartate
Carbohydrate, fat, and protein are the primary food sources for mammals with each
providing carbons for energy (Miller, 1992). Of these, only proteins contain nitrogen,
producing ammonia from catabolism. Proteins are polypeptide chains of the 20 different
amino acids, arranged in any order, up to thousands of AA's long. AA's are composed of
carbon, hydrogen, oxygen, nitrogen, and occasionally sulfur. Each AA has four
components:
1)
2)
3)
4)

An amine group (NH2),
A carboxyl group (COOH-),
A unique side "R" chain, and
A hydrogen.

The amino group of each AA is attached to the α carbon (the carbon next to the
carboxyl carbon) of a carboxylic acid (Brooks et al., 1996). Peptide bonds attach the amine
group of one AA to the carboxyl group of another, forming long strands called proteins.
Metabolism of proteins and AA’s has several key bioenergetic characteristics, including:
1)
2)
3)
4)
5)

No significant storage pool specific for energy, analogous to storage of
glycogen or triacylglycerol
AA carbons are precursors for gluconeogenesis
AA’s catabolize to produce other AA’s
Substrate of anaplerosis for the TCA cycle (supply TCA intermediates)
Ammonia as a product.

The digestion of protein into AA’s begins in the stomach. Here, pepsin (under the
influence of HCl) splits the large protein molecules into smaller units, called polypeptides.
Proteinases and peptidases degrade the polypeptides into individual AA's in the small
intestine. AA’s are absorbed primarily by the microvilli, and transported to the liver via the
hepatic portal system. Data in laboratory animals from Neame and Wiseman (1956) and
Finkelstein et al. (1983) indicate that portal absorption of aspartic acid, for example, begins
about 10 minutes after introduction to the small intestine lumen, peaking at 30 minutes, and
remaining above resting levels for 1-2 hours. During the absorptive state, AA’s are utilized
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for hepatic protein synthesis, and conversion into triacylglycerol. In contrast to the storage
fate(s) for CHO (i.e. glycogen) and fat (i.e. triacylglycerol), there are no bioenergetic
storage depot(s) specific for protein or AA. Fates of excess digestive protein are:
1)
2)
3)

Conversion into triacylglycerol, and
Degradation into ammonia and urea by the liver, or
Degradation into ammonia by the intestinal flora by urease.

As pointed out by McArdle "all protein exists as important constituents of
metabolic, transport, and hormonal systems" (McArdle et al., 1996). During exercise,
glucagon, glucocorticoids, and catecholemines work together to catabolize proteins,
particularly muscle proteins, for energy production. AA bioenergetic activity is promoted
by:
1)
2)
3)

Glucagon and catecholemines (e.g., a high protein, low carbohydrate diet)
Glucocorticoids (severe stress, e.g. burns, exercise, trauma, surgery, disease)
Low fuel reserves.

Glucagon (released from the pancreas) promotes hepatic glycogenolysis and blood glucose
elevation. Catecholemines (released from the medulla of the adrenal glands), activate
catabolism of stored substrate (e.g. lipolysis, glycogenolysis) for energy production.
Glucocorticoids (released from the adrenal glands) cause proteins (e.g. actin, myosin) from
muscles and connective tissue to be broken down into AA’s to make glucose for energy.
The bioenergetic effect(s) of glucagon and epinephrine are more immediate than
glucocorticoids.
As illustrated below in reactions (1), (2), and (3) the two primary processes for
stripping AA carbons for bioenergetics are transamination and oxidative deamination.
Glutamate serves as a substrate (and nitrogen carrier) in all three reactions. In
transamination, the amino group of an amino acid is transferred to a keto acid, thus
producing a second amino acid and keto acid. The two major routes of transamination are
glutamate-pyruvate transaminase (SGPT) (reaction 1), and SGOT (serum glutamate-OAA
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transaminase, or aspartate aminotransferase) (reaction 2), each requiring pyridoxal
phosphate as a coenzyme. Since transamination occurs in muscle and (in particular) the
liver, both SGPT and SGOT are useful for analysis of bioenergetics and acute liver
function. Mole’ and Johnson (1971) have demonstrated elevated SGPT (also called alanine
transaminase, or alanine aminotransferase, ALT) with endurance activity, activating
alanine metabolism and production (reaction 1).
SGPT
Pyruvate + Glutamate <==========> Alanine + α-ketoglutarate
(liver)
(muscle)

(1)

As illustrated in reaction (2), the second transamination reaction, SGOT, links the
amino acid(s) glutamate and aspartate with the TCA intermediates OAA and αketoglutarate. In addition to linking bioenergetics, aspartate is a major carrier of catabolic
nitrogen to the urea cycle for excretion. The terminal nitrogen products of ammonia and
urea leave the body via sweat, the lungs, and/or diluted in urine (Czarnowski et al., 1995).
SGOT
OAA + Glutamate <==========> Aspartate + α-ketoglutarate (2)
Oxidative deamination occurs in the mitochondrial matrix, utilizing NAD+ as the
oxidizing agent. As illustrated in reaction (3), oxidative deamination assists the excretion
of amino acid nitrogen from the body. Glutamate is converted by oxidative deamination to
α-ketoglutarate and NADH, a reaction catalyzed by glutamate dehydrogenase (GDH).
NH4+ serves as the nitrogen product. In amino acid catabolism, glutamate is a common
nitrogen carrier, serving as an intermediate in both transamination (reactions 1 and 2) and
oxidative deamination (reaction 3).
GDH
H2O + Glutamate + NAD+ <==========> α-ketoglutarate + NH4+ + NADH
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(3)

Reactions 1 - 3 illustrate the concept of anaplerosis - how OAA, aspartate,
glutamate, α-ketoglutarate, and ammonia link AA metabolism, gluconeogenesis, while
regenerating TCA cycle intermediates. Aspartate is converted to OAA via transamination,
i.e. transfers the amine group to glutamate while providing the carbon backbone for OAA.
Aspartate is also converted to fumarate in the PNC, and the urea cycle, once again
providing carbons for anaplerosis. Fumarate re-enters the TCA cycle, and is converted to
OAA by TCA cycle enzymes. High ammonia levels drive the α-ketoglutarate GDH
reaction (reaction 3) toward glutamate formation, thus depleting α-ketoglutarate, an
essential TCA cycle intermediate.
AA carbon chains contribute to bioenergetics by providing the carbon backbone(s)
for pyruvate, TCA cycle intermediates, or acetyl-CoA (and derivatives). AA’s are
classified by either function (intake need) or bioenergetic point of entry. The functional
classifications are:
1)
2)
3)

Nonessential – dispensable
Essential – indispensable (mammalian cells lack enzymes to synthesize the
carbon skeletons)
Conditionally essential – essential under certain conditions (e.g. infancy)

The bioenergetic classifications are:
1)
2)

Glucogenic – AA carbon chains enter as pyruvate, or TCA cycle
intermediate(s),
Ketogenic – AA carbon chains enter as acetyl-CoA or acetoacetate

The bioenergetic entry points for glucogenic AA’s are:
1)
2)
3)
4)
5)

Pyruvate - cysteine, alanine, glycine, serine
α-ketoglutarate - glutamate, glutamine, histidine, proline, arginine
Succinyl-CoA - isoleucine, methionine, threonine, valine
Fumarate - tyrosine, phenylalanine, aspartate
OAA - asparagine, aspartate

The bioenergetic entry points for ketogenic AA’s are:
1)
2)

Acetyl-CoA - isoleucine, leucine, tryptophan
Acetoacetyl-CoA - phenylalanine, lysine, leucine, tyrosine
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Therefore, tyrosine, phenylalanine, and isoleucine are classified both glucogenic and
ketogenic, because their carbons may enter bioenergetics in either category.
FA's yield exclusively acetyl-CoA in β-oxidation; therefore, ketogenic AA (e.g.,
leucine) carbons are not a source of carbohydrate for gluconeogenesis. Gluconeogenesis
does not result from the carbons of ketogenic AA’s because: 1) the irreversible nature of
PDH prevents pyruvate formation from acetyl-CoA, and 2) the 2-C atoms of acetyl-CoA
are released as 2 molecules of CO2 in the TCA cycle, and thus are eliminated. However,
the catabolism of ketogenic AA’s also produces NADH and FADH2, thus providing high
energy reducing equivalents for ATP production via gluconeogenesis and the ETC.
Fasting, starvation, and/or prolonged exercise deplete glycogen and blood glucose
levels. In response to hypoglycemia, the body synthesizes new glucose (gluconeogenesis)
via lactate, glycerol and AA’s. Data from Mole and Johnson (1971), and Jungas et al.
(1992), indicate that ~ 60% of the ATP produced from gluconeogenesis occurs in the liver,
35% from AA oxidation in muscle and small intestine, and ~ 5% from oxidation of
acetoacetate.
Gluconeogenesis is a reversal of glycolysis, producing glucose as the end product of
pyruvate catabolism. The process is costly, requiring six ATP for the conversion of
pyruvate to glucose (compared to two ATP for glycolysis, and one ATP for β-oxidation)
(Miller, 1992). The three irreversible glycolytic enzyme(s) of pyruvate kinase, PFK, and
hexokinase are bypassed and substituted for in gluconeogenesis.
To bypass pyruvate kinase in gluconeogenesis, pyruvate is converted to
phosphoenolpyruvate in a two-reaction process, with the 4-C TCA intermediate OAA
serves as the intermediate. In the first reaction, pyruvate is converted to OAA by pyruvate
carboxylase (PCB), driven by ATP and the cofactor biotin.
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PCB
Pyruvate + CO2 + ATP <================> OAA + ADP + Pi
Biotin

(1)

In the second reaction, OAA is converted to phosphoenolpyruvate (PEP) via PEPCK,
driven by GTP:
PEPCK
OAA + GTP <==============> PEP + CO2 + GDP

(2)

Gluconeogenesis then proceeds as a reversal of glycolysis, in the process bypassing two
more irreversible glycolytic enzymes: 1) PFK by fructose 1-6 diphosphatase, and 2)
hexokinase by glucose 6-phosphatase, eventually forming glucose as the product of
gluconeogenesis.
Summarizing, beginning with pyruvate, gluconeogenesis is a reversal of the
reversible glycolytic reactions, bypassing the highly exergonic glycolytic reactions of:
1)
2)
3)

Pyruvate kinase (via pyruvate carboxylase and PEPCK);
PFK (via fructose 1-6 diphosphatase), and
Hexokinase (via glucose 6-phosphatase).

Gluconeogenesis is activated during impaired glucose availability, and/or
insufficient ATP production (by the TCA cycle and the ETC) to meet demand. Important
gluconeogenesis products (nitrogen and/or carbon) include ammonia, alanine, pyruvate,
lactate, OAA, glucose, and ATP. As noted by Stryer (1995), accumulation of acetyl-CoA
and pyruvate shifts bioenergetics in the direction of OAA formation and gluconeogenesis,
by the action of pyruvate carboxylase. Further, data in animal models (Lancha et al., 1995)
suggests that training status affects pyruvate carboxylase activity. For example, in
response to high-intensity exercise, pyruvate carboxylase activity is higher in untrained
(12x vs. rest) rat soleus versus trained (3x vs. rest). This suggests a glycogen sparing effect
with training, in contrast to a greater rate of gluconeogenesis (versus β-oxidation) with
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reduced training. Therefore, lesser-trained subjects exhibit higher exercising blood
ammonia values, due in part to accelerated activity of BCAA catabolism for
gluconeogenesis.
The branched chain AA's leucine, valine, isoleucine constitute a large percentage
(20 - 30%) of dietary protein. During exercise, BCAA’s are the primary AA's recruited for
oxidizable substrate, and are catabolized more readily in peripheral tissues such as skeletal
muscle, heart, adipose tissue, and kidney. On the other hand, human intestine and the liver
have low levels of BCAA transaminase activity and BCAA keto acid dehydrogenase
complex (Taniguchi et al., 1996).
Breakdown of BCAA’s results in additional substrate (ketogenic and glucogenic)
for energy, and as such, results in comparatively higher blood ammonia levels (Darmaun
and Dechelotte, 1991) versus that say, of glycolysis or β-oxidation, because of the
metabolism of the nitrogen skeleton. Working muscle releases the nitrogen component
primarily in the form(s) of the amino acid(s) glutamine and alanine. BCAA catabolism
begins with the transamination of the BCAA (leucine, valine, isoleucine) reacting with αketoglutarate, producing the following bioenergetic branched chain keto acid(s):
1)
2)
3)

HMG-CoA, then acetoacetate and acetyl-CoA (via leucine)
Propionyl-CoA, then succinyl-CoA (via valine)
Propionyl-CoA and acetyl-CoA (via isoleucine)

BCAA catabolism also yield(s) NADH and FADH2 via gluconeogenesis and the
TCA cycle, thus providing high energy reducing equivalents for the ETC and ATP
production. However, catabolism of the purely ketogenic BCAA leucine yields 2 carbon
atoms (as acetyl-CoA), which are eventually released as CO2 in the TCA cycle. Valine and
isoleucine are both precursors to propionyl-CoA (a substrate for the TCA intermediate
succinyl-CoA) and thus enter gluconeogenesis via OAA. However, catabolism of
isoleucine yields both propionyl-CoA and acetyl-CoA, and therefore is both ketogenic and
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glucogenic. Valine, yielding exclusively succinyl-CoA as a product, is purely glucogenic.
Ketogenic AA’s are not a source of glucose via gluconeogenesis for two reasons: 1) the
irreversible nature of PDH prevents pyruvate formation from acetyl-CoA, and 2) the 2-C
atoms of acetyl-CoA are released as two CO2 in the TCA cycle, thus leaving no remaining
carbons for gluconeogenesis.
The transfer of carbons between alanine and pyruvate between muscle and liver is
termed the glucose-alanine Cori Cycle. The Cori Cycle links gluconeogenesis,
alanine/pyruvate transamination, and liver and muscle bioenergetics (Babij et al., 1983;
Eriksson et al., 1985). This process assists the transport of glucogenic carbons back to
working muscle, while also serving as a nitrogen reservoir and buffer for elevated ammonia
(Jungas et al., 1992). During exercise, the transamination of pyruvate into alanine in
muscle via SGPT (i.e. alanine aminotransferase) elevates alanine in proportion to exercise
intensity, duration, and BCAA catabolism (equation (1)) as follows:
SGPT
Pyruvate + Glutamate <==========> Alanine + α-ketoglutarate
(liver)
(muscle)

(1)

Alanine is the primary carrier of nitrogen and carbon atoms to the liver for the
bioenergetic transfer to pyruvate. In the liver, alanine is transaminated (via SGPT) back to
pyruvate (glutamate serving as the nitrogen carrier), which may be transported back to the
working muscle for energy.
AA catabolism for energy production yields ammonia as a direct product, and
therefore, contributes to both exercise hyperammonemia and OAA depletion (by draining
the precursor α-ketoglutarate). This is important, because catabolism of glucogenic AA’s
characteristically provide the carbon backbone for pyruvate or TCA cycle intermediates (αketoglutarate, succinyl-CoA, fumarate, OAA), while ketogenic AA’s provide bioenergetic
carbons for acetyl CoA (or derivatives). In situations of excessive ammonia production,
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such as during high-intensity exercise and/or elevated AA catabolism, draining of the TCA
intermediate α-ketoglutarate occurs in the process of glutamate (α-ketoglutarate + NH3 <=>
glutamate) and glutamine (glutamate + NH3 <=> glutamine) production (Goldstein, 1976;
Levin et al., 1969; Tannen, 1978).
Thus, hyperammonemia and α-ketoglutarate availability limit the desirable
production of OAA by the TCA cycle. Further, Ohira et al. (1987) demonstrated that
aspartate aminotransferase activity increases with exercise. Therefore, aspartate
aminotransferase activity assists OAA homeostasis for maintenance of TCA cycle
continuity and efficiency. Additionally, concerning training status, Miller et al. (1987)
demonstrated lower aspartate levels with exhaustive exercise and lack of training,
indicating regulation of performance by aspartate availability. Further, Lancha et al. (1994)
demonstrated with exhaustive exercise in trained and untrained rats supplemented with
aspartate and asparagine, a three-fold greater conversion (vs. placebo) of acetyl-CoA and
OAA into citrate and coenzyme-A. In another study, Lancha et al. (1995) demonstrated
increased plasma aspartate, glycogen content, FFA’s, and prolonged (+42%) swim time to
exhaustion with supplementation of aspartate, asparagine, and carnitine. These data
suggest that OAA and aspartate metabolism link exercise performance, training, and
aspartate supplementation by promoting efficiency of TCA cycle bioenergetics with
continuity of glycolysis, β-oxidation, and gluconeogenesis.
1.2.9 Ammonia Removal: Glutamine, Alanine, Urea Cycle, Pyrimidines
Minor fluctuations in blood ammonia concentration are a normal response to
digestion, mild-moderate muscular contraction, and/or elevated AA catabolism (e.g.
BCAA’s). However, as blood ammonia rises to levels observed in clinical
hyperammonemia and intense exercise (> [100 µM/L]), the risk increases for impaired 1)
clinical status, 2) metabolic function, and 3) exercise performance. It is therefore desirable
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to reduce excess blood ammonia as quickly and efficiently as possible. The following
sections summarize the major biochemical mechanisms for the removal of blood ammonia
for homeostatic maintenance.
The physiological and nutritional state of the individual affects the flow of carbons
(for ATP production) and nitrogens, and the subsequent clearance of waste products such
as ammonia. The amino acid(s) glutamine and alanine are the major metabolic depots of
ammonia in muscle and blood during exercise (Nurjhan et al., 1995). Both assist the
reduction of hyperammonemia, by transporting nitrogen and ammonia in a less-toxic form
between the working muscle and liver. While alanine is the major transport form of
glucose to and from muscle and the liver, glutamine is the major AA carrier of nitrogen out
of muscle, in response to elevated intramuscular ATP and AA metabolism. An increase in
blood glutamine concentration and changes in pH promote a shift in glutamine synthetase
to produce ammonia in vitro (i.e. glutamine => glutamate + NH3). According to Tannen
(1978), the amide groups of glutamine account for 30 - 40% of the NH3 excreted in the
urine.
The shifting of the reversible glutamine synthetase (glutamate + NH3<=>
glutamine) to the right indicates excessive ammonia in the form of muscle, plasma, or
blood glutamine (Babij et al., 1983; Duda and Handler, 1957; Eriksson et al., 1985).
During exercise, as ammonia levels rise and arterial glutamate declines, working leg
muscles exhibit a significant glutamate uptake -- promoting a rise in muscle and blood
glutamine concentration (Babij et al. 1983; Dudley et al., 1983; Eriksson et al., 1985). In
addition, the transamination of α-ketoglutarate to glutamate (α-ketoglutarate + NH3 <=>
glutamate) supplies additional glutamate substrate for glutamine formation. Therefore,
hyperammonemia and the associated glutamate and glutamine sinks drain the TCA
intermediate α-ketoglutarate of carbons, and as suggested by data from Lancha et al.
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(1994), suggests reduced aspartate and OAA availability with exhaustive exercise, thus
inhibiting TCA cycle continuity and athletic endurance.
The primary metabolic pathway for the detoxification of blood ammonia is urea
production in the liver by the Krebs-Henseleit urea cycle (Krebs and Henseleit, 1932;
Onstad and Zieve, 1979). Urea cycle activity is promoted by elevated concentrations of
blood ammonia. The purpose of the urea cycle is to convert (the more toxic) ammonia into
(the less toxic) urea for dilution and excretion by the kidneys. The urea cycle becomes
more active during exercise, to clear elevated blood ammonia into urea nitrogen to preserve
metabolic function. Ammonia enters the urea cycle by reacting with HCO3- and two ATP
to form carbamoyl phosphate (Katunuma et al., 1966). Carbamoyl phosphate donates the
NH3 component as inorganic nitrogen to the urea cycle, while aspartate donates the amino
nitrogen while releasing the carbon chain as fumarate. Carbamoyl phosphate then reacts
with ornithine to form citrulline (Grossi et al., 1967). Citruilline reacts with incoming
aspartate (which donates a nitrogen group, and carries the carbons for fumarate) to form
argininosuccinate, producing arginine and fumarate (Briggs and Freedland, 1976).
Arginine is cleaved into ornithine and urea, while fumarate is utilized as a substrate in the
TCA cycle. Ornithine may combine again with carbamoyl phosphate from ammonia entry,
while the less toxic urea (versus that of ammonia) is transported to the kidneys for dilution
and excretion in the urine.
Urea synthesis is controlled by the concentration(s) of urea cycle intermediates, and
activity of the enzymes carbamoyl phosphatase, argininosuccinate synthetase, and arginase
(Buttery and Roswell, 1974; Katunuma et al., 1966; Kramer and Freeland, 1972; Ratner,
1975). Laboratory data indicates that argininosuccinate synthetase has the lowest activity
of the urea cycle enzymes (Briggs and Freedland, 1976; Brown et al., 1959; Freedland and
Sodikoff, 1962). Together with citrulline accumulation and low concentrations of
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succeeding intermediates (argininosuccinate and arginine), these data suggest a limiting
rate of argininosuccinate synthetase activity under conditions of hyperammonemia (Brown
et al., 1959; Buttery and Roswell, 1974; Ratner, 1975).
At rest, protein intake and urea cycle activity are the controlling factors for blood
NH3 levels (Levin et al., 1969). However, during intense exercise decreased hepatic blood
flow up to 30% - 70% below normal data (Rowell et al., 1964) and enzyme limitation
(Cohen, 1981) restrict urea production (Ferreira et al., 1998). Therefore, urea production is
reflective of blood ammonia levels, removal capacity (and efficiency) of the urea cycle, and
the physiological state and efficiency of the individual. Progressive symptomatic
complications of hyperammonemia result, if ammonia remains highly elevated for
prolonged periods.
Clinical studies of hyperammonemia (Batshaw, 1984; Maestri et al., 1996) reveal
that additional ammonia detoxification pathways assist the urea cycle for conversion of
ammonia into less toxic compounds for excretion. For instance, these pathways are
recruited with high ammonia levels produced by 1) excess protein intake, and/or 2)
insufficient urea cycle conversion of ammonia into urea. In particular, formation of serial
glutamine (glutamine synthetase) and urinary pyrimidines (e.g. hippurate,
phenylacetylglutamine, and orotic acid) assist the urea cycle to clear ammonia. In
response, the urinary pyrimidine products of orotic acid, uridine, and uricil are elevated
(Levin et al., 1969). As noted by Visek (1982), ‘the quantity of orotic acid in the urine of
rats and man is inversely related to the capacity of the organism for urea synthesis’.
Further, data from Visek (1979) demonstrate that orotic acid formation by intoxication with
ammonium salts is reduced if animals are pretreated with ornithine, citrulline, or arginine.
In addition, Milner and Visek (1974) showed that orotate excretion tends to increase as the
percentage of dietary arginine decreases. Thus, medical clinicians suspect urea cycle
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defects or insufficiency when, in the resting state, excessive amounts of ammonia,
glutamine, and pyrimidine metabolites are excreted indicating saturation of the Km of urea
production. On this note, clinical data from Batshaw (1984) and Maestri et al. (1996) have
shown drops in mortality due to hyperammonemia with acute administration of lactulose,
sodium benzoate, or sodium phenylacetate to enhance pyrimidine production. However,
there are no published reports to date concerning lowering of EIH by sodium benzoate or
lactulose, while only one paper to date (Eto et al., 1994) has investigated the effects on
blood ammonia during exercise following administration of glutamate (with arginine).
Results of this study showed blood ammonia was significantly lower, by up to 40%, during
steady-state exercise at ~ 75% VO2max following ingestion of 20 grams of a glutamatearginine salt in healthy young adult males.
1.2.10 Summary
The rise in blood ammonia concentration is a normal response to exercise and
elevated AA catabolism (e.g. BCAA’s). However, it is apparent that as blood ammonia
levels rise to that observed in clinical hyperammonemia (> [100 µM/L]), the risk increases
for undesirable metabolic function and impaired clinical status. Therefore, it is desirable to
lower and/or remove excess ammonia as quickly and efficiently as possible. Ammonia and
aspartate link ATP hydrolysis, AA bioenergetics, and urea metabolism, summarized as
follows:
1)
2)
3)
4)
5)

NH3 is a by-product of ATP hydrolysis, AA catabolism, and urea formation
Aspartate is a substrate in the PNC for AMP resynthesis, promoting desirable
maintenance of total adenine nucleotides (AMP + ADP + ATP)
Aspartate shuttles high-energy equivalents into the inner mitochondria for
ATP production via the electron transport chain
The PNC and urea cycle both utilize aspartate to produce the anaplerotic
TCA intermediate fumarate
Aspartate is an amino nitrogen donor and substrate in transamination, the
PNC, and the urea cycle.
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1.3 Blood Ammonia Response to Exercise
In apparently healthy individuals, resting fasting blood ammonia levels are
normally < 50 µM/L (Batshaw, 1984). Strenuous physical activity may elevate blood
ammonia concentrations 10-fold and higher, both during and following the period of
contraction. Values observed during intense exercise are often well above the minimum of
[100 µM/L] for the interpretation of clinical hyperammonemia (Bessman and Bradley,
1955; Katz et al., 1986; Rennie et al., 1981). As reviewed recently by Yuan and Chan
(2000), the major bioenergetic sources for NH3 during exercise are AMP deaminase, PNC
activity, and/or catabolism of branched chain amino acids (BCAA's). Though muscular
ammonia concentrations are several-fold higher versus that of blood ammonia during
intense exercise, it is unclear whether the difference reflects primarily the accelerated
production in muscle, insufficient intramuscular buffering, or impairment in serial
clearance (e.g. restricted hepatic conversion to urea).
Table 1.2 lists various factors that affect blood ammonia concentrations in clinical
situations and in response to exercise. Blood levels of ammonia and lactic acid follow
similar courses during various levels of exercise intensity. Well-documented phenomena,
each is produced (more predominantly) in fast-twitch Type IIb skeletal muscle fibers vs.
Type I fibers (Banister, 1983; Banister et al., 1985; Meyer and Terjung, 1979). Blood
lactate and ammonia are moderately correlated (r = .6 - .82) during high-intensity work (>
70% VO2max) (Babij et al., 1983; Buono et al., 1984; Eriksson et al., 1985). Further, Buono
et al. (1984) noted a strong correlation (r = .96) between the alinear rise in blood ammonia
and the lactate anaerobic threshold. During intense exercise, blood ammonia
concentrations rise 4 to 20 fold, usually reaching ~ 100 - 500 µM/L at exhaustion (Banister
et al., 1983; Katz et al., 1986; Wilkerson et al., 1977).
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Table 1.2. Factors affecting blood ammonia levels.

Factor
Gender
Modality

[NH3] change
Male > Female
Bike > Treadmill

Exercise Duration

↑

Exercise Intensity
Endurance Training
FT vs. ST Fibers

↑
↓ (training specific)
FT > ST

High PRO Diet

↑

Ambient Heat
Arm training
Leg training
Creatine Loading
β-blockade
Urea Cycle Disease
McArdles Disease
BCAA ingestion
Urea Cycle Substrate
Supplementation
Urea Cycle Substrate
Supplementation
Urea Cycle Substrate
Supplementation
Carnitine
Supplementation
Benzoate
Aspartate
Supplementation
Zinc Supplementation

↑
↓ (training specific)
↓ (training specific)
↓
↑
↑
↑
↑
No change

Reference(s)
Derave et al. (1997)
Bouckaert and Pannier (1995)
Wilkerson et al. (1975)
Brouns et al. (1990),
Graham et al. (1995a)
(Table 1.2 continued)
Hegeloch et al. (1990)
Graham et al. (1997)
Gerez and Kirsten (1965)
DuRuisseau et al., (1956)
Winder et al. (1974)
Czarnowski et al. (1995) Jungas
et al. (1992)
Snow et al. (1993
Nelson (unpublished data)
Nelson (unpublished data)
Greenhaff et al. (1993)
Jensen-Urstad et al. (1993)
Lockwood et al. (1979)
Wagenmakers et al. (1990)
Calders et al. (1997)
Edwards and Day (2000)

↓ (clinical)

Greenstein et al. (1956)

↓ (clinical)

Grossi et al. (1967)

↓
↓
↓

Costell et al. (1984)
Sarhan et al. (1994)
Kubota and Ishizaki (1993)
Kendrick (1976)

↓

Riggio et al. (1992)

On the other hand, immediately following intense exercise blood ammonia
concentrations are more variable versus lactate (Babij et al., 1983; Buono et al., 1984;
Meyer and Terjung, 1979; Schwartz et al., 1958). Blood NH3 may rise, stabilize, or decline
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rapidly versus the well-known lactate rise following intense exercise (Banister et al., 1983;
Schwartz et al., 1958; Wilkerson et al., 1977). NH3 clearance is affected by specificity of
training, status of conditioning, terminating intensity, and exercise duration. In general, a
more efficient metabolic state (i.e. a higher level of state of training) lowers blood
ammonia concentration at submaximal exercise intensities, enhances ammonia reduction
during recovery, and enhances performance (Graham et al., 1997). Concerning training
status and blood ammonia concentrations, Graham et al. (1995a) and Graham et al. (1997)
note that highly-trained subjects exhibit:
1)
2)
3)
4)

Lower blood ammonia at a given exercise intensity (vs. untrained),
Faster clearance following exercise,
Longer endurance at a given ammonia level, and
Longer time (vs. untrained) to reach a given ammonia blood level at
exhaustion.

1.4 Physiological Impact of Elevated Ammonia
Several physiological, metabolic, and nutritional factors mediate blood ammonia
levels. For example, the following raise blood ammonia concentration:
1)
2)
3)
4)
5)
6)
7)

Increasing exercise intensity (i.e. increasing AMP deaminase, PNC activity)
(Hellsten et al., 1999),
Male gender (versus females) (Lynch et al., 2000),
Glycogen depletion (Broberg and Sahlin, 1988),
High protein/low carbohydrate diet (i.e. ammonia produced by gut flora
urease, BCAA metabolism) (Greenhaff et al., 1991; MacLean et al., 1992;
Snow et al, 2000),
Heat (Snow et al., 1993),
β-blockade (Jensen-Urstad et al., 1993), and
BCAA ingestion (MacLean et al., 1996).

Further, as reviewed by Mutch and Banister, (1983), ammonia is produced endogenously in
the brain due to the GABA cycle and the deamination of brain catecholemines, and as
suggested by data from Cooper et al. (1979) and Lockwood et al. (1979) NH3 may cross the
blood brain barrier. Additional data from Hindfelt (1983), Lockwood et al., (1979), and
Najarian et al. (1958) indicate that elevated brain ammonia affects energy metabolism and
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leads to mental confusion, ataxia, convulsion, and cramps in both animals and man. With
prolonged exertion, and/ metabolic and contractile stimuli blood ammonia levels rise, and
fatigue results. Fatigue is generally agreed to be due to a variable combination of 1) a
depleted substrate supply (i.e. ATP, phosphocreatine, glycogen, glucose), 2) accelerated
undesirable metabolite (e.g. lactate) and waste (CO2, NH3, H+) formation, and 3) disruption
of central nervous system function (e.g. buildup of tryptophan and seratonin).
Figure 1.1 highlights the deleterious effects of hyperammonemia. The
cascading deleterious effects of ammonia on exercise metabolism are largely a result of
a lack of training coupled with accelerated sympathetic discharge. For instance,
epinephrine, cortisol, and/or hypoxia increase ammonia output, in part, because of the
catabolism of the protein/AA content (i.e. muscle proteins, BCAA’s, aspartate) of the
tissue (Goodman and Lowenstein, 1977) to keep up with ATP demand. The major ratelimiting enzyme of glycolysis, phosphofructokinase (PFK), is inhibited by
physiological levels of ATP at acidic pH values (Lowenstein, 1972; Mutch and
Banister, 1983), but, is stimulated by [NH3]. Work by Felig and Wahren (1971),
Lowenstein (1972), and Sugden and Newsholme (1975) indicate that stimulation of
PFK by ammonia occurs without a change in pH, thus increasing the availability of
pyruvate for the pyruvate/alanine cycle which further depletes glycogen and glucose.
Ammonia further inhibits liver mitochondrial respiration (and citrate and
isocitrate oxidation). Data from Katanuma et al. (1966) and Brylla and Nidzwiecka
(1979) indicate that NH3 accumulation inhibits both pyruvate carboxylation and
decarboxylation - the initial steps in 1) gluconeogenesis, and 2) the conversion into
acetyl Co-A for TCA entry via glycolysis, respectively. Thus, elevated blood ammonia
accelerates non-oxidative carbohydrate metabolism for ATP production, as well as
inhibiting oxidative ATP production.
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CNS toxicity may
result if prolonged

Symptoms include
dizziness, ataxia,
dyspnea

Strong link with
physiological fatigue

HYPERAMMONEMIA
Blood [NH3] > 100uM/l

Inhibits
muscular
contraction

Increases
phosphofructokinase
activity

Figure 1.1. Deleterious effects of hyperammonemia.
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Ammonia flux thus affects the ATP/ADP ratio, acid base balance, glycolytic
activity, pyruvate carboxylation and decarboxylation, and tricarboxylic acid cycle
activity (Banister et al., 1985; Hindfelt, 1983; Lowenstein, 1972). Further, ammonia
increases VE, and contributes to hyperventilation (Hindfelt, 1983; Mutch and Banister,
1983). Mechanisms include elevated activity of respiratory muscles, and/or direct
stimulation/interference of humoral input to the respiratory center (Hindfelt, 1983;
Mutch and Banister, 1983). Ammonia is a weak base, and reacts reversibly with H+ to
+

produce ammonium (NH3 + H

<=> NH4+). Exercising muscle retains up to 90% of

NH3 within the muscle cell as NH4+ (Katz et al., 1986; Rosado et al., 1962). The
cellular membrane is highly permeable to NH3, but has a poor permeability to NH4+.
Thus, the release of NH3 into the circulation is associated with a net loss of hydrogen
ions (Katz et al., 1986). As demonstrated by Heald (1975), it appears desirable to
reduce high levels of intramuscular ammonia to maintain electrical excitability and
tension of individual muscle fibers.
Historically, as reviewed by Lantigua et al. (1980) and Felig (1984), concerns have
arisen over the adverse effects (e.g. ‘electrocardiographical abnormalities’, ‘serious
arrhythmias’, and ‘cardiac disturbances’) in 3 of the 6 cases precipitating death, from
accompanying nutritional hyperammonemia in those on high liquid protein diets. Despite
the high rate of success for achieving weight reduction, results from these cases indicate
that those on very low calorie (< 500 kcal per day) protein diets utilizing a base protein
with very low biological value (e.g. collagen hydrosylate) are at an even higher risk for
adverse consequences. According to Felig (1984), in the 1970’s when liquid-protein diets
were the rage for the ‘over the counter’ treatment of obesity, 60 deaths were reported in
over 100,000 participants using this protein as the primary source of nutrition. Further
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inspection by Isner et al. (1979) found that in (at least) 17 of the cases, use of the liquid
protein (with low biological value) diet for two months was implicated as the basis for the
ventricular arrhythmias that precipitated death. Further, in some of these cases, extended
hyperammonemia was considered a precipitating factor exacerbating adverse metabolic
effects. According to Jackson (1999), the most toxic of the individual amino acids is
methionine; and, the adverse effects of methionine are more evident on a low protein diet
than with adequate protein intake. Furthermore, data from Riggio et al. (1992) suggests a
link between zinc deficiency and impairment of the urea cycle enzyme ornithine
transcarbamylase. Thus, the lack of dietary zinc inherent in a low protein diet reduces the
efficiency of ammonia removal. Therefore, the potential for hyperammonemia (and
associated adverse effects) increases with elevated protein intake, and especially in those
on low calorie diets using a higher percentage of protein. In these situations, it is apparent
that the use of a protein with high biological value is of greater importance, as is
consideration of supplementation with minerals and ammonia reducing amino acids (e.g.
aspartate, arginine, ornithine, citrulline).
1.5 Impact of Reducing Hyperammonemia: Clinical Trials and Exercise Trials
1.5.1 Clinical Trials
Historically, treatment for reducing clinical hyperammonemia (Batshaw, 1984;
Najarian et al., 1958) targets:
1)
2)
3)

Inhibition of bacterial urease (i.e. neomyocin),
Supplementation with ammonia reducing amino acid(s) in the pathways of
transamination (glutamate therapy, i.e. NH3 + glutamate <=> glutamine) and
urea synthesis (e.g. aspartate, arginine, and ornithine), and
Administration of agents (e.g. sodium benzoate, phenylacetate, lactulose) to
enhance pyrimidine synthesis (e.g. orotic acid).

Current clinical methods to lower hyperammonemia (i.e. in cases of hepatic
encephalopathy) include 1) restricting dietary protein intake, 2) enhancing the
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detoxification reactions in the body (transamination, urea cycle, pyrimidine production)
(Levin et al., 1969; Mutch and Banister, 1983), and 3) correcting the metabolic etiology. In
humans, administration of up to 25 grams of arginine, ornithine, glutamate, and/or benzoate
reduces clinical hyperammonemia (CH) and associated symptoms (Artz et al., 1958;
Najarian et al., 1958; Strauven et al., 1976). Clinical settings currently utilize ammoniareducing amino acid(s) (e.g. aspartate, ornithine, glutamate, and arginine) in combination
with metabolic agents (i.e. sodium benzoate, carnitine, and lactulose) to significantly and
consistently reduce CH and hepatic encephalopathy and improve prognosis. The following
paragraphs discuss the rationale and clinical impact of reducing hyperammonemia and
treating fatigue with supplementation of ammonia reducing (and/or urea producing) amino
acids.
The addition of the urea cycle intermediate(s) arginine or ornithine in vitro
accelerates urea formation in liver slices (Krebs and Henseleit, 1932; Kubota and Ishizaki,
1993). In clinical trials, Fahey (1957) and Fahey et al. (1958) further demonstrate that
administration of arginine (or other urea cycle intermediates such as ornithine, citrulline,
aspartate) eliminates NH3 accumulation and the associated toxic effects (death,
convulsions). Data in laboratory animals from Winitz et al. (1956) and Salvatore et al.
(1964) show that elevations in blood ammonia and urea accompany a lethal dose of
ammonium acetate, and, the toxic effects are removed once arginine, ornithine, and/or
aspartate are administered. Fahey (1957) and Fahey et al. (1958) demonstrated in humans
that administering an essential amino acid (AA) infusion that lacked arginine and histidine
exacerbated CH in patients without 'any evidence of liver disease'. Further, the associated
symptoms of hyperammonemia – (e.g. nausea and retching) were reduced or eliminated
when L-Arginine, L-Ornithine, or L-Citrulline were added at a molar concentration of 1-
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2%. L-Ornithine appeared to be equally as effective as L-Arginine, L-Citrulline slightly
less effective, while D-Arginine and L-Glutamate had no protective effect.
These cases illustrate that the severity of clinical hyperammonemia and associated
symptoms are reduced when the L-amino acids in the urea cycle are supplemented in an
AA infusion. As shown by Fahey et al. (1958), when no urea cycle substrate is
supplemented in an AA infusion, AA’s peak immediately after infusion, blood ammonia
peaks 2 hours after, and plasma urea peaks 4 hours after. However, when the infusion
includes urea cycle L-AA’s (such as L-Arginine), 1) the alpha amino changes are not
altered, 2) urea peaks earlier, and 3) ammonia does not rise at all (Fahey et al., 1958).
Further, the administration of amino acids whose metabolism is outside of the urea cycle
(e.g. BCAA's) exhibit little or no effect toward the reduction of ammonia, and in fact, some
AA’s raise NH3 levels and exacerbate associated symptoms further (Fahey, 1957; and
Fahey et al., 1958).
Clinical studies in the 1950’s and the early 1960’s revealed improvements in
clinical prognosis of hyperammonemia following administration of aspartate and/or urea
cycle intermediates. Shortly thereafter, aspartate supplementation was found effective for
the clinical treatment of fatigue (New drugs and Spartase, 1963). Prescribed initially in a
dosage of 1g x BID for the management of fatigue syndrome (New drugs and Spartase,
1963), the theoretical basis for aspartate treatment is to provide additional substrate to the
urea cycle, enhancing the clearance of the more toxic metabolic ammonia into the less toxic
urea, and thus improve clinical outlook. The following series of papers trace the
development of aspartate supplementation for the treatment of clinical fatigue.
In a 4-week double-blind study by Shaw et al. (1962), 57 patients complaining of
fatigue without demonstrable organic disease received potassium and magnesium
aspartates, while 28 similar patients received a placebo. By the end of the study, 49 of the
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57 patients (86%) receiving aspartates noted improvement both during the day and after a
full day’s schedule, compared to 7 of 28 (25%) with placebo. Response in the
experimental group generally took about 4 days to take effect.
Fornica (1962) conducted a placebo-controlled study involving 84 women and 16
men with persistent tiredness believed to be unrelated to depression. Some of the patients
had been symptomatic for more than two years. Aspartate was administered to 6% of the
group for 2 weeks, and to 68% for 4-6 weeks. The remaining 26% received placebo. A
positive therapeutic response developed gradually over 4 - 10 days in 87% of the aspartate
treated patients. After 4-6 weeks, most improved patients stopped the supplements and
continued to do well.
Hicks et al. (1964) conducted a double-blind study of 145 patients, whose fatigue
had a variety of bases, including anxiety neuroses, gastrointestinal disturbances,
menopause, the postpartum period and fatigue as a sequel to influenza. Of those, 85% of
those given potassium and magnesium aspartates reported an increase in strength or
physical activity compared to only 9 % of patients on the placebo.
In conclusion, as reviewed by Gaby (1982), clinical trials have shown that in nearly
3,000 patients, 75-91% experienced pronounced relief of fatigue with supplements of
potassium and magnesium aspartate. In general, one gram of aspartate daily improves
prognosis from clinical fatigue within 4 - 10 days of supplementation. Therefore, results
from these studies suggest that 1 gram QD of aspartate is generally effective in the
treatment of clinical fatigue.
1.5.2 Exercise Trials: Introduction
It is well documented that physical activity elevates blood ammonia (Parnas, 1929;
Wilkerson et al., 1975; and Edwards and Day, 2000;). Exercise-induced hyperammonemia
(EIH) is detrimental to short-term maintenance of optimal high-intensity physical function
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and performance (Heald, 1975; Washio and Mashima, 1963). Historically, clinical therapy
for hyperammonemia has utilized administration of urea cycle intermediates (i.e. arginine,
ornithine, aspartate), glutamate, and conjugated conversion (e.g. via administration of
sodium benzoate, lactulose) of ammonia into urinary pyrimidines (Kubota and Ishizaki,
1993). Despite clinical success for reducing hyperammonemia by the intake of ammoniareducing amino acids in the urea cycle (e.g. arginine, ornithine, aspartate, citrulline), only a
handful of investigations report the possible performance enhancement of these in healthy
populations. Exercise studies show little or no effect (Denis et al., 1991; Eto et al., 1994;
and Edwards and Day, 2000) for reducing EIH, and no effect on performance
enhancement, with supplementation of ammonia-reducing amino acids in the urea cycle.
On the other hand, animal studies report success with aspartate supplementation to
improve exercise performance; however, reproduction of results is inconsistent. The most
popular theory for performance enhancement is that aspartate supplementation reduces
blood ammonia accumulation during exercise (Washio and Mahima, 1963; Heald et al.
1975; and Mutch and Banister, 1982). However, as presented in Table 1.3, the anaplerotic
roles of aspartate may provide clues for the mechanisms of how aspartate supplementation
improves exercise performance. These include 1) contributing carbons to the TCA cycle
(i.e. OAA, fumarate), and/or 2) contributing metabolic substrate (aspartate) for the PNC
(i.e. AMP maintenance) and transamination (i.e. carbon and nitrogen transfer).
Overall, methodologies, biochemical mechanisms, and target groups for aspartate
supplementation for performance improvement are not established. Animal studies are
presented in Table 1.4, and are discussed in Section 1.5.3; human studies are presented in
Table 1.5, and discussed in Section 1.5.4. An overall summary and conclusions from the
animal and human studies is presented in Section 1.6.
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Table 1.3. Anaplerotic roles of aspartate.
Metabolic
Pathway(s)
Oxidative
deamination
Transamination
Urea Cycle
Malate/Aspartate
Shuttle

Purine nucleotide
cycle

Aspartate Role
Carbons for OAA

Key Enzyme(s)
GDH

Transfer of amino
group to glutamate
Substrate

SGOT
Argininosuccinate
synthetase
NADH
dehydrogenase

Shuttle NADH
across inner
mitochondrial
membrane in the
ETC
Substrate

Bioenergetic
Result______
↑ [OAA]
↑ sparing of
α-ketoglutarate
↓ [NH3]
↑ [Fumarate]
↑ ETC
efficiency
↑ [ATP]

Adenylosuccinate
synthetase
AMP deaminase

TAN
maintenance
↑ [Fumarate]
AMP
regeneration
SGOT – serum glutamate oxaloacetate transaminase; OAA – oxaloacetate
GDH – glutamate dehydrogenase; NADH – nicotinamide adenine dinucleotide
ETC – electron transport chain; ATP – adenosine triphosphate;
AMP – adenosine monophosphate

1.5.3 Exercise Trials: Animal Models
Table 1.4 summarizes the studies of aspartic acid supplementation to improve
performance in animals. The first reported study of aspartic acid supplementation for
exercise performance in either animals or man was conducted by Laborit et al. (1958). In
this study, administration of aspartic acid prolonged swim time to exhaustion in rats while
lowering blood NH3, which indicated that exhaustion was related to the level of blood NH3.
Additional animal studies have shown blood ammonia reduction and performance
enhancement with dosages up to 500 mg/kg (Barnes et al., 1964; Kendrick, 1976; Glass et
al., 1994). However, above this amount, the beneficial effect (i.e. reducing
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Table 1.4. Summary of studies of L-Aspartic Acid and performance in animals.

Group
Rats
Rats
Rats
Rats/ dogs
Rats
Rats

Rats
Rats

Protocol
Swim to
exhaustion
Swim to
exhaustion
Swim to
exhaustion
Swim to
exhaustion
Swim to
exhaustion
Swim to
exhaustion

Swim to
exhaustion
Swim to
exhaustion

Rats

Swim to
exhaustion

Rats

Swim to
exhaustion
Swim to
exhaustion

Rats

Dosage (daily)
50 mg/kg

Performance
↑

1000 mg/kg

↑

500 mg/kg

↑

500-2000
mg/kg
12.5 mg/kg

no change

12.5 mg/kg

↑

125 mg/kg
250 mg/kg
1000 mg/kg

↑
no change
↓

1000 mg/kg

no change

6.25 mg/kg

↑

12.5 mg/kg
100 mg/kg
45 mg/kg each
aspartate,
asparagine,
carnitine
200 mg/kg

↑
↑
↑

500 mg/kg

↑

40

↑

↑

Reference
Laborit et al.
(1958)
Rosen et al.
(1962)
Barnes et al.
(1964)
Matoush et al.
(1964)
Kendrick (1976)
Tangsakul
(1977)

Trudeau and
Murphy (1993)
Glass et al.
(1994)
Lancha et al.
(1995)
Nichols et al.
(1998)
Winters et al.
(1998)

hyperammonemia and/or enhancing performance) appears to taper off, and then have no
benefit at all, with dosages equaling or exceeding 1000 mg/kg (Matoush et al., 1964;
Tangsakul, 1977; and Trudeau et al., 1993). Results from the animal studies are discussed
in the next paragraph in chronological order.
Rosen et al. (1962) investigated the effects of aspartate administration on two
groups of 40 untrained male rats swimming to exhaustion in 29 degrees C water. Results
showed that 1000 mg/kg aspartate administration increased time to exhaustion by 15% in
the aspartate group (195 minutes, placebo vs. 224 minutes, aspartate). Blood ammonia
concentrations were not reported. Results from this study suggest that 1000 mg/kg
aspartate supplementation improves long-duration time to exhaustion in swimming rats
Barnes et al. (1964) investigated the effects of aspartate administration on blood
ammonia and time to exhaustion in a series of three studies. One hundred and twelve male
(trained and untrained) rats were utilized in a swimming protocol in groups of n = 4 - 10
each. In studies 1 and 2, the supplementation was a twice-administered dose of 500 mg/kg,
while study 3 utilized a single dose, 500 mg/kg. Water temperature was 25 degrees C for
all experiments. In study 1 (untrained rats), time to exhaustion increased from ~16 minutes
to ~ 23 minutes with aspartate administration vs. placebo. Blood ammonia concentrations
were lower with aspartate treatment, (61 vs. 113 [µM/L]). In study 2, investigating the
effects of prior training, time to exhaustion again responded favorably with
supplementation, from 20 min (placebo) to 25 min (aspartate). Blood ammonia
concentrations in the trained group (3 weeks training) were also lower with aspartate
treatment, 48 µM/L (placebo) vs. 42 µM/L (aspartate). In study three, with one dose of
aspartate (500 mg/kg) in untrained rats, blood ammonia levels after a short period (~ 10
minutes) of swimming were lower, [49 µM/L] versus [103 µM/L], respectively. These
results indicate that both trained and untrained rats responded favorably (in both exercise
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performance and blood ammonia clearance) with short-term supplementation of 500 mg/kg
aspartate.
Matoush et al. (1964) investigated the effects of ~ 2000 mg/kg aspartate
supplementation on swim time to exhaustion in 40 rats (trained and untrained) and four
dogs in 17 degrees C and 25 degrees C water. There were no significant differences in any
of the groups, trained or untrained, in response to aspartate treatment. Although no blood
ammonia values were reported, one may speculate from this and other studies (Tangsakul,
1977; and Trudeau et al., 1993) that a dosage of 2000 mg/kg may be too high to elicit a
positive effect on exercise-induced hyperammonemia, or have a beneficial effect on
performance, regardless of training status.
Cutinelli et al. (1970) investigated the effects of 200 mg/kg ornithine-aspartate
(versus 0.9 % saline) administered 30’ prior to swimming 10 to 60 predetermined minutes
in 165 male untrained rats. Blood ammonia concentrations were higher than at 20 degrees
C, than at 28 degrees C, with no significant difference between treatments. Further, in the
10 minute swim test at 20 Co, supplementation with ornithine-aspartate (versus placebo)
decreased ATP, decreased creatine, and decreased GPT, with no difference in AMP and
ADP. However, versus a control group who received no treatment or exercise, these values
were all significantly higher in the supplemented group. Thus, these results suggest that
ornithine-aspartate supplementation can enhance ammonia clearance and maintain AMP
and ADP nucleotides in response to high-intensity exercise.
In two unpublished doctoral dissertation(s), Tangsakul (1977) and Kendrick (1976)
demonstrated improved exercise tolerance in rats treated with chronic and acute aspartate
administration. In support of the findings of Matoush et al. (1964), animals treated over a
10-day period with a large aspartate dose (~ 4g/kg/day) exhibited no change (or a
decrement in) in WTE. Further, an acute injection of aspartate, in smaller dosage(s) one42

hour before exercise, demonstrated the following dose-dependent responses in work time to
exhaustion (WTE) (Kendrick, 1976):
1)
2)
3)
4)

1g/kg reduced WTE by ~ 41% below that of control
250 mg/kg did not alter WTE;
125 mg/kg increased WTE by ~37%, and
12.5 mg/kg K-aspartate increased WTE 90%.

These data indicate that L-Aspartic Acid intake affects WTE in a dose-dependent
fashion, and secondly, as in the Matoush et al. (1964) study, dosages exceeding 500 mg/kg
intake may inhibit and deter metabolism and performance, respectively. Results have
found that rats pretreated with aspartate, buffer the hyperammonemia brought by both
exercise and ammonium injection (Barnes et al., 1964; Kendrick, 1976). Additional results
from Kendrick (1976) indicate that aspartate administration may not alter the rise in the
muscle ammonia concentration during exercise to the degree that blood ammonia is
lowered. The authors speculated that the reduction in [blood ammonia] versus [muscular
ammonia] was likely due to a greater uptake of ammonia by the liver for urea synthesis.
This contention was supported when the administration of K-aspartate significantly
increased blood urea during work, with no effect on muscle ammonia (Kendrick, 1976).
Therefore, these results suggest the acute reduction of excessive [blood ammonia] and
accompanying symptoms (e.g. inhibition of muscular contraction, muscular dysfunction,
and central fatigue) are associated with an increase in exercise performance. Further, this
study, like several others, showed that improvements in swim time to exhaustion in rats
may occur with aspartate supplementation as low as 12.5 mg/kg (Glass et al., 1994) versus
the ~100 - 1000 mg/kg observed in previous experiments.
Trudeau and Murphy (1993) investigated the effects of 1000 mg/kg aspartate on
swimming performance in a 58 rats in a six-group double blind study investigation. Time
to exhaustion was not significantly different with aspartate supplementation (174 ± 45 min)
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versus saline treatment (179 ± 38 min). Plasma [FFA] were significantly lower (p <
0.0001) with aspartate supplementation (0.7 ± 0.3 mM vs. 1.2 ± 0.5 mM). There were no
significant differences between treatments for plasma ammonia, glucose, lactate, or muscle
(or liver) glycogen. Results from this study fail to support the prior contentions of Ahlborg
et al. (1968), and Wesson et al. (1988), that the performance benefit of aspartate
supplementation is due to a general glycogen sparing. It is possible, that although lower
plasma [FFA] were found in this study, a dose of 1000 mg/kg may be too high (versus the
~ 70 – 150 mg/kg in Ahlborg et al., (1968), and Wesson et al. (1988)) to elicit beneficial
effects in other hypothesized markers (blood ammonia concentration, muscle and liver
glycogen) and long duration exercise performance.
A series of three abstracts by Drexel University reported the effects of various
aspartate dosages on the exercise performance of rats. Glass et al. (1994) examined the
effect of 0, 6.25, 12.5, or 100 mg/kg aspartate on swim time to exhaustion in 24 female
rats. Aspartate supplementation was associated with a ‘dose-related increase in swim time
(< 2-fold) in all rats’. Water temperature was a constant 30 degrees C. Nichols et al.
(1998) investigated the effects of 200 mg/kg of aspartate supplementation, and/or
carbohydrate loading, on swim time to exhaustion in untrained rats. Carbohydrate loading
resulted in a 50% increase, aspartate loading resulted in a 3-fold increase, while the
combination of the two resulted in a 3.4-fold increase. Winters et al. (1998) investigated
the effects of 500 mg/kg of aspartate supplementation on swim time to exhaustion in
female untrained rats, one hour after oral gavage. The aspartate treatment resulted in a
two-fold increase in time to exhaustion versus water intake only. Water swim temperature
was 30 degrees C. These results are in general agreement with the previous investigations
of aspartate supplementation < 500 mg/kg in rat studies (Laborit et al., 1958; Barnes et al.,
1964; and Nichols et al., 1998) to improve swimming performance.
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Therefore, the regime of aspartate supplementation to improve exercise tolerance in
rats (trained and untrained) appears to be 12.5 mg/kg - 500 mg/kg BID, over the 24 hours
preceding exhaustive exercise. Of note is that: 1) most of the animal studies utilized
swimming methodology, and 2) improvements in performance and reductions in
ammonemia are independent of both training status and gender. A possible explanation for
the performance benefit observed in these studies is that aspartate supplementation may
delay the onset of an ammonia threshold by lowering exercise ammonia (similar to the
lowering of the lactate threshold by training), and thus prolong high-intensity endurance
and performance. Further, serial data from Wesson et al., (1988), Trudeau and Murphy
(1993), and Lancha et al. (1995) demonstrate that aspartate supplementation reduces
plasma [FFA] in response to intense medium-to-long duration exercise. The mechanism
and the impact of this are unclear. However, Trudeau and Murphy (1993) found no
differences in muscle or liver glycogen (between aspartate supplementation and placebo) at
rest or exhaustion, to support a glycogen sparing effect. Two other possibilities exist for
the lowering of [FFA] by aspartate supplementation: one, as cited by Brooks et al. (1996),
is reduced epinephrine activity on adipose tissue which reduces lipase; two, aspartate
supplementation may provide substrate for TCA cycle intermediates and the malate
aspartate shuttle, enhancing transport of reducing equivalents across the inner
mitochondrial membrane for ATP production. As evidenced recently (Gibala et al., 1997)
in short-term (< 5 min) activity, large increases in succinate, malate, and fumarate (> 90%
of the total TCA cycle substrate pool) are observed during the first minute of muscular
contraction. Therefore, TCA cycle activity is accelerated during short-term intense
exercise. Further, additional aspartate substrate in these circumstances may increase
production of fumarate by the PNC and urea cycle. Additional work is needed to provide
further insight into the etiology of the lowering of FFA and improvement of performance
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with aspartate supplementation. In conclusion, results from the animal studies suggest that
supplementation with ~ 12.5 – 200 mg//kg of aspartate over 24 hours improves swimming
performance in rats, independent of gender and training status.
1.5.4 Exercise Trials: Human Models
Table 1.5 summarizes the studies of aspartic acid supplementation to improve
performance in humans. In comparison to the animal studies, the results from human
studies of aspartate supplementation are more widely variable. In contrast to the animal
studies which use primarily swimming as the testing modality, the human studies have used
cycling (e.g. Maughan and Sadler, 1983; and Wesson et al., 1988), treadmill (Hagan et al.,
1982), weight lifting (Fallis et al., 1963; and Tuttle et al., 1995), field training (Consolazio
et al., 1964), outdoor running (Ritter et al., 1998; and Colombani et al., 2000), and static
arm force (DeHaan et al., 1985). Though inconclusive, the most significant reductions in
EIH and improvements in exercise performance with aspartate supplementation occur with
1) subjects that are highly-trained to the modality, 2) short term high-intensity exercise
with large muscle groups, and 3) a protocol that produces a sufficient amount of ammonia
to be classified as exercise-induced hyperammonemia. The first reported study of aspartic
acid supplementation for enhancement of exercise performance in humans was by Fallis et
al. (1963). In general, aspartate dosages have ranged from 1 - 15g QD, with the most
significant findings for improving performance occurring with dosages between 5 - 15g
(e.g. Ahlborg et al., 1968; Wesson et al., 1988), although significant improvements have
occurred with smaller dosages (Gupta and Srivastava, 1973; and Franz and Chintanaseri,
1977). Critique of the human studies is presented in the following paragraphs in
chronological order.
Fallis et al. (1963) published a study that investigated the effects of 1g of daily
aspartate supplementation versus placebo on weight lifting performance. Twenty-six
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Table 1.5. Summary of studies of L-Aspartic Acid and performance in humans.

Protocol

Dosage
(daily)

Performance

Weight lifting

1000 mg

no change

Fallis et al. (1963)

Field training

2000 mg

no change

Consolazio et al. (1964)

~80% VO2max to
exhaustion (cycling)

7000 mg

↑

Ahlborg et al. (1968)

60% VO2max to
exhaustion (cycling)

3500 mg

↑

Gupta and Srivastava
(1973)

2200 mg

↑

Franz and
Chintanaseri(1977)

7200 mg

no change

Hagan et al. (1982)

73.5% W170/kg to
exhaustion
62% VO2max to
exhaustion (treadmill
walking)

Reference

75% VO2max to
exhaustion (cycling)

6000 mg

no change

Maughan and Sadler
(1983)

40% max static arm force

7640 mg

no change

De Haan et al. (1985)

75% VO2max to
exhaustion(cycling)

10,000 mg

↑

Wesson et al. (1988)

Weight lifting

150 mg/kg

no change

Tuttle et al. (1995)

One mile run time

1440 mg

↑

Ritter et al. (1998)

Marathon run

15,000 mg

no change

Colombani et al. (2000)

inmates of the Maryland State Penitentiary volunteered for the study. Subjects were
experienced weight lifters, considered to be at peak performance. In a counterbalanced
order, the subjects were given placebo for 10 days, and aspartate for 10 days, and recorded
the maximum daily number of bench presses, squats, and recovery time. No significant
differences were found between treatments. Blood ammonia concentrations were not
reported in this study. However, exercise protocols of this type (i.e. weight training) in
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general do not raise blood ammonia to the levels of hyperammonemia for a sustained
period for aspartate to have an effect.
Consolazio et al. (1964) investigated the effects of 2 grams of daily
supplementation of aspartic acid on the respiratory responses to 5 weeks of aspartate
intake. Twelve healthy young men were matched for body weight, and randomly assigned
to an aspartate group or a placebo group. A 9-week study, with two weeks of initial
training, revealed no significant differences between groups in VO2, VCO2, O2 debt, RQ,
recovery after an all-out run, maximal breathing capacity, or timed vital capacity. The
authors concluded that there was no convincing evidence of the beneficial effects of
aspartate therapy for delaying the onset of physiological fatigue in humans, in terms of
respiratory parameters. Unfortunately, neither blood ammonia nor blood urea values
reported, nor was there a high-intensity exhaustive component to assess effectiveness of
treatment. Thus, aspartate supplementation coupled with a training regime has no effect on
improvement in respiratory parameters.
Ahlborg et al. (1968) conducted a controlled study on six moderately-trained men,
who exercised to exhaustion on a bicycle ergometer for 4 consecutive days at a workload
designed to elicit exhaustion at ~ 90 minutes. Placebo was administered on days 1, 2, and
4, and 7 grams of aspartate was administered on day 3. Mean work times to exhaustion
were not significantly different between days 1, 2, and 4; however, on day 3, subjects
cycled for ~ 128 min. - an increase in endurance by ~ 50%. There were no significant
differences in heart rate, respiratory rate, or weight change. It was hypothesized by the
authors, that the administration of aspartate decreased the rate of glycogen utilization and
therefore prolonged exercise time. However, the study did not utilize a double blind
design, nor report blood ammonia or urea to substantiate these conclusions.
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A similar follow-up study on five subjects (VO2max - 42.5 ml/kg/min) by Gupta and
Srivastava (1973) demonstrated an increase in exercise work time to exhaustion with
aspartate intake. Five healthy young volunteers with a baseline VO2max of 42.5 ml/kg/min
exercised at a continuous workload of 60% VO2max on a bicycle ergometer, with a 22.6%
improvement (68.4 min vs. 83.6 min) in WTE following 3.5 g (.875 g x 4) of aspartate
supplementation versus placebo. VO2, HR, O2 debt, urinary creatine, blood sugar, and
urinary 17-hydroxycorticosteroids were not significantly different between trials. The
subjects in both the Ahlborg et al. (1968) and Gupta and Srivastava (1973) studies were
allowed intake of cold water ad libitum during exercise to avoid dehydration. Blood
ammonia and urea concentrations were not reported, nor was the single or double-blind
nature specified. Therefore, other than no change in blood glucose, the possible
mechanisms for improvement in this study are difficult to ascertain.
Hagan et al. (1982) investigated physiological responses to treadmill walking for 90
minutes at approximately 62% VO2max in response to K+Mg+2 aspartate treatment (7.2g
over 24 hours), placebo, or no treatment in seven healthy males (VO2max 59.5 ml/kg/min).
No significant differences were observed in VO2, VCO2, R, HR, and BP; and for pre- and
post-exercise changes in rectal temperature, serum lactic acid, creatine kinase, lactic
dehydrogenase, and percentage change in plasma volume. However, the methodology
protocol was not of sufficient intensity or duration to produce exhaustion. This study
reveals that physiological responses to low to moderately-intensity protocols are not
affected by aspartate ingestion.
Maughan and Sadler (1983) investigated the effects of 6 grams per day of aspartate
ingestion (versus placebo) on eight healthy young male subjects, who exercised to
exhaustion on a bicycle ergometer at a constant workload requiring approximately 75%
VO2max using a double-blind protocol. Exhaustion was reached after 82.7 ± 23.5 minutes
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(mean ± SD) following aspartate treatment and after 85.4 ± 26.5 minutes following the
placebo. There were no significant differences across treatments for blood glucose, lactate,
ammonia, or FFA concentrations. As in the Hagan et al. (1982) study, results from this
study suggest that aspartate supplementation has no effect on ammonia levels and
performance response with moderate exercise.
De Haan et al. (1985) examined the effects of 7.64 g of daily K+ Mg+2 aspartate
supplementation on force production and endurance time for arm exercise. In a series of
twelve sessions, twenty healthy male students (19-26 yr) performed arm exercise at 40% of
maximal force until exhaustion, and repeated the effort following a 5-minute recovery
period. Each session lasted 10 - 15 min. Following session three, the subjects were divided
into three groups (control, placebo, and aspartate) for the remaining 9 trials. Results
between groups indicated no significant increases in either the exerted force or endurance
time. Blood parameters were not reported. Once again, it is speculated that the low
relative exercise intensity failed to raise ammonia levels to the point where aspartate could
exert a beneficial effect; further, blood ammonia was not reported.
Wesson et al. (1988) investigated high-intensity cycling endurance in response to
aspartate intake, and measured blood ammonia, glucose, and FFA. Seven healthy young
male athletes (VO2max - 53.1 ml/kg/min) performed leg exercise to exhaustion at a
workload ~75% VO2max at 50 rpm on a bicycle ergometer. The test was administered after
ingestion of 10g of potassium-magnesium aspartate or placebo over a 24-hour period
utilizing a double-blind design. Time to exhaustion significantly (p < 0.01) increased by
~14% following aspartate ingestion (87.6 min vs. 75.7 min) vs. placebo. Further, blood
ammonia levels were lower in the aspartate condition at rest, during exercise, 15 min post
exercise, but not at exhaustion ~ [110 µM/L]. This may indicate an improvement in the
efficiency of ammonia removal, or in bioenergetic metabolism to prolong high-intensity
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endurance and performance. The aspartate group also had higher (p < 0.05) blood [FFA] at
exhaustion (0.74 mM vs. 0.60 mM), with no difference at the other time points. Other
findings of note were: 1) a higher HR at exhaustion (168 bpm vs. 163 bpm) for the
aspartate treatment vs. placebo trial, and 2) a significant reversal 15 min post-exercise with
the aspartate condition having a significantly lower HR (90 bpm vs. 98 bpm) vs. placebo.
Blood glucose remained stable ~ [5 mM/L] across treatments. The conclusions from this
study were that aspartate is an ergogenic aid due to the ammonia lowering effect and the
glycogen sparing of increased availability of FFA’s.
Work by Denis et al. (1991), and Eto et al. (1994) investigated the effects of other
AA combination(s) designed to lower the ammonia response to steady state high-intensity
(~80% VO2max) cycling. However, in these studies, there was neither an exhaustive
component nor a performance measure. In the Eto et al. study (n=3), ingestion of 20g of
arginine-glutamate (AG) two hours prior to cycling significantly lowered (p < 0.01) blood
[NH3] in the AG group at 60 min (98 ug/dl) vs. placebo (67 ug/dl). Resting blood ammonia
concentrations were not different across treatments. Conversely, Denis et al. (1991) found
no difference in blood [NH3] at 45’ of cycling at 80% VO2max following chronic ingestion
of 20g of chronic arginine + aspartate (AA) ingestion (5g x QID x 10 days) vs. placebo. Of
note, in both of these high-intensity (but steady state) studies, blood ammonia levels did not
rise to [100 µM/L]. These results indicate, that in humans, blood [NH3] > 100 µM/L
during exercise is not tolerated well by the body, and work stoppage occurs quickly.
Furthermore, these human studies also show that when blood NH3 concentrations during
high-intensity steady-state work are below 100 µM/L (e.g. 60 – 80 µM/L), work may be
tolerated much longer (i.e. hours), without exceeding the critical balance between ammonia
buildup, ammonia removal, and onset of fatigue.
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Tuttle et al. (1995) investigated the effects of 150 mg/kg of daily aspartate
supplementation (versus placebo) on weight lifting performance and blood ammonia,
lactate, and RPE response in twelve healthy young men utilizing a double blind,
counterbalanced protocol. The exercise testing phases (65% of one repetition maximum,
bench press to failure) were administered one week apart, with a week long weight-training
regime that consisted of 3-5 sets, at approximately 70% of 1 repetition maximum, for 8
repetitions per set. At the conclusion of the study, no significant differences in blood
ammonia concentrations [µM/L] with (aspartate versus placebo) were found at rest, during
exercise, or post exercise. Exercise blood ammonia concentrations ranged from 66.3 – 88.5
µM/L with no difference between treatments. As expected, post-exercise blood ammonia
concentrations were higher in both groups versus pre-test, however, there was no change in
lactate versus baseline with either treatment. There was no difference in the number of
repetitions completed (9.5 versus 10.3, respectively) during the exercise test following the
aspartate or placebo treatments. These results indicate aspartate supplementation has no
effect on blood ammonia concentrations or performance in response to weight training.
Columbani et al. (1999) investigated the effects of 15 grams of arginine aspartate
supplemented daily for two weeks before a marathon run in 20 endurance-trained males in
a double-blind crossover design. Blood samples were collected at four time points, as
follows: 1) before the run, 2) after 31 km, 3) at the end of the run, and 4) during recovery.
Results indicated that carbohydrate, fat metabolites, cortisol, and ammonia were unaffected
by supplementation. However, plasma somatotropic hormone, glucagon, and urea were
significantly increased, and most of amino acids were reduced. The mean running time
was 194 minutes (placebo) and 196 minutes (supplement), and not significantly different.
This study demonstrated no obvious benefit with chronic arginine-aspartate
supplementation and marathon performance.
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Ritter et al. (1999) investigated the effects of five consecutive days (4 x 360 mg
QD) aspartate supplementation (or placebo) on one mile run time in endurance-trained
men. Mean mile run time improved in the aspartate group from 6:01 to 5:53. However, in
the placebo group, mean times also improved from 5:47 pre-treatment to 5:43 post
treatment. These results suggest that aspartate treatment may result in significant ergogenic
benefits in trained athletes, however, this protocol failed to utilize a double blind protocol
nor report blood ammonia values to validate the findings. Results from human studies are
discussed inclusively with the animal studies in Section 1.6 below.
1.6 Summary and Conclusions
The merit of aspartic acid as an ergogenic aid in humans is unresolved. Findings
indicate that species, testing modality, testing intensity, training specificity, and training
status affect blood ammonia concentrations and physical performance in response to LAspartic Acid ingestion. Of these, it appears that exercise intensity and status of training in
reference to the testing modality has the greatest influence upon the metabolism of
ammonia and aspartate and performance response. The effect of gender is unknown.
Possibly, a more consistent or specific subject pool (i.e. testing subjects in training
specific modalities) might reveal a consistent pattern in results or differences between
groups. Measurements of plasma catecholemines, cortisol, insulin, glucagon, amino acids,
nitrogen metabolism enzymes (SGPT, SGOT, GDH), adenine nucleotides, blood lactate,
and ammonia would provide additional metabolic and endocrine data. The review of
literature suggests that in order for aspartate supplementation to have an effect on EIH, the
exercise intensity should be a minimum of 75% VO2max, and total daily dosage of aspartate
should be ~ 5 to 15 grams. Finally, there may be unknown factors affecting the results,
such as diet, weight, gender, and purity of the amino acid, and protocol of aspartate
administration.
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As mentioned previously, administration of aspartic acid improves the status and
symptoms of clinical fatigue. There are strong indications that aspartate supplementation
improves performance in the swimming rat. On the other hand, the effectiveness of
aspartate supplementation for reducing EIH and improving exercise performance in
humans is inconsistent. The studies demonstrating the most dramatic improvements in
humans (Ahlborg et al., 1968; Franz et al., 1977; Gupta and Srivastava, 1973) did not
report blood ammonia, FFA, or assess serial nitrogen biochemistry or assess glycogen
sparing. On the other hand, Kendrick (1976) and Tangsakul (1977) reported in rats
supplemented with 12.5 mg/kg aspartate a 90% increase in swim time to exhaustion and
concurrent reductions ammonia and increases in blood urea. In contrast, Matoush et al.
(1964), found no effect of aspartic acid salts on swimming performance on rats or dogs,
however, the dosages of aspartate in this study were relatively high, i.e. 2000 mg/kg.
Subsequent investigations in humans, tried various dosages and protocols, but no consistent
successful trends in methodology were established. Endurance protocols (e.g. walking at
62% VO2max) low-moderately-intensity arm work (40% of maximal force), weightlifting,
and cycling at 75% VO2max have revealed no change in work time to exhaustion following
similar doses of aspartate treatment (De Haan et al., 1985; Hagan et al., 1982; Maughan
and Sadler, 1983). Further, data from Fallis et al. (1963) and Tuttle et al. (1995) indicates
that short-term weight lifting protocols may not elevate ammonia to the point (e.g. > [100
µM/L]) where aspartate ingestion for reduction in hyperammonemia can be effective.
As presented previously in Table 1.3, the anaplerotic roles of aspartate provide
clues into the bioenergetic mechanisms for enhanced work capacity with supplementation.
As noted by Gibala et al. (1997), ammonia and aspartate metabolism link (i.e.
‘anaplerosis’) the PNC and TCA cycle. However, as cited by Graham et al. (1997) in
reference to the PNC, it is unclear as to “what stimulates the key enzymes, or how the
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tissue manages to obtain adequate amounts of aspartate, a key substrate”. As evidenced
recently (Gibala et al., 1997) in short-term (< 5 min) activity, large increases in succinate,
malate, and fumarate (> 90% of the total TCA cycle substrate pool) are observed during the
first minute of muscular contraction. Therefore, accelerated activity of the TCA cycle is
promoted in short-term intense exercise. Further, Lancha et al. (1995) found increases in
pyruvate carboxylase activity (and time to exhaustion) in swimming rats with aspartate
supplementation. However, the human studies exhibiting enhancements in performance
via aspartate ingestion lack measurements of appropriate blood values (e.g. enzyme, NH3,
urea, AA, FFA) to discern the appropriate physiological mechanism(s) (Ahlborg et al.,
1968; Franz and Chintanaseri, 1977; Gupta and Srivastava, 1973).
As demonstrated by Lancha et al. (1995) and Wesson et al. (1988) aspartate intake
increases FFA utilization during long exhaustive high-intensity (i.e. > 75% VO2max)
exercise thus sparing muscle glycogen (vs. placebo). Animal studies have utilized
swimming as the primary mode, while human studies have concentrated on moderatelyintensity long duration stationary cycling and walking, with a further shortage of studies on
females and highly-trained subjects. Bicycling studies are the most promising in humans
with regard to aspartic acid supplementation and performance, possibly because of the
prolonged localized recruitment of Type IIa - IIb muscle fibers at high workloads,
promoting high levels of blood NH3.
Summarizing, postulated mechanisms of aspartate supplementation to increase
work tolerance include:
1)
2)
3)
4)
5)

Reducing blood ammonia
Increasing urea synthesis
Increasing aspartate substrate in the PNC, promoting the regeneration of
AMP and maintenance of total adenine nucleotide levels
Providing OAA for the TCA cycle via the transamination of aspartate to
OAA (aspartate + α-ketoglutarate <=> OAA + glutamate)
Increasing aspartate availability for the urea cycle, thus promoting
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6)
7)
8)
9)
10)

conversion into less-toxic urea
Providing carbons for fumarate for the TCA cycle, via anaplerotic
production by the PNC and urea cycle
Increasing glycogen synthesis
Increasing FFA availability, thus sparing muscle glycogen (Lancha et al.,
1995; Stubbs and Krebs, 1975)
Providing substrate for gluconeogenesis (via fumarate, OAA)
Shuttling reducing equivalents across the inner mitochondrial membrane for
the ETC.

Therefore, the available literature in animals and humans suggests that ~ 5 - 12.5 g
x 2 of aspartate ingested over a 24-hour period preceding intense exercise may enhance
exercise performance. As shown by Cutinelli et al. (1970), aspartate supplementation
promotes the maintenance of AMP (by the PNC), thus enhancing the desirable maintenance
of the total adenine nucleotide pool (ATP + ADP + AMP). Further, aspartate may increase
the anaplerotic availability of the TCA cycle intermediate fumarate by promoting fumarate
formation in both the PNC and urea cycle. Unfortunately, there are limited studies
investigating this area during high-intensity exercise performance, when aspartate levels
decline and blood ammonia levels continue to rise. Thus, the mechanisms, dosage regime,
and potential of aspartate supplementation to improve ammonia clearance and highintensity exercise performance in humans are unresolved. To address the above concerns,
it is hypothesized that 5 - 15 grams of aspartate BID over a 24-hour period preceding highintensity exercise will decrease blood ammonia levels, and increase short term exhaustive
bursts in power.
In summary, although the impact of aspartate supplementation on performance
appears reflective of specificity of training, the degree of effectiveness on gender is
unclear. Secondly, the reliability of the blood ammonia assay across exercise sessions is
unclear as well, as is the dose-response effect of variable L-Aspartic Acid supplementation
on exercise hyperammonemia. Third, the effect of aspartate on high-intensity performance
and hyperammonemia is unclear comparing well-trained versus lesser-trained men.
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Therefore, to test these areas and hypotheses, the dissertation consisted of a preliminary
phase of three studies (summarized in the introduction to Chapter 2), followed by a second
phase of three experiments (presented in Chapters 2, 3, and 4, respectively). Each
experiment utilized an incremental arm ergometer protocol, accompanied by a 24-hour
supplementation regime of aspartate or placebo. The purposes of the three experiments
were:
Experiment 1: a)
b)

Assessed the reliability of blood ammonia in college-age subjects
across five high-intensity exercise testing sessions holding duration
and power constant
Assessed the blood ammonia response in college-age subjects to
aspartate intake vs. placebo, counterbalanced across five highintensity exercise sessions holding duration and power constant

Experiment 2:

Assessed high-intensity exercise performance over two sessions in
highly-upper body trained and moderately upper body trained
college-age men, following aspartate supplementation or placebo,
utilizing a double blind counterbalanced design.

Experiment 3:

Assessed high-intensity exercise performance over two sessions in
moderately upper body trained college-age women, following
aspartate supplementation or placebo, utilizing a double-blind
counterbalanced design.
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CHAPTER 2. PRELIMINARY STUDIES OF BLOOD AMMONIA REDUCTION
AGENTS AND THE RELIABILITY OF THE AMMONIA ASSAY ACROSS EXERCISE
SESSIONS
2.1 Introduction and Rationale
Short-term and long-term decreases in blood ammonia concentration are associated
with improvements in high-intensity exercise performance (Wesson et al., 1988; Graham et
al., 1995). Assessment of blood [NH3] during high-intensity exercise is becoming an
increasingly prevalent marker for 1) status of activity-specific conditioning, 2) protein and
amino acid metabolism, 3) degree of effort and 4) assessment of performance.
Furthermore, the symptoms of high-intensity exercise-induced hyperammonemia (i.e.
ataxia, dizziness, confusion, nausea), mimic that of clinical hyperammonemia where blood
[NH3] exceeds 100 µM/L (Batshaw, 1994). The reduction of hyperammonemia, and
associated symptoms, is desirable for optimal physiological function and athletic
performance.
Data from Barnes et al. (1964), Kendrick (1976), and Wesson et al. (1988), suggest
that reduced hyperammonemia and improved exercise performance are in some cases,
associated with the acute intake (~5 - 15 grams) of the ammonia reducing L-amino acids
(e.g. aspartate, arginine, ornithine, glutamate). However, there is insufficient information
on the 1) overall reliability of the blood ammonia assay across multiple exercise sessions,
and 2) dose-response effect of amino acid ingestion (e.g. aspartic acid) on blood ammonia
reduction to validate the blood ammonia measurement with high-intensity exercise.
Therefore, the purpose of this chapter is to 1) summarize three pilot studies investigating
blood ammonia reduction and high-intensity performance with ingestion of the ammoniareducing amino acids, providing background and rationale for 2) a reliability investigation
of the blood ammonia assay across exercise sessions.

58

2.1.1 Summary of Pilot Work
Reliability studies involving invasive biochemical assays, high-intensity exercise,
dietary control, and humans are difficult to accomplish with an adequate number (i.e. n >
10) of subjects due to 1) the invasiveness of blood draws and/or muscle biopsies, 2) the
required control of diet, caffeine, tobacco, exercise habits, and other factors, 3) the high
dropout rate, 4) the higher likelihood of an adverse physiological or medical event, and 5)
the intrinsic subject motivation to complete the study. In this regard, publications in
exercise biochemistry often appear with sample sizes considered ‘smaller than usual’ (i.e., n
< 6) in contrast to non-exercise biochemistry disciplines. Consequently, publications of this
type (e.g. the reliability of the blood ammonia assay during exercise across time) of exercise
physiology research are rare, of higher risk, and difficult to conduct. However, biochemical
reliability investigations are necessary to validate potential biochemical changes in response
to treatment. With this in mind, three pilot studies each with sample sizes < 10 were
conducted (preceding a more thorough reliability investigation) to assess the potential
trends of selective amino acid ingestion to lower blood ammonia and/or increase blood urea
and performance during high-intensity exercise.
The first pilot study (i.e. pilot study 1, double-blind) investigated the effects of
supplementation of 2g each of glutamate, arginine, ornithine, and aspartate (versus placebo)
on high-intensity leg ergometry performance, resting and post-exercise blood [NH3], lactate,
and urea in moderately-trained college-age males (n = 3). With treatment, there was a
significant drop in blood [NH3], an increase in urea, and no significant change in lactate or
performance in response to treatment (For detailed methodology and results, see appendix
B.).
A second pilot study (i.e. pilot study 2) in healthy college students (n = 8) isolated
the effects of ingestion of 10g each of arginine and ornithine (urea cycle substrates) on
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resting and post-exercise blood NH3, lactate, creatinine, total protein, urea and time to
exhaustion in response to incremental treadmill exercise. Results indicated ~ 40% increase
in urea with treatment (versus placebo), with no significant differences in blood ammonia,
LA, total protein, creatinine, or time to exhaustion. These results suggest 1) isolated urea
cycle substrate ingestion has a greater effect on blood urea elevation than on blood NH3
reduction, and 2) high-intensity performance is not affected by short-term ingestion of
isolated urea cycle amino acids (For detailed methodology and results, see appendix C.).
A third pilot study (i.e. pilot study 3) investigated the effect of variable dosage of
aspartate (0, 5, 10, 15g) on immediate post-exercise blood NH3 and lactate in surfers (n =
5). Work time and power output were constant per subject across four exercise sessions
utilizing an incremental arm ergometer protocol. Results indicated a dose-dependent drop
in blood NH3 in response to L-Aspartic Acid supplementation, with no change in lactate
(For detailed methodology and results, see appendix D.). Results from this study indicated
10 - 15g L-Aspartic Acid prior to intense arm-crank activity as the optimal dose (of 0, 5, 10,
or 15g) to lower blood ammonia concentration in moderately-trained subjects. However,
yet to be resolved from these pilot studies and previous work with the reduction of exerciseinduced hyperammonemia and improvement in performance with aspartate supplementation
(Barnes et al., 1964; Kendrick, 1976; and Wesson et al., 1988) is the reliability of the blood
ammonia assay across exercise sessions under placebo and/or L-Aspartic Acid treatment.
Therefore, to 1) assess the reliability of the blood ammonia assay under either
placebo or L-Aspartic Acid condition(s) across exercise sessions, and 2) validate the pilot
study results of blood ammonia reduction with L-Aspartic Acid treatment; and 3) provide
reference for future exercise-induced hyperammonemia studies, the following reliability
experiment (with sample size > 10) was conducted.
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2.2 Methods
2.2.1 Subjects
Fifteen recreationally upper body trained (e.g. weight training, surfing, swimming)
college-age male (n = 11) and female (n = 4) students attending Brigham Young University
– Hawaii (BYU-H) volunteered for the study, approved by the Institutional Review Board
of the university. Subjects were informed of the nature of the study, the possible risks
associated with participation, and of their right to withdraw at any time before providing
written consent. Subject characteristics (mean, SEM, SD, minimum, and maximum) for
these fifteen students are presented in Table 2.1. Subjects were instructed to abstain from
alcoholic beverages, caffeine, and tobacco for the duration of the study and to keep dietary
and exercise habits consistent across sessions. All reported at least one year of experience
of upper body recreational training 2-3x/week (i.e. weight training, surfing, swimming).
None were members of intercollegiate athletic teams. Training status was measured in
wattage (W·min-1) at an RPE of 17 (6-20 scale) on an incremental arm ergometer protocol.
2.2.2 Protocol
A counterbalanced latin square design determined the order of L-Aspartic Acid (A)
or placebo (P) supplementation prior to five exercise sessions. Figure 2.1 illustrates
regimen for supplementation assignment. Subjects were assigned to either protocol (a), (b),
or (c) in that order, upon registration. Two sessions followed 12.5g x 2 QD of L-Aspartic
Acid supplementation, while three followed placebo. A 48-hour washout separated each
session. Of the initial pool of 25 registrants, 15 completed at least four sessions, which
included three placebo sessions. Of the 15 subjects, seven were assigned to protocol (a),
four to protocol (b), and four to protocol (c). Due to technical difficulties, bloodwork was
available for only ten subjects who completed the two sessions of L-Aspartic Acid
supplementation. Therefore, complete blood ammonia data was available for fifteen
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Table 2.1. Descriptive characteristics of the subjects (n = 15) in experiment 1.

Subject
Initials
NN
CS
JS
KU
AH
NG
JB
KN
MR
JA
JS
DN
JE
SA
YN

Subject #
(M/F)
1F
2F
3F
4M
5F
6M
7M
8M
9M
10M
11M
12M
13M
14M
15M

Age
(yr)
20
22
22
23
20
22
22
22
22
24
22
24
22
33
27

Height
(cm)
167.6
167.6
162.6
193.0
165.1
170.2
172.7
170.2
172.7
182.9
175.3
170.2
180.3
180.3
177.8

Weight
(kg)
59.1
57.3
68.2
88.6
52.3
68.2
77.3
68.2
77.3
85.5
75.0
66.8
83.2
94.1
70.5

Dosage
(mg/kg)
211.5
218.3
183.3
141.0
239.1
183.3
161.8
183.3
161.8
146.3
166.7
187.1
150.3
132.9
177.4

W.min-1
@RPE17
75.0
125.0
100.0
150.0
100.0
150.0
175.0
150.0
175.0
200.0
200.0
150.0
150.0
150.0
175.0

Mean
23.1
178.4
73.8
171.3
158.3
SEM
0.8
2.6
2.9
6.6
9.3
SD
3.2
7.8
8.7
19.7
28.0
Minimum
20.0
170.2
61.4
141.0
100.0
Maximum
33.0
193.0
88.6
203.7
200.0
RPE - Rating of perceived exertion (6-20) scale
mg/kg – Relative dosage per kg body weight of 12.5 grams of L-Aspartic Acid

sessions following placebo, and ten sessions following L-Aspartic Acid supplementation.
Two drink powder packets (either two of A, or two of P) were distributed to the subject(s)
24 hours prior to each session. Subjects were instructed to mix the contents of each in 8 12 ounces of water, and ingest one packet mixed in water 24 hours and ingest the other
packet 1 hour before testing, respectively. Of the five sessions, two followed ingestion of
A, while three followed ingestion of P. Contents of packet A were 12.5g of L-Aspartic
Acid (Source Naturals, Inc., Scotts Valley, CA) mixed in 20g of powdered Powerade©
(The Minute Maid Company for Coca-Cola USA, Northlake, IL). Packet P contained
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Protocol (a)
Ingestion P

P

Session # -

1

A

A

P

2

P

A

3

A

P

P

4

5

Protocol (b)
Ingestion P

P

Session #

1

P

P

A

2

A

P

3

P

A

A

4

5

Protocol (c)
Ingestion A

A

Session #

1

P

P

A

2

A

3

P

P

4

P

P

5

Figure 2.1. Order and regime of three counterbalanced protocols for supplementation
assignment (P – placebo; A – L-Aspartic Acid) across five exercise sessions.
Subjects were assigned to protocol (a), (b), or (c) in the order of signup for participation.
(
= ingestion ~ 24 hours pre-test;
= ingestion ~ 1 hour pre-test)
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20g of powdered Powerade© only. Powders were weighed to within 0.1g on a VWR
Sargent Welch Calibrated Scale (VWR Scientific Products #WLS2648-30). Staff
instructions for distributing L-Aspartic Acid (A) or placebo (P) packets packet(s) to
subjects are presented in Appendix D.
Subjects reported to the laboratory for five sessions of seated incremental arm
ergometry (Monark Model #881) testing. At least 48 hours separated each session.
Testing began at 25 W·min-1, and increased in 25 W·min-1 increments every 30 seconds at a
constant 100 rpm. The test was terminated upon stage completion when rating of perceived
exertion of 17 (6-20 scale) was achieved. The individual duration time achieved in session
1 was recorded, and all subsequent tests went the same length of time with the same
workload ramp. Cadence and revolutions were monitored and tracked, respectively, via an
integrated electronic readout. Verbal feedback was used to help subjects stay at target
cadence. Revolutions achieved were used to calculate wattage output. The intra-subject
exercise protocol duration time and number of stages completed was kept the same across
sessions. Inter-subject number of stages completed varied. Protocol duration, total
revolutions, and mean terminal wattage in the RPE 17 stage (W·min-1) were tabulated and
recorded.
Seated blood samples were drawn 3 minutes post exercise. Following alcohol
preparation of skin, a 21 gauge 1" Vacutainer© (Becton Dickinson and Co. Vacutainer
Systems, Franklin Lakes, NJ) double-sided blood collection needle (#36-7212) was
inserted into a superficial antecubital vein. A red top Vacutainer© tube with sterile interior
was then inserted into the surrounding needle hub, and a 4-6 ml blood sample drawn for
about 15 seconds. Blood samples were placed immediately into an ice bath for 10 minutes,
and centrifuged for 10' at 3400 rpm (Fisher Scientific Centrific Model 228). Serum was
transferred via disposable 3.2 ml polyethylene transfer pipettes (#13-711-7, Fisher
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Scientific, Pittsburgh, PA) into labeled 1.5 ml micro polypropylene metal-free test tubes (#
223-9480, Bio-Rad Laboratories, Hercules, CA), sealed with attached caps, and frozen
immediately at 20 degrees Celsius for subsequent batch analysis. Serum [NH3] was
determined via a Kodak Ektachem Analyzer (Eastman Kodak Company, Rochester, NY)
using Ektachem NH3/Amon Clinical Chemistry Slides (Johnson and Johnson Clinical
Diagnostics, Rochester, NY) using a phenol hypochlorite colorimetric technique.
2.2.3 Statistical Analyses
The SPSS statistical package was used to assess the intraclass correlation
coefficient (ICC) between placebo sessions 1,2, and 3 (i.e. P1, P2, P3) and between the two
L-Aspartic Acid sessions (i.e, A1, A2). An analysis of variance with repeated measures
was used to assess differences between sessions of placebo treatment (P1, P2, and P3) and
L – Aspartic Acid supplementation (A1 and A2), using GB-STAT software. Tukey’s posthoc t-tests were utilized when the overall F value was significant. Individual intraclass
correlation coeffecients were calculated also between the individual placebo sessions (P1
vs. P2, P1 vs. P3, and P2 vs. P3), and between the L-Aspartic Acid supplementation
sessions (A1 vs. A2). α was set apriori at .05.
2.3 Results
As specified per analyses, results are presented as the actual value, or as mean ±
SEM. Figure 2.2 illustrates the consistency of the individual blood ammonia responses
[µM/L] across the three exercise sessions with placebo treatment. Figure 2.3 illustrates the
individual blood ammonia responses [µM/L] to two exercise sessions with L-Aspartic Acid
supplementation. The ICC was highly significant (r = 0.90, p < 0.0001) for the blood
ammonia concentrations [µM/L] across the three placebo sessions. The intraclass
correlation coefficient between the two sessions for L-Aspartic Acid treatment was also
significant, r = 0.76, p < 0.01. The individual intraclass correlation coefficients
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Figure 2.2. Individual responses in blood NH3 [µM/L] following treatment with placebo
across three exercise sessions (n = 15).
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Figure 2.3. Individual responses in blood NH3 [µM/L] following treatment with L-Aspartic
Acid across two exercise sessions (n = 10).
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between P1, P2, and P3 were also highly significant (P1 vs. P2, r = 0.91, p < 0.0001; P2 vs.
P3, r = 0.90, p < 0.0001; P1 vs. P3, r = 0.89, p < 0.0001). There were no significant withingroup differences (p > 0.05) between the placebo sessions or the L-Aspartic Acid sessions.
Figure 2.4 illustrates the significantly reduced blood ammonia concentrations with
the sessions of L-Aspartic Acid treatment versus placebo (F = 25.6 p < 0.0001). The
means ± SEM of blood [NH3] across the treatments were: P1 = 180 ± 13, P2 = 190 ± 14;
and P3 = 184 ± 13, and A1 = 165 ± 14, and A2 = 163 ± 14. There were no significant
differences (p > 0.05) in [blood ammonia] between P1, P2, and P3, or between A1 and A2.
The lowest blood [NH3] per subject was with L-Aspartic Acid supplementation.
2.4 Discussion
This investigation is the first to report the test-retest reliability of the blood
ammonia assay across high-intensity exercise testing sessions. Results indicate that the
urease/phenol hypochlorite method (with the Kodak© Ektachem Vitros II Analyzer) is
highly reproducible across three separate testing days in a controlled environment with
recreationally-trained college-age males and females. However, until future information
becomes available, one should exercise caution for application across additional testing
methods, dietary fluctuations, subject populations, and/or exercise habits. These results
show the blood ammonia assay to be highly reliable (i.e., r > .90, p < 0.0001) across
multiple exercise sessions with placebo treatment in the short term (i.e. < two weeks). The
present investigation suggests also a greater variability in the reproducibility of the blood
ammonia assay with L-Aspartic Acid supplementation. Although statistically significant,
the reliability of the ammonia assay across exercise sessions with L-Aspartic Acid
supplementation is less significant (i.e. r = 0.74, p < 0.05) than that of placebo. This
difference may be due to greater aspartate intake in foodstuffs (e.g. meat), and/or intra- and
intersubject variability in metabolic aspartate bioefficiency associated with training status.
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Figure 2.4. Mean blood NH3 [µM/L] across three placebo sessions (P1, P2, P3) and two LAspartic Acid treatment sessions (A1, A2).
*p < 0.05, (A1, A2 versus each of P1, P2, P3)
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For instance, it is well known that moderately-trained subjects (similar to those trained in
this study) have reduced ammonia clearing capabilities versus that of highly-trained
subjects (Graham et al., 1997). Although the sample sizes in the present study differed
between the two treatments (i.e., placebo, n = 15 x 3; L-Aspartic Acid, n = 10 x 2), the
blood ammonia concentrations were significantly lower (as hypothesized) with L-Aspartic
Acid supplementation versus placebo, while keeping intra-subject power output constant
across sessions.
To conclude, these results show the blood ammonia assay to be a highly
reproducible short-term tool across exercise sessions under controlled conditions.
However, until sufficient information becomes available, one should exercise caution when
applying these results to subject groups undergoing changes in diet or training status.
Further, though significantly reproducible but more variable versus placebo, this
investigation provides evidence also that the blood ammonia assay is a reliable
measurement in exercise studies utilizing L-Aspartic Acid supplementation, particularly
with recreationally-trained college students. To apply this reproducibility to other subject
pools, regimes of amino acid supplementation, dietary or testing protocols, and/or long
term changes in training statuses needs to be investigated further.
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CHAPTER 3. IMPACT OF L-ASPARTIC ACID SUPPLEMENTATION ON EXERCISE
HYPERAMMONEMIA AND PERFORMANCE IN HIGHLY-TRAINED AND
MODERATELY-TRAINED MEN
3.1 Introduction
Ammonia, a product of dietary and exercise metabolism, is inversely associated
with exercise performance. Symptoms of clinical hyperammonemia, such as those
described by Batshaw (1984) (e.g.. nausea, ataxia, dizziness), mimic those observed during
intense exercise, where normal resting blood [NH3] of ~10-40 µM/L may exceed 500 µM/L
(Fischbach, 1988). Data from Barnes et al. (1964), Kendrick (1976), and Wesson et al.
(1988) indicate that acute intake (~5 - 15 grams over 24 hours) of the non-toxic amino acid
aspartate is among the techniques known to reduces exercise-induced hyperammonemia
and in some cases improves exercise performance. However, the effect of aspartate on
performance is unknown comparing well-trained versus lesser-trained men. Therefore, this
experiment was conducted to investigate the effect of aspartate ingestion on high-intensity
exercise hyperammonemia and performance in highly-trained and moderately-trained men.
Strenuous physical activity elevates blood ammonia concentrations primarily by
accelerating activity of the purine nucleotide cycle (i.e. AMP deaminase) and deamination
of branched chain amino acids (Lowenstein, 1972, MacLean et al., 1996). As determined
by Lo and Dudley (1987) and Levin et al. (1969), blood ammonia levels are inversely
associated with exercise training status and performance, and rise during intense exercise to
levels included in the diagnostic criteria (i.e. > [100 µM/L]) for clinical hyperammonemia.
The undesirable symptoms of exacerbated clinical hyperammonemia (i.e. oncoming
nausea, ataxia, dizziness) are likewise observed during intense exercise, where a normal
resting blood [NH3] of ~10-40 µM/L rises to well over [100 µM/L].
The non-essential amino acid L-Aspartate is one of several amino acids (Najarian et
al., 1958) known to reduce the hyperammonemia associated with hepatic disorders, and, in
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some instances improve exercise performance in healthy populations (Ahlborg et al., 1968;
Gupta et al., 1973; Wesson et al., 1988). Though controversial, a review of literature of the
past 40 years indicates that an acute reduction in transient hyperammonemia in trained
individuals may enhance performance during high-intensity exercise, where blood
ammonia levels peak. The regimen for supplementation at present indicates dosage QD
between 5 - 15 grams over 24 hours to be most effective; however due to a myriad of
testing modalities, subject characteristics, and dosage regimes the acute application of LAspartic Acid to reduce exercise-induced hyperammonemia (EIH) to enhance highintensity performance is unclear (Gupta et al., 1973; Wesson et al., 1988).
This study investigated the hypothesis that acute aspartic acid intake will 1) lower
hyperammonemia and 2) improve high-intensity arm-crank power in both highly upper
body trained intercollegiate male water polo players and moderately upper–body trained
college students.
3.2 Methods
3.2.1 Subjects
Nine highly upper body trained intercollegiate water polo players (WP) and nine
moderately upper body trained (MOD) college-age male students attending Brigham
Young University – Hawaii (BYU-H) volunteered for the study, which had the approval of
the Institutional Review Board of the university. Subject characteristics (mean, SEM, SD,
minimum, and maximum) for WP and MOD are presented in Table 3.1 and Table 3.2,
respectively. Subjects were fully informed of the nature of the study, the possible risks
associated with participation, and their right to withdraw at any time. Their understanding
of this was provided by written informed consent. WP consisted of in-season
intercollegiate water polo athletes, who supplemented daily swim workouts with weight
training 3-5x/week. MOD subjects were recreationally-trained in activities including
72

Table 3.1. Descriptive characteristics for intercollegiate water polo (WP) players (n = 9).

Subject
Initials
CS
CA
JB
KD
RS
SP
VM
AW
DY

Subject #
(M/F)
1
2
3
4
5
6
7
8
9

Age
(yr)
18
18
18
18
18
18
19
23
18

Height
(cm)
180.3
180.3
182.9
172.7
190.5
180.3
190.5
180.3
180.3

Weight
(kg)
79.5
84.1
84.1
65.9
72.7
77.3
93.2
84.5
84.1

Dosage
(mg/kg)
157.1
148.6
148.6
189.7
171.9
161.8
134.1
147.8
148.6

W.min-1
@end of
warm-up
200.0
200.0
200.0
200.0
200.0
200.0
200.0
200.0
200.0

Mean
18.7
182.0
80.6
156.5
200.0
SEM
0.6
1.8
2.6
5.4
0.0
SD
1.7
5.5
7.9
16.3
0.0
Minimum
18.0
172.7
65.9
134.1
200.0
Maximum
23.0
190.5
93.2
189.7
200.0
mg/kg – relative dosage of 12.5 grams of L-Aspartic Acid per kg body weight
Table 3.2. Descriptive characteristics for moderately-trained (MOD) subjects (n = 9).

Subject
Initials
AM
CJ
EM
DN
RO
DN
JA
NG
JB

Subject #
(M/F)
1
2
3
4
5
6
7
8
9

Age
(yr)
22
23
24
23
20
24
24
22
22

Height
(cm)
185.42
172.72
180.34
193.04
177.80
170.20
182.90
170.20
172.70

Weight
(kg)
72.7
61.4
71.4
88.6
72.7
66.8
85.5
68.2
77.3

Dosage
(mg/kg)
171.9
203.7
175.2
141.0
171.9
187.1
146.3
183.3
161.8

W.min-1
@RPE 17
150.0
100.0
175.0
150.0
175.0
150.0
200.0
150.0
175.0

Mean
22.7
178.4
73.8
171.3
158.3
SEM
0.4
2.6
2.9
6.6
9.3
SD
1.3
7.8
8.7
19.7
28.0
Minimum
20.0
170.2
61.4
141.0
100.0
Maximum
24.0
193.0
88.6
203.7
200.0
RPE - rating of perceived exertion (6-20) scale
mg/kg – relative dosage of 12.5 grams of L-Aspartic Acid per kg body weight
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tennis, swimming, surfing, and weight training. Pertaining to diet, subjects were instructed
to abstain from alcoholic beverages, caffeine, and tobacco for the duration of the study, and
further, to keep dietary and exercise habits consistent across sessions. Training status was
assessed by wattage (W·min-1) achieved at an RPE of 17 (6-20 scale) on an incremental
arm ergometer protocol.
Arm ergometry was chosen as the testing modality because it was specific to the
upper body training status of the subjects. In addition, arm ergometry involved a smaller
muscle mass, and therefore less endurance and less lab time. Further, testing via arm crank
limited the confounding factors, which might have been observed due to inter-individual
variations in day-to-day leg activity patterns.
3.2.2 Protocol
A counterbalanced double blind design determined order of L-Aspartic Acid (A) or
placebo (P) supplementation, while a third party distributed two drink powder packets to
the subject(s) prior to each session. Subjects were instructed to mix the contents in 8
ounces of water, and ingest one packet 24 hours and the second packet 1 hour prior to
testing. One session followed ingestion of 12.5g x 2 of aspartate (Source Naturals, Inc.,
Scotts Valley, CA) mixed in 20g of powdered Powerade© (The Minute Maid Company for
Coca-Cola USA, Northlake, IL), while the other session followed ingestion of 20g of
powdered Powerade© only. Powders were weighed to within 0.1g on a VWR Sargent
Welch Calibrated Scale (VWR Scientific Products #WLS2648-30).
Subjects reported to the laboratory for two sessions of incremental seated arm
ergometry (Monark Model #881). At least 48 hours separated each session. The exercise
protocol consisted of two parts: 1) an incremental warm-up at a constant 100 rpm
immediately followed by 2) all-out performance (sprint to volitional exhaustion). The
purpose of the warm-up was to have the subject achieve an RPE of 17 (very hard) to
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precede the sprint. The warm-up consisted of a series of 30-second stages, at an initial
intensity of 25 W·min-1, with an increase of 25 W·min-1 each stage. The all-out power test
to exhaustion began at the 4-minute mark for WP, and at completion of the RPE 17 (6-20
scale) stage for MOD. Warm-up duration across sessions was kept the same intra-subject,
while inter-subject the warm-up duration varied for MOD. Cadence (rpm) was monitored
during warm-up by both technician and subject via electronic readout to maintain the
correct cranking rate. Rpm and total revolutions were monitored and tracked, respectively,
via an integrated electronic readout. Verbal feedback was used to help subjects stay at
target cadence during warm-up. The warm-up portion ended, and the performance phase
began, when the subject completed the stage in which the RPE of 17 was attained. At that
point, with a countdown of 5-4-3-2-1, at a command of “GO!”, the subjects turned the
crank “as fast as possible for as long as possible” until volitional exhaustion where
cadence, total revolutions, and time achieved were not visible to the subject. Warm-up
duration (seconds), performance duration (seconds), warm-up revolutions, and performance
revolutions were tabulated, and from this data, warm-up and performance power (W·min-1)
were calculated via:

W·min-1 = (standard ergometer wattage / standard revolutions) x (revolutions / seconds) x
(60 seconds / 1 minute)
Seated blood samples were drawn 3 minutes post exercise. Following alcohol
preparation of skin, a 21 gauge 1" Vacutainer© (Becton Dickinson and Co. Vacutainer
Systems, Franklin Lakes, NJ) double-sided blood collection needle (#36-7212) was
inserted into a superficial antecubital vein. A red top Vacutainer© tube with sterile interior
was then inserted into the surrounding needle hub, and a 4-6 ml blood sample drawn for
about 15 seconds. Blood samples were placed immediately into an ice bath for 10 minutes,
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and centrifuged for 10' at 3400 rpm (Fisher Scientific Centrific Model 228). Serum was
transferred via disposable 3.2 ml polyethylene transfer pipettes (#13-711-7, Fisher
Scientific, Pittsburgh, PA) into labeled 1.5 ml micro polypropylene metal-free test tubes (#
223-9480, Bio-Rad Laboratories, Hercules, CA), sealed with attached caps, and frozen
immediately at 20 degrees Celsius for subsequent batch analysis. Serum [NH3] were
determined via a Kodak Ektachem Analyzer (Eastman Kodak Company, Rochester, NY)
using Ektachem NH3/Amon Clinical Chemistry Slides (Johnson and Johnson Clinical
Diagnostics, Rochester, NY) using a phenol hypochlorite colorimetric technique.
3.2.3 Statistical Analyses
Performance power (W·min-1) and blood [NH3] were compared across treatments
and groups using a 2 x 2 ANOVA with repeated measures, with post-hoc differences
determined using Tukey’s test. All statistical analyses were conducted using GB-STAT
software. Significance was considered at p < 0.05.
3.3 Results
As specified per analyses, results are reported as the mean ± SEM, the actual value,
the absolute change, or the percentage change in response to treatment. Figure 3.1 shows
the individual blood ammonia concentrations [µM/L] following exercise in response to LAspartic Acid (L-Asp) supplementation or placebo in intercollegiate water polo players
(WP). Eight of the 9 of WP, or 89% demonstrated lower blood ammonia concentration
with L-Aspartic Acid supplementation (versus placebo). Figure 3.2 shows individual blood
ammonia concentrations [µM/L] following exercise in response to L-Aspartic Acid (L-Asp)
or placebo in moderately-trained college males (MOD). As observed with WP, eight of the
9 of MOD, or 89% demonstrated lower blood ammonia concentration with L-Aspartic Acid
supplementation.
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Figure 3.1. Individual responses in blood NH3 [µM/L] following treatment with either LAspartic Acid (L-Asp) or placebo in intercollegiate water polo players (n = 9).
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Figure 3.2. Individual responses in blood NH3 [µM/L] following treatment with either LAspartic Acid (L-Asp) or placebo in moderately-trained college-age males (n = 9).
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Figure 3.3 illustrates the individual responses in performance power (W·min-1) to LAspartic Acid treatment versus placebo in intercollegiate water polo players. Seven of the
9 WP subjects, or 77%, demonstrated greater power production with L-Aspartic Acid
supplementation. Figure 3.4 illustrates the individual responses in power production
(W·min-1) to L-Aspartic Acid treatment versus placebo in moderately-trained college
males. Only four of the 9 MOD subjects, or 44%, demonstrated greater power production
with L-Aspartic Acid supplementation.
Figure 3.5 illustrates the comparative percentage change in blood NH3 [µM/L] and
performance power (W·min-1) in WP and MOD in response to L-Aspartic Acid
supplementation vs. placebo. Blood NH3 [µM/L] dropped significantly (F = 23.19, p <
0.0001) with A (versus P) in WP by 16.7% (241.0 ± 18.4 vs. 200.6 ± 20.5, p < 0.01) and in
MOD by 15.5% (219.7 ± 20.8 vs. 185.6 ± 27.5, p < 0.05). On the other hand, performance
power (W·min-1) increased significantly (p < 0.01) with A (versus P) in WP by 22.7% (270
± 19.7 vs. 227.6 ± 14.3) with no significant change (p > 0.05) in MOD at 11.5% (220.1 ±
9.1 vs. 204.4 ± 8.3). There was no significant difference (p > 0.05) in mean warm-up
terminal wattage (W·min-1) between treatments (175 aspartate vs. 177 placebo).
Figure 3.6 illustrates individual changes (vs. placebo) in blood ammonia [µM/L]
relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in WP. As the
relative L-Aspartic Acid dose (mg/kg) decreased in WP, to below 160 mg/kg, there was a
tendency for blood ammonia concentration to drop (vs. placebo) by as much as [100
µM/L], which occurred at about 130 mg/kg. Figure 3.7 illustrates the individual changes
(vs. placebo) in blood ammonia [µM/L] relative to the L-Aspartic Acid dose adjusted for
body weight (mg/kg) in MOD. As observed in WP, blood ammonia [µM/L] tended to drop
with lower dosages, however, with a higher degree of variability in MOD versus WP.
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Figure 3.3. Individual responses in performance power (W·min-1) following treatment with
either L-Aspartic Acid (L-Asp) or placebo in intercollegiate water polo players (n = 9).
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Figure 3.4. Individual responses in performance power (W·min-1) following treatment with
either L-Aspartic Acid (L-Asp) or placebo in moderately-trained college-age males (n = 9).
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Figure 3.5. Mean percentage changes (vs. placebo) in blood NH3 [µM/L] and performance
power (W·min-1) in response to L-Aspartic Acid supplementation in water polo players
(WP) and moderately-trained males (MOD).
*p < 0.05 versus placebo.
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Figure 3.6. Individual changes (vs. placebo) in blood NH3 [µM/L] relative to the L-Aspartic
Acid dose adjusted for body weight (mg/kg) in intercollegiate water polo players.
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Figure 3.7. Individual changes (vs. placebo) in blood NH3 [µM/L] relative to the L-Aspartic
Acid dose adjusted for body weight (mg/kg) in moderately-trained males.
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Figure 3.8 illustrates the individual changes (vs. placebo) in performance power
(W·min-1) relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in WP.
There was a trend for a greater magnitude of performance enhancement (e.g. > 100 W·min1

improvement) as the relative supplementation dosage was reduced, e.g., to below 150

mg/kg. Figure 3.9 illustrates the individual changes (vs. placebo) in performance power
(W·min-1) relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in MOD.
This figure contrasts smaller (and fewer) improvements in power in MOD versus WP, with
a higher (mean ± SD) relative dose per unit body weight (mg/kg) noted for MOD versus
WP (171.3 ± 19.7 vs. 156.6 ± 16.3 mg/kg, respectively).
3.4 Discussion
This investigation tested the hypothesis that acute aspartic acid intake would 1)
lower hyperammonemia and 2) improve high-intensity arm-crank power in two groups of
college-age males. One group was highly-trained (i.e. in-season intercollegiate water polo
players) for upper body activity, and the other was moderately-trained (i.e. weight training,
surfing) for upper body activity. Both test groups included comparison to a placebo. We
found a significant increase in short-term, high-intensity, upper body power output
following L-Aspartic Acid supplementation in the highly-trained intercollegiate water polo
players, but not in the moderately-trained group. Blood ammonia concentrations were
lower with L-Aspartic Acid supplementation in both groups.
The current investigation found that 12.5 g x 2 QD of aspartate reduced exerciseinduced hyperammonemia and enhanced short-term power in highly-trained male
intercollegiate water polo players. On the other hand, acutely reducing NH3 by aspartate
supplementation did not conclusively improve short-term arm power in moderately-trained
males. This suggests that hyperammonemia and performance response to aspartate
supplementation are reflective of status and specificity of training. These improvements in
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Figure 3.8. Individual changes (vs. placebo) in performance power (W·min-1) relative to the
L-Aspartic Acid dose adjusted for body weight (mg/kg) in intercollegiate water polo
players.
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Figure 3.9. Individual changes (vs. placebo) in performance power (W·min-1) relative to the
L-Aspartic Acid dose adjusted for body weight (mg/kg) in moderately-trained males.
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trained subjects agree with the data of Wesson et al. (1988) and Ritter et al. (1998), and are
at odds with Columbani et al. (2000). The small (i.e. ~10 - 20%) drop in hyperammonemia
in the moderately-trained group may not have been great enough to create an observable
increase in short-term power, which is in agreement with results with arm work by DeHaan
et al. (1985) and Tuttle et al. (1995). However, these studies with upper body activity were
of low to moderate intensity, which tend to keep blood ammonia levels under [100 µM/L]
(Tuttle et al., 1995). In the current study, the L-Aspartic Acid dose (mean ± SD) expressed
in terms of mg/kg body weight was 156.6 ± 16.3 versus 171.3 ± 19.7 in WP and MOD,
respectively. The finding of the successful reduction of hyperammonemia coupled with
lack of performance improvement in the lesser-trained group warrants further work in
moderately-trained subjects to possibly consider different doses (e.g. 5, 7.5, 10g x 2 QD,
relative to body mass) of L-Aspartic Acid.
Possibly, gluconeogenesis was activated to a greater extent in the moderatelytrained group (versus well-trained) to meet ATP demand. This in turn would elevate the
rate of production of alanine, pyruvate, lactate, OAA, glucose, ATP, and ammonia. The
effects of aspartate supplementation on the production of each are unclear, however, as
noted by Stryer (1995), accumulation of acetyl-CoA and pyruvate shifts bioenergetics
toward OAA formation and gluconeogenesis, and thus away from the TCA cycle by the
action of pyruvate carboxylase. Furthermore, studies conducted on animals show aspartate
supplementation in untrained subjects (in singular and in combination) accelerates pyruvate
carboxylase activity more than in well-trained individuals (Lancha et al., 1995, Lancha,
1997). For example, in response to high-intensity exercise, pyruvate carboxylase activity is
higher in untrained (12x vs. rest) rat soleus versus trained (3x vs. rest). This suggests a
glycogen sparing effect and less reliance on gluconeogenesis for ATP production with
training, and a greater rate of gluconeogenesis for ATP production with reduced training.
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However, as shown by Lancha et al. (1994), Lancha et al. (1995), and Lancha (1997),
gluconeogenesis is accelerated at exhaustion. Therefore, one would also expect higher
submaximal NH3 values in lesser-trained subjects relative to power output, and more
closely related ammonia values at exhaustion independent of training status. This
expectation is consistent with observations made in this study.
It is possible that the ammonia removal response to aspartate supplementation was
reduced in the moderately-trained subjects because the aspartate was used instead for
gluconeogenesis. Aspartate is a substrate in both transamination (i.e. for gluconeogenesis)
and in the urea cycle (for ammonia removal). During intense exercise, the bioenergetic
flow of carbon and nitrogen changes to meet the primary demand for ATP production (i.e.
gluconeogenesis). As a result, ammonia removal is compromised and hyperammonemia
ensues. Previous work in our laboratory has found that isolating and enhancing urea
production by supplementation with urea cycle amino acids (e.g. 10g each of L-arginine
and L-Ornithine) did not improve high-intensity performance in moderately-trained
subjects (Edwards and Day, 2000). In the present study, aspartate was more likely utilized
for gluconeogenesis in the moderately-trained subjects (versus the well-trained) than for
ammonia removal, which would account for the small reduction in ammonia across
treatments and lack of power improvement. Therefore, there may be a threshold reduction
in hyperammonemia (i.e. > 15%) required to create an observable performance
improvement. These results warrant measurements of blood aspartate, oxaloacetate,
aspartate aminotransferase, and pyruvate carboxylase to assess carbon and nitrogen
bioenergetic flow with aspartate supplementation and high-intensity exercise.
An interesting sidelight from this research is the influence lactic acid has on highintensity fatigue. Lactate levels and associated H+ release are associated with fatigue (Hill
et al., 1924). However, this dissertation found similar lactate levels for placebo and L89

Aspartic Acid supplementation, with greater performance in highly-trained subjects with LAspartic Acid supplementation. This suggests that blood [NH3] (coupled with creatine
phosphate depletion) may influence fatigue more than [blood lactate] in highly-trained
individuals performing high-intensity arm work.
In summary, L-Aspartic Acid supplementation yields a significant increase in shortterm, high-intensity, upper body power output in highly-trained intercollegiate water polo
players, but not in moderately-trained subjects. While blood ammonia concentrations were
lower with L-Aspartic Acid supplementation in both groups, the reduction in the
moderately-trained group may reflect a larger portion of the aspartate diverted for
gluconeogenesis. The metabolic ability of the higher trained subjects to remove blood
ammonia and increase power in response to aspartate supplementation implies that
hyperammonemia regulates fatigue more so than lactate in highly-trained subjects. For
supplementation to be effective in moderately-trained populations, future work should
focus on defining the existence of NH3 reduction thresholds.
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CHAPTER 4. IMPACT OF L-ASPARTIC ACID SUPPLEMENTATION ON HIGHINTENSITY EXERCISE HYPERAMMONEMIA AND PERFORMANCE IN FEMALES
4.1 Introduction
Strenuous physical activity (i.e. short-term intense work) elevates blood ammonia
concentrations primarily by accelerating activity of the purine nucleotide cycle (i.e. AMP
deaminase) and deamination of branched chain amino acids (Lowenstein, 1972, MacLean
et al., 1996). As determined by Lo and Dudley (1987) and Levin et al. (1969), blood
ammonia levels are inversely associated with exercise training status and performance, and
rise during intense exercise to levels included in the diagnostic criteria (i.e. > [100 µM/L])
for clinical hyperammonemia (Batshaw, 1984). Symptoms of exacerbated clinical
hyperammonemia (i.e. nausea, ataxia, dizziness) are likewise observed during intense
exercise, where a normal resting blood [NH3] of ~10-40 µM/L (Fischbach, 1988) rises to
well over [100 µM/L].
Intake of the amino acid L-Aspartate is one of several amino acids (Najarian et al.,
1958) that reduce the hyperammonemia associated with hepatic disorders, and, in some
instances improves exercise performance in healthy populations (Ahlborg et al., 1968;
Gupta et al., 1973; Wesson et al., 1988). Though controversial, a review of literature of the
past 40 years indicates that an acute reduction in transient hyperammonemia in males by ~
5 – 15 g QD of aspartate supplementation (Wesson et al., 1988, and Ritter et al., 1998) may
enhance high-intensity exercise performance. However, the ability of L-Aspartic Acid
supplementation to reduce exercise-induced hyperammonemia to enhance high-intensity
exercise performance is unknown in females. Thus, the following experiment was
conducted to address this concern.
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4.2 Methods
4.2.1 Subjects
Eighteen recreationally upper body trained college-age females (FEM) attending
Brigham Young University – Hawaii (BYU-H) volunteered for the study. Subject
characteristics (mean, SEM, SD, minimum, and maximum) are presented in Table 4.1.
Body weight (mean ± SD) (kg) was 61±7 (51-75). The study had the approval of the
Institutional Review Board of the university, and subjects were informed of the nature of
the study, the possible risks associated with participation, and of their right to withdraw at
any time before providing written consent.
Subjects were instructed to abstain from alcoholic beverages, caffeine, and tobacco
for the duration of the study, and, further, to keep dietary and exercise habits consistent
across sessions. All subjects reported at least one year of experience of upper body
recreational training 2-3x/week (i.e. weight training, surfing, swimming). None were
members of an athletic team involving strenuous upper body training (e.g. swimming,
water polo). Training status was characterized by the wattage (W·min-1) attained during the
terminal stage of an incremental arm ergometer protocol at which an RPE of 17 (6-20
scale) was achieved.
Arm ergometry was chosen as the testing modality because it was specific to the
upper body training status of the subjects. In addition, arm ergometry involved a smaller
muscle mass, and therefore less endurance and less lab time. Further, testing via arm crank
limited the confounding factors, which might have been observed due to inter-individual
variations in day-to-day leg activity patterns.
4.2.2 Protocol
A counterbalanced double blind design determined the order of L-Aspartic Acid (A)
or placebo (P) supplementation. A third party (office secretary) distributed two drink
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powder packets to the subjects prior to each session. Subjects were instructed to mix the
contents of each packet in 8 ounces of water, and ingest one drink 24 hours and the second

Table 4.1. Descriptive characteristics for recreationally-trained (FEM) females (n = 18).

Subject
Initials
AM
AH
CS
EP
EA
HH
JB
JS
KD
KW
LE
MR
NN
SC
SB
SM
TB
TF

Subject #
(M/F)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Age
(yr)
21
20
22
20
20
22
20
22
22
22
25
21
20
20
21
20
19
26

Height
(cm)
157.5
165.1
167.6
172.7
177.8
170.2
167.6
162.6
165.1
167.6
180.3
160.0
167.6
165.1
167.6
172.7
167.6
165.1

Weight
(kg)
52.7
52.3
57.3
72.7
61.4
63.6
51.4
68.2
47.7
52.3
75.0
56.8
59.1
61.4
59.1
65.0
63.6
61.8

Dosage
(mg/kg)
237.1
239.1
218.3
171.9
203.7
196.4
243.4
183.3
261.9
239.1
166.7
220.0
211.5
203.7
211.5
192.3
196.4
202.2

W.min-1
@RPE 17
100
100
125
125
100
100
100
100
100
100
100
75
75
100
100
100
100
75

Mean
21.3
167.8
60.1
211.0
98.6
SEM
0.4
1.3
1.7
6.1
3.2
SD
1.8
5.6
7.4
25.7
13.5
Minimum
19.0
157.5
47.7
166.7
75.0
Maximum
26.0
180.3
75.0
261.9
125.0
RPE - Rating of perceived exertion (6-20) scale
mg/kg – Relative dosage of 12.5 grams of L-Aspartic Acid per kg body weight

drink 1 hour prior to testing. One session followed ingestion of 12.5g x 2 of aspartate
(Source Naturals, Inc., Scotts Valley, CA) mixed in 20g of powdered Powerade© (The
Minute Maid Company for Coca-Cola USA, Northlake, IL), while the other session
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followed ingestion of 20g x 2 of powdered Powerade© only. Powders were weighed to
within 0.1g on a VWR Sargent Welch Calibrated Scale (VWR Scientific Products
#WLS2648-30).
Subjects reported to the laboratory for two sessions of incremental seated arm
ergometry (Monark Model #881). At least 48 hours separated each session. The exercise
protocol consisted of two parts: 1) an incremental warm-up at a constant 100 rpm
immediately followed by 2) all-out performance sprint to volitional exhaustion. The
purpose of the warm-up was to have the subject achieve an RPE of 17 (very hard) to
precede the sprint. The warm-up consisted of a series of 30-second stages, beginning with
an initial intensity of 25W, and followed with an increase of 25W every 30 seconds until
completion of the stage where an RPE of 17 was reached. Warm-up duration across
sessions was the same intra-subject, while inter-subject the warm-up duration varied.
Cadence (rpm) was monitored via electronic readout and the subject encouraged to
maintain the correct cranking rate. RPM and total revolutions were monitored and tracked,
respectively, via an integrated electronic readout. Verbal feedback was used to help
subjects stay at target cadence during warm-up. The all-out power test to exhaustion began
at completion of the warm-up stage where RPE reached 17 (6-20 scale). At that point, with
a countdown of 5-4-3-2-1, and at a command of “GO!”, the subjects turned the crank “as
fast as possible for as long as possible”. Warm-up revolutions, performance duration
(seconds), and performance revolutions were recorded, and warm-up and performance
power (W·min-1) were calculated via the formula:

W·min-1 = (standard ergometer wattage / standard revolutions) x (revolutions / seconds) x
(60 seconds / 1 minute)
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Seated blood samples were drawn 3 minutes post exercise. Following alcohol
preparation of skin, a 21 gauge 1" Vacutainer© (Becton Dickinson and Co. Vacutainer
Systems, Franklin Lakes, NJ) double-sided blood collection needle (#36-7212) was
inserted into a superficial antecubital vein. A red top Vacutainer© tube with sterile interior
was then inserted into the surrounding needle hub, and a 4-6 ml blood sample drawn for
about 15 seconds. Blood samples were placed immediately into an ice bath for 10 minutes,
and centrifuged for 10' at 3400 rpm (Fisher Scientific Centrific Model 228). Serum was
transferred via disposable 3.2 ml polyethylene transfer pipettes (#13-711-7, Fisher
Scientific, Pittsburgh, PA) into labeled 1.5 ml micro polypropylene metal-free test tubes (#
223-9480, Bio-Rad Laboratories, Hercules, CA), sealed with attached caps, and frozen
immediately at 20 degrees Celsius for subsequent batch analysis. Serum [NH3] was
determined via a Kodak Ektachem Analyzer (Eastman Kodak Company, Rochester, NY)
using Ektachem NH3/Amon Clinical Chemistry Slides (Johnson and Johnson Clinical
Diagnostics, Rochester, NY) using a phenol hypochlorite colorimetric technique.
4.2.3 Statistical Analyses
Performance power (W·min-1) and serum [NH3] were compared across treatments
and groups using a repeated measures analysis of variance, with potential post-hoc
differences analyzed using Tukey’s t-tests. GB STAT statistical software was used for all
analyses. Significance was set at p < 0.05.
4.3 Results
As specified per analyses, results are reported as the mean ± SEM, the actual value,
the absolute change, or the percentage change (vs. placebo) in response to treatment.
Figure 4.1 illustrates individual blood ammonia responses [µM/L] following either LAspartic Acid (L-Asp) or placebo in recreationally-trained college-age females. Nine of
the eighteen subjects, or 50%, exhibited a reduction in blood ammonia concentrations with
95

Blood NH3 [uM/L]

400

L-Asp
Placebo

300

200

100
1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18
Subject #

Figure 4.1. Individual responses in blood NH3 [µM/L] following treatment with either LAspartic Acid (L-Asp) or placebo in recreationally-trained college-age females (n = 18).
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supplementation, indicating a higher degree of variability in response with recreationallytrained college-age female subjects versus that observed in similar age males.
Figure 4.2 shows individual responses in performance power (W·min-1) following
treatment with either L-Aspartic Acid (L-Asp) or placebo in recreationally-trained collegeage females. Thirteen of the 18, or 72%, demonstrated greater power production with LAspartic Acid supplementation. However, the increases were relatively small when
compared to the power increases observed in the male studies.
Figure 4.3 illustrates the comparative (%) change in power and NH3 with LAspartic Acid supplementation versus placebo. There was no significant difference in
(mean ± SEM) post-exercise blood [NH3] between L-Aspartic Acid supplementation and
placebo (204 ± 14 µM/L vs. 212 ± 10, respectively). Additionally, there was no significant
change in performance power (W·min-1) between L-Aspartic Acid supplementation and
placebo (172 ± 40 vs. 169 ± 36, respectively). Finally, no significant difference (p > 0.05)
existed between treatments in warm-up power (W·min-1).
Figure 4.4 illustrates individual responses in absolute change (vs. placebo) in blood
NH3 [µM/L] relative to the L-Aspartic Acid dose adjusted for body weight (mg/kg) in
recreationally-trained females. Further, Figure 4.5 illustrates individual responses in
absolute change (vs. placebo) in performance power (W·min-1) relative to the L-Aspartic
Acid dose adjusted for body weight (mg/kg) in recreationally-trained females. These
illustrations reflect the apparent randomness in response of blood ammonia and
performance power at the prescribed dose. In general, females have a higher relative
(mg/kg)) dose versus males, thus, responses (or lack of) may be reflective of the relatively
larger dose. Of note, in the current experiment the relative dose (mean ± SD) for FEM
expressed in terms of mg/kg was 211.0 ± 25.7. At this average dose there was no trend for
reduced hyperammonemia or performance improvement in recreationally-trained females.
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Figure 4.2. Individual responses in performance power (W·min-1) following treatment with
either L-Aspartic Acid (L-Asp) or placebo in recreationally-trained college-age females (n
= 18).
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Figure 4.3. Mean percentage changes (vs. placebo) in blood NH3 [µM/L] and performance
power (W·min-1) in response to L-Aspartic Acid supplementation in recreationally-trained
college-age females.
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Figure 4.4. Individual changes in blood NH3 [µM/L] relative to the L-Aspartic Acid dose
adjusted for body weight (mg/kg) in recreationally-trained females.
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Figure 4.5. Individual changes (vs. placebo) in performance power (W·min-1) relative to the
L-Aspartic Acid dose adjusted for body weight (mg/kg) in recreationally-trained females.
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4.4 Discussion
This investigation is the first to report the effects of L-Aspartic Acid
supplementation on exercise-induced hyperammonemia and high-intensity performance in
females. We hypothesized that 12.5 g x 2 QD L-Aspartic Acid supplementation would
increase short-term arm crank power and reduce associated hyperammonemia. However,
hyperammonemia and performance power showed no significant response to treatment in
recreationally-trained females. This is in agreement with the male studies of Hagan et al.
(1982), Maughan and Sadler (1983), and De Haan et al. (1985), and is in contrast to the in
studies in men that have shown performance improvement (Ahlborg et al., 1968; Franz and
Chintanaseri, 1977; and Wesson et al., 1988), and the aforementioned investigation in this
dissertation. The lack of response may be due to body mass, training status (recreationallytrained), testing modality, and/or training specificity. The possible interactions of these
factors with aspartate supplementation are discussed below.
It is possible that the aspartate supplementation dose (12.5g x 2 QD, or ~ 205 mg/kg
x 2 QD) in females was too high to the relative smaller body mass. While the mechanisms
and regimen are unclear in humans, rat studies show an inverted dose response with
hyperammonemia and exercise performance with aspartate supplementation (Laborit et al.,
1958; Barnes et al., 1964; and Trudeau et al., 1993). Animal studies generally show a
favorable response with doses between 10 mg/kg – 500 mg/kg QD (Laborit et al., 1958;
Barnes et al., 1964; and Kendrick, 1976); doses over 500 mg/kg either increase
performance (Rosen et al., 1962), have no effect (Matoush et al., 1964; Trudeau et al.,
1993) or exacerbate hyperammonemia and worsen performance (Kendrick, 1976).
Therefore, a lower dose of L-Aspartic Acid (i.e. 6g x 2 QD, or ~ 50 mg/kg - 100 mg/kg x 2
QD) in recreationally-trained females may generate a more desirable dose-response benefit.
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Finally, since females generally have less absolute lean mass versus males, the magnitude
of ‘overdose’ may have been even greater.
Training status (i.e. recreationally-trained) of the subjects may have also affected
the lack of bioenergetic and performance response. Ammonia is a well-known factor in
fatigue, with trained individuals removing ammonia more efficiently versus lesser-trained
subjects (Graham et al., 1995a, Graham et al. 1997). Further, Lancha et al. (1995)
demonstrated that pyruvate carboxylase activity is higher in untrained (12x vs. rest) rat
soleus versus trained (3x vs. rest) with high-intensity exercise. Consequently, accelerated
branched-chain amino acid catabolism for ATP production promotes higher exercising
blood ammonia values. Additionally, Lancha (1997) found higher pyruvate carboxylase
activity with aspartate and asparagine supplementation in untrained rats at all times in
response to high-intensity exercise (versus control). This finding however did not occur in
trained rats. Therefore, the L-Aspartic Acid supplement in the present study may have
been recruited more as a substrate for gluconeogenesis instead of for ammonia removal.
This in turn would 1) produce greater ammonia per unit of ATP, 2) reduce a major source
of the ammonia removal mechanism, and 3) make less aspartate available as a substrate for
ammonia removal in the urea cycle. Therefore, the net result would be unchanged blood
ammonia values (or slightly higher than anticipated) and lack of performance
improvement.
Additionally, the lack of specificity of the training of the subjects to the testing
modality may have failed to affect the bioenergetic (and thus performance) response to
aspartate supplementation. As mentioned previously, Lancha et al. (1995), showed that in
response to high-intensity exercise, pyruvate carboxylase activity is higher in untrained rat
soleus versus trained. Secondly, Lancha et al. (1994) demonstrated in both trained and
untrained rats supplemented with aspartate and asparagine, a three-fold greater conversion
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(vs. placebo) of acetyl-CoA and OAA into citrate and coenzyme-A during exhaustive
exercise. Third, Lancha et al. (1995) demonstrated increased plasma aspartate, glycogen
content, FFA’s, and prolonged (+42%) swim time to exhaustion with supplementation of
aspartate, asparagine, and carnitine. Therefore, these data suggest that the bioenergetic
response to aspartate supplementation is reflective of training status, promoting a much
larger activity of both gluconeogenesis and the oxidative systems. On the other hand, if
one assumes recreationally-trained subjects have a reduced capacity of (or receptiveness to)
the pathways affected by aspartate, then a greater (or lower) availability of aspartate may
have no effect at all on ATP production or ammonia removal. In other words, if highintensity exercise pathways are either not present (in greater amounts) or are unresponsive
to aspartate supplementation, then no outward effect will be observed.
Therefore, these results suggest that response to L-Aspartic Acid supplementation
in recreationally-trained females may be dependent on both body mass and training status,
either singularly or in combination. In summary, the present investigation found no effect
of L-Aspartic Acid supplementation on short-term power or hyperammonemia in
recreationally-trained females. For supplementation to be effective, future work may
consider 1) a more highly-trained group of females, 2) a dose-response study in
proportional to the lower body mass in females (i.e. 0 mg/kg, 50 mg/kg, 100 mg/kg, 150
mg/kg ), and /or 3) a protocol more specific to the metabolic status of the subject group.
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CHAPTER 5. SUMMARY, QUESTIONS AND ANSWERS, AND CONCLUSION
5.1 Summary
This series of investigations is the first to report the effects of L-Aspartic Acid
supplementation on ammonia reduction and high-intensity arm-power. We found a
significant increase in short-term, high-intensity, upper body power output following LAspartic Acid supplementation in highly-trained intercollegiate water polo players, but not
in moderately-trained or recreationally-trained subjects. Previous reports in the literature
have concentrated on medium to long duration time to exhaustion. This dissertation is also
the first series of studies to investigate the dose-response effect of L-Aspartate ingestion
and blood ammonia, and assess the reliability of the ammonia assay across sessions.
Results from this dissertation determined the ammonia assay to be reliable, validating the
assessment of blood ammonia concentration in response to aspartate supplementation and
high-intensity exercise.
Pilot work provided general trends as to the metabolic (glycolytic and nitrogen) and
performance effects of various combinations of ammonia reducing amino acids. Pilot
results suggest that blood urea elevation exclusively does not deter, nor promote exerciseinduced hyperammonemia nor increase exercise performance. Secondly, of the ammonia
reducing amino acids (i.e. glutamate, arginine, ornithine, and aspartate), L-aspartate
appears to be the most effective for reducing short-term exercise-induced
hyperammonemia, if ingested in the 5 - 15g x 2 range over the 24 hours preceding exercise.
Furthermore, a carryover/storage effect with aspartate ingestion enhances blood ammonia
reduction across consecutive days of high-intensity exercise. Although previous work has
shown that aspartate supplementation over the week preceding long duration exercise (e.g..
a marathon) is not beneficial, the performance effect of high-intensity exercise in response
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to L-Aspartic Acid storage is unknown. Results from this dissertation suggest that highintensity short-term power and blood ammonia response to aspartate supplementation are
training status dependent. This is in contrast with the hypothesis of a general lowering of
exercise-induced hyperammonemia with L-Aspartic Acid supplementation and
improvement in performance independent of training status. The effect on exerciseinduced hyperammonemia by L-Aspartic Acid supplementation appears to be proportional
to training status (i.e. the highly-trained water polo group had the largest drop, followed by
the moderately-trained males, with no effect on blood [NH3] in recreationally-trained
females). In other words, the more highly-trained subjects responded more favorably in
both reduction of hyperammonemia and improvement in performance with aspartate
supplementation, while the lesser trained groups did not. This drop in blood ammonia was
associated with increased short-term power output in highly-trained intercollegiate water
polo players. Application of these results would include athletic events where small
increases in power may be desirable, i.e. water-polo sprinting.
The absolute aspartate (or placebo) dose regime per session per subject was
identical across the three investigations in the dissertation. Due to greater overall body
weight, males therefore have a lower (mean ± SD) relative lower dosage (mg/kg) of 12.5 g
of L-Aspartic Acid (156.6 ± 16.3, and 171 ± 19.7, WP and MOD, respectively) than the
females (211.0 ± 25.7). Therefore, as illustrated in Figure(s) 5.1 and 5.2, it is conceivable
that per unit of body weight (mg/kg) the 12.5 g dosage in the recreationally-trained females
was too high to elicit favorable responses in either hyperammonemia or performance
power. Although human results are inconclusive, data in animal models (Matoush et al.,
1964; Kendrick, 1976; and Trudeau et al., 1993) suggest an inverted dose-response effect
(lack of ammonia reduction and/or performance improvement) as dosages exceed a certain
level (i.e. in animals, approximately 500 mg/kg, independent of training status or gender).
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Figure 5.1. Individual changes (vs. placebo) in blood ammonia [µM/L] relative to the LAspartic Acid dose adjusted for body weight (mg/kg) in males and females.
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Figure 5.2. Individual changes (vs. placebo) in performance power (W·min-1) relative to the
L-Aspartic Acid dose adjusted for body weight (mg/kg) in males and females.
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Results from the dissertation suggest this to be relative doses exceeding 175 mg/kg in
college-age males and females, independent of training.
The training status of the subjects may also have affected the metabolic response to
aspartate supplementation. Previous work by Neame and Wiseman (1957) shows that
blood levels of aspartate peak in the circulation between 20 and 40 minutes following
introduction to the intestinal lumen, with concurrent mesenteric alanine blood levels rising
almost 2-fold. Alanine is a major source of both bioenergetic carbon and nitrogen, which
thus affects blood ammonia concentration. Further, it is possible the relative lack of
training in the oxidative systems in the lesser trained subjects, and increased activity of
gluconeogenesis diverted aspartate away from the TCA cycle and the urea cycle. This
would explain the lack of an observable performance improvement or enhanced reduction
of hyperammonemia with lack of training.
This dissertation is also the first to report the impact of L-Aspartic Acid
supplementation on blood ammonia concentration and high-intensity power response in
females exclusively. Figure(s) 5.1 and 5.2 illustrate the general favorable trend with a
reduction in hyperammonemia and increase in power with a relatively lower L-Aspartic
Acid supplementation dose expressed in terms of body weight (mg/kg). However, these
results indicate no treatment effect on either blood ammonia concentration or high-intensity
power in recreationally-trained females with 12.5g x 2 QD of L-Aspartic Acid
supplementation. However, the females did not exhibit reduced hyperammonemia or an
increase in power as observed in the more highly-trained men. The possibility exists that
the females were overdosed per unit of body weight, thus warranting more dosage titration
work relative to total body mass (and lean mass as well). Furthermore, more work is
needed in females who are more specifically trained to the testing modality (e.g. cross-
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country runners, treadmill running, female surfers) to therefore rule out the possible effect
of gender.
The type of protocol may have affected the toleration of exercise above the
anaerobic threshold in the lesser trained groups. In addition, the lack of metabolic system
response to aspartate supplementation in the lesser trained may also be due to lack of
specific training to the arm crank movement. The metabolic ability of the higher trained
subjects to remove blood ammonia and increase power in response to aspartate
supplementation, implies that hyperammonemia regulates fatigue more so than lactate in
highly-trained subjects.
Therefore, it appears that both ammonia clearance and aspartate bioenergetic
metabolism (i.e. aspartate substrate, alanine, fumarate, OAA, adenine nucleotide
production) affect power production in response to L-Aspartic Acid supplementation.
Results from this dissertation suggest the impact is regulated by training status, relative
aspartate dosage, and specificity of training. Athletes participating in sports as competitive
swimming, water polo sprinting, and wheelchair racing may benefit from supplementation.
Although supplementation appears effective in well-trained subjects, the suggested amount
of supplementation relative to body weight (mg/kg) and status of training is unclear, and
warrants further work.
In summary, these results suggest that aspartate ingestion may be an effective
nutritional tool for highly-trained athletes in competitions requiring short-term power
bursts (e.g. water polo sprinting), where a small improvement in power may be desirable.
Caution should be exercised for applying a crossover effect into the other competitive
athletic modalities, and for applications involving active recruitment of lesser-trained
muscle groups of the trained populations.
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5.2 Questions and Answers
5.2.1 Questions Answered
The following questions were answered by this dissertation:
1)

Does aspartate supplementation reduce blood [NH3] and improve highintensity short-term power?

Answer:

2)

In some cases. Yes in the well-trained test group. No for the
recreationally-trained group. No for the moderately-trained group
although small drops in NH3 levels were observed.

Is there a dose-response effect between variable ingestion (0,5,10,15g) of
aspartate and high-intensity blood [NH3]?

Answer: Yes and No. A general lowering of hyperammonemia is observed with
5, 10, or 15 g of aspartate versus placebo. However, it appears there is
no difference in response between 10 and 15 grams. Status and
specificity of training affect the magnitude of response.
3)

Is there an inverse relationship between maximal performance indices and
blood [NH3] at exhaustion, with state of training?

Answer:

4)

Is there an 'ammonia tolerance' threshold, i.e. an absolute blood
concentration or percentage change from rest, where the subject requests to
stop?

Answer:

5)

Probably. Ammonia tolerance seems to depend on training status, task
familiarity, and intensity familiarity. With short-term protocols, blood
[NH3] between 200 and 250 µM/L are tolerated with difficulty; with
NH3 > [250 µM/L] the subject requests to stop.

Is ammonia tolerance and power output during high-intensity exercise more
reflective of status of specificity of training?

Answer:

6)

The relationship is unclear, but doubtful. Present work showed similar
NH3 levels (~ [200 – 250 µM/L]) across training status at exhaustion
independent of that status - but higher power output with trained
subjects.

Yes. The highly-trained test group were able to generate more power
than the moderately-trained test group at similar NH3 concentrations and
further, respond favorably to aspartate supplementation reduce blood
ammonia, and increase power even more.

Is there a crossover effect of blood ammonia clearance, in regard to training
status across testing modalities (arm ergometry testing vs. leg-trained
subjects)?
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Answer:
7)

Were the levels of NH3 at exhaustion lower in women versus men?

Answer:

8)

Not observed in the present study, marginal improvement at best.

Yes and No. In absolute terms, NH3 levels for the women in this
dissertation were comparable to males. Relative to power output, NH3
levels for women were higher; however, the effect of gender is
unknown, suggesting future work in a higher-trained group of females
well-trained to the testing modality.

How much blood ammonia reduction (%, [µM/L]) is required to observe
changes in high-intensity power?

Answer:

Depends on training status. In the highly-trained test group NH3
reductions of least 15% yielded an observable increase in power output.
In the other tests groups, supplementation did not result in appreciable
decreases in NH3; warranting future dose-response work.

5.2.2 Future Questions to be Investigated
1)

Is there a dose-response effect between variable ingestion (0,5,10,15g) of
aspartate, and maximal short-term performance power?

Answer:
2)

Do females have a different ammonia tolerance capacity versus males?

Answer:

3)

Unknown

Unclear. To address this, future work may consider 1) a more highlytrained group of females, 2) a dose-response study in proportional to the
lower body mass in females (i.e. 0 mg/kg, 50 mg/kg, 100 mg/kg, 150
mg/kg), and /or 3) a protocol more specific to subject metabolic status.

Do subjects have a crossover 'ammonia tolerance' threshold(s) of specificity
of training, for arms vs. legs?

Answer:

Doubtful, marginal at best

5.3 Conclusion
It appears from this dissertation that 12.5 g x 2 QD of aspartate reduces
hyperammonemia and enhances short-term power in intercollegiate water polo players.
However, in moderately-trained males or recreationally-trained females, 12.5 g x 2 QD of
aspartate does not attenuate hyperammonemia to the degree to improve power.
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APPENDIX A. SUBJECT CONSENT
The Impact of Aspartate Ingestion and Ammonia Reduction on Exercise Metabolism and
Performance (Randy Day, Ph.D., William W. Edwards, M.S.)
In order to investigate the effects of amino acid ingestion on upper body performance, I
hereby volunteer to participate in an experiment conducted by the Dept. Of Biology of
BYU-Hawaii. I have been informed of the nature of the experiment, and of the risks
involved in an exercise test. I understand that an amino acid supplement will be mixed in a
commercial performance beverage for consumption prior to testing, and agree to keep my
dietary and exercise habits consistent across testing days, and to abstain from caffeine,
alcohol, and tobacco use for the duration of the experiment.
I acknowledge that a venous forearm blood draw will be performed following each exercise
test by trained personnel. The data obtained from my participation will receive impersonal
statistical treatment, with my rights to privacy protected. My personal identity remains
anonymous unless permission is granted otherwise.
Furthermore, I may withdraw from the experiment at any time. Any questions concerning
the experiment have been answered to my satisfaction, and I understand that I may ask
further questions once the experiment is complete.

___________________________________
Name (printed)
___________________________________
Signature
Date

_______________________

___________________________________
Witness
Date

_______________________
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APPENDIX B. PILOT STUDY 1: THE EFFECTS OF SUPPLEMENTATION OF
AMMONIA REDUCING AMINO ACIDS ON EXERCISE METABOLISM AND HIGHINTENSITY PERFORMANCE
B.1 Introduction
Previous work has suggested that an acute reduction in blood ammonia by ingestion
of ammonia reducing amino acids may improve medium and long duration athletic
performance. However, it is unclear as to whether the reduction in blood ammonia in this
manner may improve short-term high-intensity performance (endurance, strength, power,
speed) where blood ammonia values peak. Therefore, this study explored the effect of
ingestion of a combination of ammonia-reducing amino acids on blood ammonia, urea,
lactate, and exhaustion time in response to high-intensity cycling ergometry.
B.2 Methods
B.2.1 Subjects
Three moderately-trained college-age males were informed of the nature of the
study, and of the possible risks involved, before giving written consent in accordance with
university guidelines and approval by the institutional review board of Louisiana State
University, Baton Rouge, LA. Descriptive statistics are presented in Table B.1.
B.2.2 Protocol
All exercise tests were performed on a calibrated friction-braked bicycle ergometer
(Monark #860) at a pedal frequency of 80 rpm. Each subject performed a preliminary
incremental exercise test for assessment of VO2max. Following instrument calibrations and
a 2-minute exercise warm-up, the testing began at a resistance of 50 watts, and increased 50
watts/minute until metronome cadence dropped to lower than 60 rpm with best effort.
Oxygen consumption, carbon dioxide production (VCO2), and expired ventilation
(VE) were measured via open-circuit spirometry. Normoxic inspired gas volumes were
monitored by a dry gas meter. Subjects breathed through a low-resistance (Rudolph)
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Table B.1. Descriptive characteristics of subjects in pilot study 1.

Variable
Age (yr)
Weight (kg)
VO2max
(ml.kg.min-1)
VO2max
(L/min)
VESTPDmax
(L/min)
RQmax
HRmax
kpmax

Subject 1
(MC)
26

Subject 2
(RM)
27

Subject 3
(BW)
26

68.2

68.6

66.4

55.3

61.5

52.1

3.8

4.2

3.5

118
1.2
184
3.2

114
1.17
193
5

114
1.22
180
3.5

non-rebreathing valve, with expired gases passing into and through a 5-liter mixing
chamber. O2 and CO2 gas fractions (FEO2, FECO2) were analyzed by the Beckman OM-11
and LB-2, respectively, and interfaced with an Apple IIe computer. Heart rate was
monitored by one-lead electrocardiography (CM5).
A crossover method of experimentation was employed, and hence each subject
served as his own control. Testing was conducted at least 8 hours post-prandial, following
a 12-hour period of ingestion of either placebo or 2g each of L-Aspartate, L-Ornithine, LArginine, and L-Glutamate. Half the dosage was consumed 12 hours before testing, with
the other half consumed 1 hour before testing. Corn starch served as the placebo. A
double-blind experimental design and a counterbalanced order of testing determined the
order of active substance/placebo administration.
Subjects exercised to exhaustion on two occasions on a bicycle ergometer at a
power output corresponding to 120% VO2max, following placebo or amino acid ingestion.
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Following a 2-minute warm-up at .75 kp, subjects pedaled at 120% VO2max until cadence
fell below 60 rpm with best effort.
B.2.3 Biochemical Analyses
A 5 ml blood sample was collected from a superficial forearm vein via indwelling
catheter with the subject in a seated position at rest, and at 1 and 4 minutes post-exercise.
Each was assayed in duplicate for blood lactate (lactate dehydrogenase method), plasma
NH3 (phenol hypochlorite method), and plasma urea (urease/phenol hypochlorite method)
utilizing Sigma Chemical Co. (St. Louis, Mo.) diagnostic kits. Each sample was injected
immediately into a green-top Vacutainer@ tube (heparinized) and immediately placed
within an ice bath. One ml of the sample was then mixed with 2 ml of a cold 7%
perchlorate solution, centrifuged (5000 rpm x 2 minutes), and the supernatant frozen for
subsequent lactate determination. The remainder of the blood sample was centrifuged
(5000 rpm x 2 minutes), and the harvested plasma frozen (-20 Co) within 30 minutes after
collection.
B.3 Results
Results are presented in Table B.2. Blood samples (seated, resting) acquired at rest,
one minute post-exercise (X1) and four minutes post-exercise (X4) showed a general trend
of lowering of blood ammonia and rising of blood urea with supplementation. Time to
exhaustion was not significantly different between treatments.
B.4 Summary
Results from this pilot study indicate that a combination of aspartate, glutamate,
arginine, and ornithine supplementation increases blood urea production and reduces blood
ammonia concentration versus placebo, but has no effect on high-intensity short term
performance. A larger sample size and isolation of these amino acids will further elucidate
the clearance pattern and mechanisms of blood ammonia removal.
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Table B.2. Individual plasma NH3 [µM/L], blood urea nitrogen [mg/dl], and time to
exhaustion (seconds) in response to placebo (P) or L-Aspartate, L-Glutamate, L-Ornithine,
and L-Arginine (A) supplementation.
Subject
1 MC
2 RM
3 BW

P R [NH3]
64
21
14

Mean
SEM
SD
Minimum
Maximum

33.0
15.6
27.1
14
64

Subject P R [BUN]
1 MC
19
2 RM
16
3 BW
14

A R [NH3] P X1 [NH3] A X1 [NH3] P X4 [NH3] A X4 [NH3]
20
115
50
110
51
13
26
17
32
22
33
48
16
46
24
22.0
5.9
10.1
13
33

63.0
26.8
46.4
26
115

27.7
11.2
19.3
16
50

62.7
24.0
41.6
32
110

32.3
9.4
16.2
22
51

A R [BUN] P X1 [BUN] A X1 [BUN] P X4 [BUN] A X4 BUN]
17
17
17
17
23
10
14
23
12
22
18
24
28
24
22

Mean
SEM
SD
Minimum
Maximum

16.3
1.5
2.5
14
19

15.0
2.5
4.4
10
18

Subject
1 MC
2 RM
3 BW

P WTE
89.9
171.4
154.5

A WTE
82.4
178.4
148

18.3
3.0
5.1
14
24

22.7
3.2
5.5
17
28

17.7
3.5
6.0
12
24

22.3
0.3
0.6
22
23

Mean
138.6
136.3
SEM
24.8
28.3
SD
43.0
49.1
Minimum
89.9
82.4
Maximum
171.4
178.4
P = placebo; A = amino acid supplementation; R = at rest; X1 = 1 minute post-exercise;
X4 = 4 minutes post-exercise; NH3 = plasma ammonia concentration [µM/L]; BUN =
blood urea nitrogen [mg/dl]; SEM = standard error of measurement; SD = standard
deviation from the mean; WTE = work time to exhaustion (seconds).
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APPENDIX C. PILOT STUDY 2: THE EFFECTS OF L-ARGININE AND LORNITHINE SUPPLEMENTATION ON AMMONIA CLEARANCE AND EXERCISE
PERFORMANCE
C.1 Introduction
The non-essential non-toxic amino acids L-Arginine (L-Arg) and L-Ornithine (LOrn) clinically attenuate hyperammonemia associated with hepatic encephalopathy (Fahey,
1957; Salvatore et al., 1964; Batshaw, 1984). Pilot work in our laboratory has also found
sharp drops in blood ammonia and rise in blood urea nitrogen in response to short-term
high-intensity cycle ergometry with supplementation of ammonia reducing amino acids
including L-Arginine and L-Ornithine (i.e. aspartate, glutamate, arginine, ornithine).
However, due to varying biochemical pathways, it is unclear as to the magnitude of the
effect contributed by the different types of amino acids. Further, to date there are no
published scientific reports as to supplementation of the ammonia-clearing urea cycle
amino acids L-Arginine and L-Ornithine to improve 1) exercise-induced hyperammonemia,
2) time to exhaustion, and 3) urea cycle activity. Therefore, the purpose of this pilot study
was to isolate and explore the effects of L-Arginine and L-Ornithine supplementation on
blood ammonia and urea, and time to exhaustion with ramp treadmill exercise.
C.2 Methods
Ten moderately-trained (VO2max 52.2 ml/kg/min ± 2.2 SEM) college males
exercised to exhaustion on two occasions, using a modified Bruce protocol. Subject
characteristics are presented in Table C.2. VO2max was measured using a Sensormedics
2900 metabolic cart. Subjects ingested either 10g L-Arginine and 10g L-Ornithine (A), or
placebo (P), administered 12 hours and 30’ before the treadmill test. Forearm venous
samples were taken at 0, 1, 3, and 5 minutes during seated recovery, and centrifuged within
one minute of collection. Plasma samples were placed into an ice bath and assayed within
five minutes for urea nitrogen [BUN] and [NH3] by a Kodak Ektachem DT60 analyzer.
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Table C.1. Descriptive characteristics of subjects in pilot study 2.

Subject
1
2
3
4
5
6
7
8
9
10

Age
(yr)
18
23
25
22
22
25
23
20
21
21

Weight
(kg)
75
74
75
65
102
79
90
75
68
61

VO2max
(ml.kg.min-1)
56.5
49.2
51.1
56.7
39.0
54.9
43.5
60.5
58.8
51.3

Mean
22.0
76.4
52.2
SEM
0.7
3.8
2.2
SD
2.2
12.0
6.8
Minimum
18.0
61.0
39.0
Maximum
25.0
102.0
60.5
SEM – standard error of measurement; SD – standard deviation from the mean
C.3 Results
Table C.2 presents individual BUN responses [mg/dl] to 10g L-Arginine and 10g LOrnithine (A) and placebo (P), while Table C.3 presents individual blood ammonia
responses [µM/L], respectively. [BUN] was ~ 40% higher in the A group vs. placebo
during recovery. Blood [NH3] continued to rise after exercise, but did not differ between
treatment groups. Time to exhaustion and VO2max did not differ across treatments (10.63
minutes, A; vs. 10.5 minutes, P).
C.4 Summary
This study was designed to examine the effects of L-Arginine and L-Ornithine
supplementation on ammonia metabolism and urea cycle activity following maximal
exercise. We found a large significant increase in the output of urea following L-Arginine
and L-Ornithine supplementation; however, a similar change in blood ammonia reduction
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Table C.2. Individual blood urea nitrogen [mg/dl] at rest (R), exhaustion (X0), and during
recovery (X1, X3, and X5) in response to placebo (P) or 10g L-Arginine and 10g LOrnithine (A) supplementation. Complete bloodwork was available for n = 8.
Subject P R [BUN] P X0 [BUN] P X1 [BUN] P X3 [BUN] P X5 [BUN]
1
11
11
12
12
11
2
11
11
12
11
10
3
11
11
10
10
10
4
12
11
9
11
10
5
10
9
11
9
9
6
12
10
11
10
10
7
12
11
12
10
10
8
11
11
11
10
10
Mean
SEM
SD
Minimum
Maximum

11.3
0.2
0.7
10
12

10.6
0.3
0.7
9
11

11.0
0.4
1.1
9
12

10.4
0.3
0.9
9
12

10.0
0.2
0.5
9
11

Subject A R [BUN] A X0 [BUN] A X1 [BUN] A X3 [BUN] A X5 [BUN]
1
17
16
15
16
15
2
13
11
11
11
11
3
12
12
11
11
11
4
19
17
17
17
17
5
12
16
15
15
14
6
18
16
16
16
16
7
18
18
17
16
16
8
16
15
15
15
14
Mean
15.6
15.1
14.6
14.6
14.3
SEM
1.0
0.9
0.8
0.8
0.8
SD
2.9
2.4
2.4
2.3
2.2
Minimum
12
11
11
11
11
Maximum
19
18
17
17
17
P = placebo; A = amino acid supplementation; X0 = exhaustion; X1 = 1 minute postexercise; X3 = 3 minutes post-exercise; X5 = 5 minutes post-exercise; BUN = plasma urea
nitrogen [mg/dl]; SEM – standard error of measurement; SD – standard deviation from the
mean
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Table C.3. Individual blood NH3 [µM/L] at rest (R), exhaustion (X0), and during recovery
(X1, X3, and X5) in response to placebo (P) or 10g L-Arginine and 10g L-Ornithine (A)
supplementation. Complete bloodwork was available for n = 7.
Subject
1
2
3
4
5
6
7

P R [NH3]
46
57
78
71
87
59
125

Mean
SEM
SD
Minimum
Maximum

74.7
9.9
26.1
46
125

P X0 [NH3] P X1 [NH3] P X3 [NH3] P X5 [NH3]
152
171
169
155
188
191
196
281
163
186
279
221
165
241
244
227
206
215
199
283
206
228
250
282
255
261
277
208
190.7
13.4
35.4
152
255

213.3
12.2
32.4
171
261

230.6
16.2
42.9
169
279

236.7
18.3
48.3
155
283

Subject A R [NH3] A X0 [NH3] A X1 [NH3] A X3 [NH3] A X5 [NH3]
1
78
105
145
130
123
2
70
135
142
112
140
3
47
193
209
233
239
4
56
178
209
267
255
5
49
195
222
224
248
6
91
189
217
233
270
7
112
196
214
255
190
Mean
71.9
170.1
194.0
207.7
209.3
SEM
9.0
13.5
13.2
23.1
22.2
SD
23.8
35.8
34.8
61.2
58.8
Minimum
47
105
142
112
123
Maximum
112
196
222
267
270
P = placebo; A = amino acid supplementation; X0 = exhaustion; X1 = 1 minute postexercise; X3 = 3 minutes post-exercise; X5 = 5 minutes post-exercise; NH3 = blood
ammonia concentration [µM/L]; SEM – standard error of measurement; SD – standard
deviation from the mean
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was not observed. The pattern for the attenuation of exercise-induced hyperammonemia
varies. Some studies have shown that ammonia clearance is rapid following exercise
(Banister et al., 1983; Banister et al., 1985), while others have indicated that blood
ammonia levels continue to rise after intense exercise (Wilkerson et al., 1975; Wilkerson et
al., 1977). Several studies have suggested that there are a number of factors that regulate
ammonia clearance during recovery including muscle fiber type, training state, exercise
mode, and terminating intensity (Graham et al., 1995; Graham et al., 1995a).
Under normal, resting conditions, the majority of ammonia produced is excreted as
urea, the principal nitrogen component of urine. When the urea cycle is stressed during
intense muscular work, accessory pathways (i.e. glutamate + NH3 <=> glutamine) are
detected. In addition, an accelerated conversion of ammonia into carbamoyl phosphate for
entry into the urea cycle increases pyrimidine by-products. Both glutamine and pyrimidine
are present in urine.
Ammonia is a factor in promoting fatigue. However, the therapeutic impact and
regime for short-term ammonia reduction during exercise is not clear. L-Glutamate, LArginine, and L-Ornithine have been administered to humans at rest with sharp drops in
[NH3] (Salvatore et al., 1964; Fahey, 1957). However, these results were in clinical
situations, and thus a crossover effect to healthy, and highly-trained subjects, is
questionable. Though it appears from this study that 10g of L-Arg and 10g of L-Orn
sharply elevate blood urea nitrogen, they did not attenuate exercise-induced
hyperammonemia nor affect work time to exhaustion.
Results from this study indicate:
1)
2)

Supplementation with urea cycle intermediates is effective for short-term
urea production from exercise-induced hyperammonemia,
Blood [NH3] levels are not affected in the same magnitude as urea
production with augmented short-term ureagenesis
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3)
4)

Short-term work time to exhaustion and VO2max on the treadmill are not
enhanced by accelerated ureagenesis and
Additional ammonia metabolic pathways (i.e. synthesis of glutamine,
alanine, hippurate, phenylacetylglutamine) clear blood [NH3] in response to
intense exercise.

Results from the preceding two pilot studies raised the following questions:
1)

Does a short-term reduction in blood [NH3] affect high-intensity physical
performance indices (peak power); and, if so, what percentage of ammonia
reduction ([µM/L]) is required?

2)

Is there a crossover effect of blood ammonia clearance, in regard to training
status across testing modalities (arm ergometry vs. leg extension) in vivo?

3)

Is there a dose-response effect between variable ingestion (0,5,10,15g) of
aspartate, blood [NH3] at exhaustion, and maximal physical performance
indices?

4)

Is there an inverse relationship between maximal performance indices and
blood [NH3] at exhaustion, with state of training?

5)

Is there an 'ammonia tolerance' threshold, i.e. an absolute blood
concentration or percentage change from rest, where the subject requests to
stop?

6)

Do subjects have different 'ammonia tolerance' threshold(s), for arms vs.
legs? Alternatively, is ammonia tolerance more reflective of status of
specificity of training?

To continue the investigation of these considerations, pilot study 3 was conducted.
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APPENDIX D. PILOT STUDY 3: THE EFFECTS OF VARIABLE AMOUNTS OF LASPARTIC ACID ON BLOOD AMMONIA WITH HIGH-INTENSITY ARM WORK IN
SURFERS
D.1 Introduction
Results from previous investigations and work in our laboratory (Edwards et al.
MSSE; Edwards et al. MSSE 32(5): S329), indicate that supplementation of 10g each of LArg and L-Orn sharply elevates blood urea nitrogen in response to intense short-term
exercise. However, in contrast to hypotheses in this study, neither short-term exerciseinduced hyperammonemia nor work time to exhaustion were significantly affected.
Therefore, the metabolic and performance improvements reported in previous studies
implicate isolation of the ingestion of L-Aspartic Acid. In addition, it is well known
(Graham et al. MSSE 29:646) that training status affect the blood ammonia and
performance response to exercise. However, it is unclear as to the responsiveness of
training status to L-Aspartic Acid ingestion. Therefore, the purpose of this pilot study was
twofold: 1) to assess the dose-response relationship between 0,5,10, or 15g aspartate intake
and blood ammonia concentration in a testing modality (arm ergometry) trained group
(surfers), and 2) of these amounts, determine the dose most likely to lower blood ammonia
to improve performance.
D.2 Methods
Four healthy well-trained college-age male surfers volunteered for the study. They
were informed of the nature of the study and the risks involved before giving their consent
in accordance with university guidelines. Subjects reported for five consecutive days of
exercise testing, and instructed to keep diet consistent, and abstain from caffeine, tobacco,
and alcohol. Descriptive characteristics of the subjects are presented in Table D.1.
Subjects reported to the lab for five consecutive days of exercise testing utilizing a
seated incremental seated arm ergometry (Monark Model #881) protocol to exhaustion.
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Table D.1. Descriptive characteristics of subjects in pilot study 3.
Initials
(Subject)
MA (a)
JA (b)
DA (c)
MI (d)

Age
(yr)
23
25
24
22

Weight
(kg)
76.4
75
79.5
84.1

Height
(cm)
177.8
175.3
185.4
177.8

Years
Surfing
0.5
7
3
4

W·min-1 @
Exh
225
250
225
225

WTE
(sec)
249
246
272
257

Mean
23.5
78.8
179.1
3.6
231.3
256.0
SEM
0.6
2.0
2.2
1.3
6.3
5.8
SD
1.3
4.0
4.4
2.7
12.5
11.6
Minimum
22
75
175.3
0.5
225
246
Maximum
25
84.1
185.4
7
250
272
WTE – time to exhaustion; SEM – standard error of measurement; SD – standard deviation
from the mean
The test began at an initial intensity of 25 W·min-1 at 100 rpm and increased 25 W·min-1
every 30 seconds until exhaustion. Total time and terminal watt rate achieved per subject
on session 1 was used for all sessions. Session(s) 1 and 2 subjects consumed 0 grams LAspartic Acid, while on session(s) 3, 4, and 5, subjects ingested 5, 10, or 15g L-aspartate
(Source Naturals, Inc, Scotts Valley, CA) in counterbalanced order. The L-Aspartate was
dissolved in a commercial performance beverage and divided for consumption 23 hours
and 1 hour before testing.
Blood was drawn from a forearm vein in a seated position at rest and exhaustion.
Samples were centrifuged immediately and the supernatant analyzed immediately for
ammonia and lactate. Ammonia levels were determined using a Kodak (Eastman Kodak
Company, Rochester, NY) Ektachem NH3-/Amon Clinical Chemistry Slide Analyzer
(Johnson and Johnson Clinical Diagnostics, Rochester, NY). The procedure employs a
multilayered analytical system fixed onto a polyester support. A 10 microliter plasma
sample is added to a reagent layer consisting of a pH 9.2 buffer which effectively converts
the ammonium ion (NH4+) to ammonia (NH3). Uncharged, ammonia then passes through a
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semipermeable membrane where it reacts with bromophenol blue to produce a blue dye
which is read at a wavelength of 600 nanometers. The amount of ammonia present in the
sample is proportional to the amount of blue dye produced. Control assays were conducted
on dilutions of freeze-dried serum supplied by the company. Blood lactate was analyzed
via the Accusport@ Portable Analyzer.
D.3 Results
Complete bloodwork was available for three of the four subjects. Data from the
three sessions completed by subject 4 are included in the analyses. Individual responses by
day, and by dose, are presented in Table(s) D.2 and D.3, respectively. Blood NH3 [µM/L]
responses at exhaustion relative to 0, 5, 10, and 15 g of L-Aspartic Acid (A)
supplementation are presented in Table D.4. Subjects reached high levels of exerciseinduced hyperammonemia and lactic acidosis (mean ± SE) 197.7 ± 10.8 [µM/L], and 12.2
± 0.3 [mM]. Further, as shown in Table D.4, there was a general trend for lowering of
blood ammonia with increasing dose of L-Aspartic Acid, with no effect on lactate.
D.4 Summary
Results from this study suggest: 1) exercise hyperammonemia is attenuated by
aspartate in a dose dependent manner, and 2) there is a tapering off of hyperammonemia
reduction between 10 g and 15 g of aspartate, 3) there is a possible storage effect of daily
aspartate supplementation, and 4) hyperammonemia is reduced without a concomitant
change in lactate.
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Table D.2. Individual blood NH3 [µM/L] and blood lactate [mM] responses at rest (R) and
exhaustion (X) across five exercise sessions.
Session/Sub
1a
1b
1c
1d
2a
2b
2c
2d
3a
3b
3c
3d
4a
4b
4c
5a
5b
5c

R [NH3]
12
30
22
18
18
37
28
20
14
18
26
16
13
20
25
21
29
18

X [NH3]
258
207
231
249
235
237
231
259
227
218
175
250
170
212
146
139
143
137

R [LA]
2.3
2.5
2.5
2.4
2.6
2.3
2.7
3.0
2.7
2.4
2.5
2.7
2.2
2.4
2.5
2.2
2.8
2.6

X [LA]
11.2
13.2
11.5
12.2
12.6
13.7
13.3
13.3
11.8
13.7
12.7
12.2
12.2
13.7
11.4
12.2
9.3
11.2

Mean
21.4
206.9
2.5
12.3
SEM
1.6
10.2
0.1
0.3
SD
6.6
43.4
0.2
1.1
Minimum
12
137
2.2
9.3
Maximum
37
259
3
13.7
LA – blood lactate [mM]; SEM – standard error of measurement; SD – standard deviation
from the mean.
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Table D.3. Individual blood NH3 [µM/L] and blood lactate [mM] responses at rest (R) and
at exhaustion (X) with 0, 0, 5, 10, and 15 g of L-Aspartic Acid (A) supplementation.
A (grams) Session/Sub R [NH3]
X [NH3]
R [LA]
X [LA]
0
1a
12
258
2.3
11.2
0
1b
30
207
2.5
13.2
0
1c
22
231
2.5
11.5
0
1d
18
249
2.4
12.2
0
2a
18
235
2.6
12.6
0
2b
37
237
2.3
13.7
0
2c
28
204
2.7
13.3
0
2d
20
259
3.0
13.3
5
3a
14
227
2.7
11.8
5
4b
20
212
2.4
11.8
5
3c
26
175
2.5
12.7
10
4a
13
170
2.2
10.2
10
5b
29
143
2.8
9.3
10
5c
18
137
2.6
11.2
10
3d
16
250
2.7
12.2
15
5a
21
139
2.2
12.3
15
3b
18
218
2.4
13.7
15
4c
25
146
2.5
11.4
A – L-Aspartic Acid; Sub – Subject; R – rest; X – exhaustion; LA – blood lactate [mM]

Table D.4. Blood NH3 [µM/L] at exhaustion in response to 0, 5, 10, and 15 g of L-Aspartic
Acid (A) supplementation.
Subject
a
b
c
d

0g
258
207
231
249

0g
235
237
204
259

5g
227
212
175

10g
170
143
137
250

15g
139
218
146

Mean
236.3
233.8
204.7
175.0
167.7
SEM
11.3
11.3
15.5
26.0
25.2
SD
22.5
22.6
26.8
52.0
43.7
Minimum
207
204
175
137
139
Maximum
258
259
227
250
218
SEM – standard error of measurement; SD – standard deviation from the mean.
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APPENDIX E. RAW DATA AND ANALYSES FOR EXPERIMENT 1
Table E.1. Staff instructions for distributing placebo (P) or L-Aspartic Acid (A) packets
to subjects for experiment 1 (reliability).
1)
2)
3)
4)

Subject

Subjects report to staff for receiving powder packets at least 24 hours
prior to each exercise session
Staff hands out 2 packets to each subject
Staff instructs subject to mix one packet in 8 oz water 24 hours prior to
testing, and drink, and likewise the second packet 1 one hour prior to
testing.
Staff crosses out the A x 2, or P x 2 on the master sheet below, as
packets are distributed:

Session 1

Session 2

Session 3

Session 4

Session 5

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Px2

Px2

Px2

Ax2

Px2

Ax2

Ax2

Px2

Ax2

Px2

Px2
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Table E.2. Individual blood NH3 [µM/L] responses across three sessions of placebo (P1, P2,
P3). Blood was drawn 3 minutes post-exercise.
Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

P1 [µM/L]
179
182
151
190
91
146
134
120
256
168
207
247
259
171
193

P2 [µM/L]
211
230
139
183
107
131
150
132
293
158
219
232
276
193
200

P3 [µM/L]
199
235
138
194
88
143
163
116
237
166
189
257
230
183
225

Mean
179.6
190.3
184.2
SEM
12.6
14.1
12.6
SD
48.8
54.6
48.8
Minimum
91
107
88
Maximum
259
293
257
SEM – standard error of measurement; SD – standard deviation from the mean
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Table E.3. Individual blood NH3 [µM/L] responses across two sessions of L-Aspartic
Acid supplementation (A1, A2). Blood was drawn 3 minutes post-exercise.
Subject
1
2
3
4
5
6
7
8
9
10

A1 [µM/L]
167
162
177
124
124
98
221
158
239
177

A2 [µM/L]
201
151
168
137
139
85
246
150
162
187

Mean
164.7
162.6
SEM
13.7
13.6
SD
43.2
42.9
Minimum
98
85
Maximum
239
246
SEM – standard error of measurement; SD – standard deviation from the mean
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Table E.4. Reliability analyses of blood NH3 [µM/L] across placebo sessions (P1, P2, and
P3).
_______________________________________________________________________
RELIABILITY ANALYSIS
P1 NH3
P2 NH3
P3 NH3

Mean
179.6000
190.4667
184.2000

Std Dev
48.8186
55.0271
48.7621

Cases
15.0
15.0
15.0

Inter-item Intraclass Correlation Coefficient Matrix
P1 NH3

P2 NH3

P1 NH3

1.0000

P2 NH3

. 9109

1.0000

P3 NH3

. 9009

. 8874

P3 NH3

1.0000

Intraclass Correlation Coefficient (P1 NH3 vs. P2 NH3 vs. P3 NH3)
One-way random effect model: People Effect Random
Single Measure Intraclass Correlation = .8998
95.00% C.I.:
Lower = .7850
Upper = .9617
F = 27.9417 DF = (14, 30.0) Sig. = 0.0000 (Test Value = 0.0000 )
Intraclass Correlation Coefficient (P1 NH3 vs. P2 NH3)
One-way random effect model: People Effect Random
Single Measure Intraclass Correlation = .9109
95.00% C.I.: Lower = .7624
Upper = .9689
F = 21.4481 DF = (14, 15.0) Sig. = 0.0000 (Test Value = 0.0000 )
Intraclass Correlation Coefficient (P1 NH3 vs. P3 NH3)
One-way random effect model: People Effect Random
Single Measure Intraclass Correlation = .9009
95.00% C.I.: Lower = .7381
Upper = .9653
F = 19.1875 DF = (14, 15.0) Sig. = 0.0000 (Test Value = 0.0000 )
Intraclass Correlation Coefficient (P2 NH3 vs. P3 NH3)
One-way random effect model: People Effect Random
Single Measure Intraclass Correlation = .8874
95.00% C.I.: Lower = .7057
Upper = .9603
F = 16.7563 DF = (14, 15.0) Sig. = 0.0000 (Test Value = 0.0000 )
__________________________________________________________________
146

Table E.5. Reliability analysis of blood NH3 [µM/L] across L-Aspartic Acid
supplementation sessions (A1, A2).
_______________________________________________________________________
RELIABILITY ANALYSIS
Intraclass Correlation Coefficient Matrix
A1 NH3
A1 NH3

1.0000

A2 NH3

.7426

A2 NH3

1.0000

N of Cases = 10.0
Intraclass Correlation Coefficient
One-way random effect model: People Effect Random
Single Measure Intraclass Correlation = .7643
95.00% C.I.:
Lower = .3290
Upper = .9348
F = 7.4847 DF = (9, 10.0) Sig. = .0021 (Test Value = .0000 )
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Table E.6. Group comparisons of blood NH3 [µM/L] across three sessions of placebo
(P1, P2, P3) and two of L-Aspartic Acid supplementation (A1, A2).
______________________________________________________________________
MEAN P1 NH3 [µM/L] =
VAR. P1 NH3 [µM/L] =

179.6
695.1

MEAN P2 NH3 [µM/L] =
VAR. P2 NH3 [µM/L] =

190.5
883.1

MEAN P3 NH3 [µM/L] =
VAR. P3 NH3 [µM/L] =

184.2
693.5

MEAN A1 NH3 [µM/L] =
VAR. A1 NH3 [µM/L] =

164.7
350.3

MEAN A2 NH3 [µM/L] =
VAR. A2 NH3 [µM/L] =

162.6
345.5
ANOVA SUMMARY TABLE

SOURCE

SUM SQRES

DF

MEAN SQRES F-RATIO

BETWEEN GRPS

29215.9

4

7303.0

WITHIN SUBJ

87806.2

48

1829.3

ERROR

54633.0

192

284.6

TOTAL

171656.2

244

25.7

< 0.0001

TUKEY’S PROTECTED T-TESTS
P1 NH3

P2 NH3

P3 NH3

A1 NH3

A2 NH3

P1 NH3

0

-1.8

-.748

2.2*

2.5

P2 NH3

-1.8

0

1.089

3.7**

4.0**

P3 NH3

-.7

1.08

0

2.8**

3.1**

A1 NH3

2.2*

3.78**

2.88**

0

.3

A2 NH3

2.5*

4.08**

3.18**

.3

** p < 0.01

* p < 0.05
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.

P

0

APPENDIX F. RAW DATA AND ANALYSES FOR EXPERIMENT 2
Table F.1. Staff instructions for distributing placebo (P) or L-Aspartic Acid (A)
supplementation packets to subjects for experiment 2 (performance) in intercollegiate water
polo players (WP) and moderately-trained males (MOD).
1)
2)
3)
4)

Subject report to staff for receiving powder packets at least 24 hours prior to
each exercise session
Staff hands out 2 packets to each subject
Staff instructs subject to mix one packet in 8 oz water 24 hours prior to
testing, and drink, and likewise the second packet 1 one hour prior to
testing.
Staff crosses out the A x 2, or P x 2 on the master sheet below, as packets
are distributed:
Subject

Session 1
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Session 2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Table F.2. Individual blood NH3 [µM/L] in response to placebo (P) or L-Aspartic Acid
(A) supplementation in intercollegiate water polo players (WP). Blood was drawn 3
minutes post-exercise.
Subject
1
2
3
4
5
6
7
8
9

P [µM/L]
273
195
307
277
302
268
170
207
170

A [µM/L]
269
163
233
202
287
212
113
213
113

Mean
241.0
200.6
SEM
18.4
20.5
SD
55.3
61.5
Minimum
170
113
Maximum
307
287
SEM – standard error of measurement; SD – standard deviation from the mean

Table F.3. Individual blood NH3 [µM/L] in response to placebo (P) or L-Aspartic Acid
(A) supplementation in moderately-trained college males (MOD). Blood was drawn 3
minutes post-exercise.
Subject
1
2
3
4
5
6
7
8
9

P [µM/L]
230
150
231
172
243
133
233
243
342

A [µM/L]
193
90
166
156
222
120
128
227
368

Mean
219.7
185.6
SEM
20.8
27.5
SD
62.4
82.5
Minimum
133
90
Maximum
342
368
SEM – standard error of measurement; SD – standard deviation from the mean
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Table F.4. Individual performance power (W·min-1) in response to placebo (P) or LAspartic Acid (A) supplementation in intercollegiate water polo players (WP).
Subject
1
2
3
4
5
6
7
8
9

P (W·min-1)
255
319
254
185
208
194
228
214
191

A (W·min-1)
278
248
210
343
249
201
365
316
222

Mean
227.6
270.2
SEM
14.3
19.8
SD
42.8
59.3
Minimum
185
201
Maximum
319
365
SEM – standard error of measurement; SD – standard deviation from the mean

Table F.5. Individual performance power (W·min-1) r response to placebo (P) or LAspartic Acid (A) supplementation in moderately-trained college males (MOD).
Subject
1
2
3
4
5
6
7
8
9

P (W·min-1)
253
176
205
211
188
192
209
177
229

A (W·min-1)
209
241
188
259
200
182
231
249
222

Mean
204.4
220.1
SEM
8.4
9.1
SD
25.0
27.3
Minimum
176
182
Maximum
253
259
SEM – standard error of measurement; SD – standard deviation from the mean
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Table F.6. Group comparisons of blood NH3 [µM/L] in response to placebo (P) or LAspartic Acid supplementation (A) in intercollegiate water polo players (WP) and
moderately-trained males (MOD).
MEAN NH3 [µM/L] WP P =
VAR. NH3 [µM/L] WP P =

241.0
720.0

MEAN NH3 [µM/L] WP A =
VAR. NH3 [µM/L] WP A =

200.6
889.4

MEAN NH3 [µM/L] MOD P =
VAR. NH3 [µM/L] MOD P =

219.7
914.8

MEAN NH3 [µM/L] MOD A =
VAR. NH3 [µM/L] MOD A =

185.6
1599.5

ANOVA SUMMARY TABLE
SOURCE

SUM SQRES

DF MEAN SQRES F-RATIO

BETWEEN GRPS

60539.08951

3

20179.6965

WITHIN SUBJ

51460.88889

34

1513.55556

ERROR

88747.55556

102 870.07407

TOTAL

200747.53395

139

23.19

P
< 0.0001

TUKEY’S PROTECTED T-TESTS
WP P

WP A

MOD P

MOD A

WP P

0

2.90862**

1.53422

3.98737**

WP A

2.90862**

0

-1.3744

1.07875

MOD P

1.53422

-1.3744

0

2.45315*

MOD A

3.98737**

1.07875

2.45315*

0

** p < 0.01 * p < 0.05
______________________________________________________________________
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Table F.7. Group comparisons of performance power (W·min-1) in response to placebo
(P) or L-Aspartic Acid (A) supplementation in intercollegiate water polo players (WP)
and moderately-trained males (MOD).
MEAN W·min-1
VAR. W·min-1

WP P =
WP P =

227.5
428.1

MEAN W·min-1
VAR W·min-1

WP A =
WP A =

270.3
827.6

MEAN W·min-1 MOD P = 204.4
VAR. W·min-1 MOD P = 148.4
MEAN W·min-1 MOD A = 220.2
VAR. W·min-1 MOD A = 175.5

ANOVA SUMMARY TABLE
SOURCE

SUM SQRES

DF

MEAN SQRES

F RATIO

BETWEEN GRPS

83426.83287

3

27808.94429

76.09

WITHIN SUBJ

16435.435

34

483.39515

ERROR

37275.59833

102

365.44704

TOTAL

137137.8662

139

TUKEY’S PROTECTED T-TESTS
WP P

WP A

MOD P

MOD A

WP P

0

-4.75062**

2.56704*

.81376

WP A

-4.75062**

0

7.31766**

5.56438**

MOD P

2.56704*

7.31766**

0

-1.75328

MOD A

.81376

5.56438**

-1.75328

0

** p < 0.01

* p < 0.05
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P

< 0.0001

APPENDIX G. RAW DATA AND ANALYSES FOR EXPERIMENT 3
Table G.1. Staff instructions for distributing placebo (P) and L-Aspartic Acid (A) packets
packet(s) to subjects for experiment 3 (performance) in recreationally-trained females
(FEM).
1)
2)
3)
4)

Subject report to staff for receiving powder packets at least 24 hours prior to
each exercise session
Staff hands out 2 packets to each subject
Staff instructs subject to mix one packet in 8 oz water 24 hours prior to
testing, and drink, and likewise the second packet 1 one hour prior to
testing.
Staff crosses out the A x 2, or P x 2 on the master sheet below, as packets
are distributed:
Subject

Session 1
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Session 2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Ax2

Px2

Px2

Ax2

Table G.2. Individual blood NH3 [µM/L] in response to placebo (P) or L-Aspartic
Acid (A) supplementation in recreationally-trained female subjects (FEM). Blood was
drawn 3 minutes post-exercise.
Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

P [µM/L]
207
257
230
161
226
222
300
249
257
198
183
150
193
185
238
257
150
142

A [µM/L]
245
283
191
140
166
138
306
321
218
203
140
211
186
213
252
273
131
102

Mean
215.5
212.8
SEM
10.3
14.6
SD
42.4
60.2
Minimum
150
131
Maximum
300
321
SEM – standard error of measurement; SD – standard deviation from the mean
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Table G.3. Individual performance power (W·min-1) in response to placebo (P) or LAspartic Acid (A) supplementation in recreationally-trained female subjects (FEM).
Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

P (W·min-1)
195
199
182
171
168
138
144
140
132
272
156
135
204
146
122
171
180
194

A (W·min-1)
174
209
212
124
175
154
148
196
111
168
120
170
193
164
137
167
193
277

Mean
167.9
165.6
SEM
8.9
7.4
SD
36.7
30.3
Minimum
122
111
Maximum
272
212
SEM – standard error of measurement; SD – standard deviation from the mean
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Table G.4. Group comparisons of blood NH3 [µM/L] in response to placebo (P) or LAspartic Acid supplementation (A) in recreationally-trained female subjects (FEM).
_______________________________________________________________________
MEAN NH3 [µM/L] FEM P =
VAR. NH3 [µM/L] FEM P =

211.6
1981.5

MEAN NH3 [µM/L] FEM A =
VAR. NH3 [µM/L] FEM A =

206.6
4088.4

ANOVA SUMMARY TABLE
SOURCE

SUM SQRES

DF

MEAN SQRES

BETWEEN GRPS

225

1

225

WITHIN SUBJ

88217.55556

17

5189

ERROR

14971

17

880.64706

TOTAL

103413.55556

35

F-RATIO
.

2554

P
.6197

Table G.5. Group comparisons of performance power (W·min-1) in response to placebo (P)
or L-Aspartic Acid supplementation (A) in recreationally-trained female subjects (FEM).
_______________________________________________________________________
MEAN FEM W·min-1 P =
VAR. FEM W·min-1 P =

172.4
1235.1

MEAN FEM W·min-1 A =
VAR. FEM W·min-1 A =

179.1
1177.9
ANOVA SUMMARY TABLE

SOURCE

SUM SQRES

DF

BETWEEN GRPS

404.68028

1

404.68028

WITHIN SUBJ

28364.41472

17

1668.49498

ERROR

12657.01472

17

744.53028

TOTAL

41426.10972

35
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MEAN SQRES

F-RATIO
.54354

P
.471
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